

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|-----------|---|
| (51) International Patent Classification 7 : C12N 15/12, C07K 14/47, 16/18, A61K 38/17, G01N 33/68 | | A2 | (11) International Publication Number: WO 00/31263 |
| | | | (43) International Publication Date: 2 June 2000 (02.06.00) |
| (21) International Application Number: PCT/US99/28013 | | | CA 94040 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). |
| (22) International Filing Date: 23 November 1999 (23.11.99) | | | |
| (30) Priority Data: | | | |
| 60/109,592 23 November 1998 (23.11.98) US | | | |
| 60/118,610 4 February 1999 (04.02.99) US | | | |
| 60/127,990 6 April 1999 (06.04.99) US | | | |
| (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications | | | (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). |
| US 60/109,592 (CIP) | | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |
| Filed on 23 November 1998 (23.11.98) | | | |
| US 60/118,610 (CIP) | | | |
| Filed on 4 February 1999 (04.02.99) | | | |
| US 60/127,990 (CIP) | | | |
| Filed on 6 April 1999 (06.04.99) | | | |
| (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). | | | Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (72) Inventors; and | | | |
| (75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, | | | |
| (54) Title: GTPASE ASSOCIATED PROTEINS | | | |
| (57) Abstract <p>The invention provides human GTPase associated proteins (GTPAP) and polynucleotides which identify and encode GTPAP. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GTPAP.</p> | | | |

B2

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LJ | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

GTPASE ASSOCIATED PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of GTPase associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, and immune system disorders.

5

BACKGROUND OF THE INVENTION

Guanine nucleotide binding proteins (GTP-binding proteins) participate in a wide range of regulatory functions in all eukaryotic cells, including metabolism, cellular growth, differentiation, signal transduction, cytoskeletal organization, and intracellular vesicle transport and secretion. In higher organisms they are involved in signaling that regulates such processes as the immune response (Aussel, C. et al (1988) J. Immunol. 140:215-220), apoptosis, differentiation, and cell proliferation including oncogenesis (Dhanasekaran, N. et al. (1998) Oncogene 17:1383-1394). Exchange of bound GDP for GTP followed by hydrolysis of GTP to GDP provides the energy that enables GTP-binding proteins to alter their conformation and interact with other cellular components. The superfamily of GTP-binding proteins consists of several families and may be grouped as translational factors, heterotrimeric GTP-binding proteins involved in transmembrane signaling processes (also called G-proteins), and low molecular weight GTP-binding proteins including the proto-oncogene Ras proteins and products of rab, rap, rho, rac, smg21, smg25, YPT, SEC4, and ARF genes, and tubulins (Kaziro, Y. et al. (1991) Ann. Rev. Biochem. 60:349-400). In all cases, the GTPase activity is regulated through interactions with other proteins.

GTP-binding proteins involved in protein biosynthesis include initiation factor 2 (IF-2), elongation factor 2 (EF-Tu), and elongation factor G (EF-G), observed in prokaryotes; and initiation factor 2 (eIF-2), elongation factor 1 α (EF-1 α) and elongation factor 2 (EF-2) observed in eukaryotes (Kaziro, supra). IF-2 promotes the GTP-dependent binding of the tRNA to the small subunit of the ribosome, the step that initiates protein translation. Similarly, elongation factors promote the binding of tRNA and GTP and the displacement of GDP after hydrolysis as protein biosynthesis proceeds.

Heterotrimeric GTP-binding proteins are composed of 3 subunits (α , β and γ) which, in their inactive conformation, associate as a trimer at the inner face of the plasma membrane. G α binds GDP or GTP and contains the GTPase activity. The $\beta\gamma$ complex enhances binding of G α to a receptor. G γ is necessary for the folding and activity of G β . (Neer, E.J. et al. (1994) Nature 371:297-300.) Multiple homologs of each subunit have been identified in mammalian tissues, and different combinations of subunits have specific functions and tissue specificities. (Spiegel, A.M. (1997) J.

Inher. Metab. Dis. 20:113-121.) G protein activity is triggered by seven-transmembrane cell surface receptors (G-protein coupled receptors) which respond to lipid analogs, amino acids and their derivatives, peptides, cytokines, and specialized stimuli such as light, taste, and odor. Activation of the receptor by its stimulus causes the replacement of the G protein-bound GDP with GTP. G α -GTP dissociates from the receptor/ $\beta\gamma$ complex and each of these separated components can interact with and regulate downstream effectors. The signaling stops when G α hydrolyzes its bound GTP to GDP and reassociates with the $\beta\gamma$ complex (Neer, supra).

The alpha subunits of heterotrimeric G proteins can be divided into four distinct classes. The α -s class is sensitive to ADP-ribosylation by pertussis toxin which uncouples the receptor:G-protein interaction. This uncoupling blocks signal transduction to receptors that decrease cAMP levels which normally regulate ion channels and activate phospholipases. The inhibitory α -I class is also susceptible to modification by pertussis toxin which prevents α -I from lowering cAMP levels. Two novel classes of α subunits refractory to pertussis toxin modification are α -q, which activates phospholipase C, and α -12, which has sequence homology with the *Drosophila* gene concertina and may contribute to the regulation of embryonic development (Simon, M.I. (1991) Science 252:802-808).

The mammalian G β and G γ subunits, each about 340 amino acids long, share more than 80% homology. The G β subunit (also called transducin) contains seven repeating units, each about 43 amino acids long. The activity of both subunits may be regulated by other proteins such as calmodulin and phosducin or the neural protein GAP 43 (D. Clapham and E. Neer, 1993, Nature 365:403-406). The β and γ subunits are tightly associated. The β subunit sequences are highly conserved between species, implying that they perform a fundamentally important role in the organization and function of G-protein linked systems (Van der Voorn L. (1992) Febs. Lett. 307 (2):131-134). They contain seven tandem repeats of the WD-repeat sequence motif, a motif found in many proteins with regulatory functions. WD-repeat proteins contain from four to eight copies of a loosely conserved repeat of approximately 40 amino acids which participates in protein-protein interactions. Mutations and variant expression of β transducin proteins are linked with various disorders. Mutations in LIS1, a subunit of the human platelet activating factor acetylhydrolase, cause Miller-Dieker lissencephaly. RACK1 binds activated protein kinase C, and RbAp48 binds retinoblastoma protein. CstF is required for polyadenylation of mammalian pre-mRNA in vitro and associates with subunits of cleavage-stimulating factor. Defects in the regulation of β -catenin contribute to the neoplastic transformation of human cells. The WD40 repeats of the human F-box protein β TrCP mediate binding to β -catenin, thus regulating the targeted degradation of β -catenin by

ubiquitin ligase (Neer, *supra*; Hart, M. et al (1999) *Curr. Biol.* 9:207-210). The γ subunit primary structures are more variable than those of the β subunits. They are often post-translationally modified by isoprenylation and carboxyl-methylation of a cysteine residue four amino acids from the C-terminus; this appears to be necessary for the interaction of the $\beta\gamma$ subunit with the membrane and with other GTP-binding proteins. The $\beta\gamma$ subunit has been shown to modulate the activity of isoforms of adenylyl cyclase, phospholipase C, and some ion channels. It is involved in receptor phosphorylation via specific kinases, and has been implicated in the p21ras-dependent activation of the MAP kinase cascade and the recognition of specific receptors by GTP-binding proteins. (Clapham and Neer, *supra*).

G-proteins interact with a variety of effectors including adenylyl cyclase (Clapham and Neer, *supra*). The signaling pathway mediated by cAMP is mitogenic in hormone-dependent endocrine tissues such as adrenal cortex, thyroid, ovary, pituitary, and testes. Cancers in these tissues have been related to a mutationally activated form of a $G\alpha_s$, known as the gsp (Gs protein) oncogene (Dhanasekaran, *supra*). Another effector is phosphodiesterase, a retinal phosphoprotein, which forms a specific complex with retinal $G\beta$ and $G\gamma$ ($G\beta\gamma$) and modulates the ability of $G\beta\gamma$ to interact with retinal $G\alpha$ (Clapham and Neer, *supra*).

Irregularities in the GTP-binding protein signaling cascade may result in abnormal activation of leukocytes and lymphocytes, leading to the tissue damage and destruction seen in many inflammatory and autoimmune diseases such as rheumatoid arthritis, biliary cirrhosis, hemolytic anemia, lupus erythematosus, and thyroiditis. Abnormal cell proliferation, including cyclic AMP stimulation of brain, thyroid, adrenal, and gonadal tissue proliferation is regulated by G proteins. Mutations in $G\alpha$ subunits have been found in growth-hormone-secreting pituitary somatotroph tumors, hyperfunctioning thyroid adenomas, and ovarian and adrenal neoplasms (Meij, J.T.A. (1996) *Mol. Cell. Biochem.* 157:31-38; Ausel, *supra*).

LMW GTP-binding proteins are GTPases which regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. They consist of single polypeptides which, like the alpha subunit of the heterotrimeric GTP-binding proteins, are able to bind to and hydrolyze GTP, thus cycling between an inactive and an active state. LMW GTP-binding proteins respond to extracellular signals from receptors and activating proteins by transducing mitogenic signals involved in various cell functions. The binding and hydrolysis of GTP regulates the response of LMW GTP-binding proteins and acts as an energy source during this process (Bokoch, G. M. and Der, C. J. (1993) *FASEB J.* 7:750-759).

At least sixty members of the LMW GTP-binding protein superfamily have been identified _

and are currently grouped into the ras, rho, arf, sar1, ran, and rab subfamilies. Activated ras genes were initially found in human cancers, and subsequent studies confirmed that ras function is critical in determining whether cells continue to grow or become differentiated. Ras1 and Ras2 proteins stimulate adenylate cyclase (Kaziro, supra), affecting a broad array of cellular processes. Stimulation of cell surface receptors activates Ras which, in turn, activates cytoplasmic kinases. These kinases translocate to the nucleus and activate key transcription factors that control gene expression and protein synthesis (Barbacid, M. (1987) *Ann. Rev Biochem.* 56:779-827, Treisman, R. (1994) *Curr. Opin. Genet. Dev.* 4:96-98). Other members of the LMW GTP-binding protein superfamily have roles in signal transduction that vary with the function of the activated genes and the locations of the GTP-binding proteins that initiate the activity. Rho GTP-binding proteins control signal transduction pathways that link growth factor receptors to actin polymerization, which is necessary for normal cellular growth and division. The rab, arf, and sar1 families of proteins control the translocation of vesicles to and from membranes for protein processing, localization, and secretion. Vesicle- and target- specific identifiers (v-SNAREs and t-SNAREs) bind to each other and dock the vesicle to the acceptor membrane. The budding process is regulated by the closely related ADP ribosylation factors (ARFs) and SAR proteins, while rab proteins allow assembly of SNARE complexes and may play a role in removal of defective complexes (J. Rothman and F. Wieland (1996) *Science* 272:227-234). Ran GTP-binding proteins are located in the nucleus of cells and have a key role in nuclear protein import, the control of DNA synthesis, and cell-cycle progression (Hall, A. (1990) *Science* 249:635-640; Barbacid, M. (1987) *Ann. Rev Biochem.* 56:779-827; Ktistakis, N. (1998) *BioEssays* 20:495-504; and Sasaki, T. and Takai, Y. (1998) *Biochem. Biophys. Res. Commun.* 245:641-645).

The cycling of LMW GTP-binding proteins between the GTP-bound active form and the GDP-bound inactive form is regulated by additional proteins. Guanine nucleotide exchange factors (GEFs) increase the rate of nucleotide dissociation by several orders of magnitude, thus facilitating release of GDP and loading with GTP. The best characterized is the mammalian homologue of the *Drosophila* Son-of-Sevenless protein. Certain Ras-family proteins are also regulated by guanine nucleotide dissociation inhibitors (GDIs), which inhibit GDP dissociation. The intrinsic rate of GTP hydrolysis of the LMW GTP-binding proteins is typically very slow, but it can be stimulated by several orders of magnitude by GTPase-activating proteins (GAPs) (Geyer, M. and Wittinghofer, A. (1997) *Curr. Opin. Struct. Biol.* 7:786-792). Both GEF and GAP activity may be controlled in response to extracellular stimuli and modulated by accessory proteins such as RalBP1 and POB1. Mutant Ras-family proteins, which bind but can not hydrolyze GTP, are permanently activated, and cause cell proliferation or cancer, as do GEFs that inappropriately activate LMW GTP-binding proteins, such as the human oncogene NET1, a Rho-GEF (Drivas, G. T. et al. (1990) *Mol. Cell. Biol.*

10:1793-1798; Alberts, A. S. and Treisman, R. (1998) EMBO J. 14:4075-4085).

A novel group of GTP-binding proteins is the GTP1/OBG family, which are found in species ranging from bacteria to yeast to humans. These proteins contain characteristic GTP-binding motifs and are similar to one another but do not show sequence homology to other GTP-binding proteins.

5 The exact functions of these proteins are as yet uncertain, but they have been shown to be important for regulation of cell differentiation and development (Okamoto, S. and Ochi, K. (1998). Mol. Microbiol 30:107-119; Sazaka, T. et al. (1992) Biochem. Biophys. Res. Commun. 189:363-370).

The discovery of new GTPase associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis,
10 prevention, and treatment of cell proliferative, autoimmune/inflammatory, and immune system disorders.

SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, GTPase associated proteins,
15 referred to collectively as "GTPAP" and individually as "GTPAP-1," "GTPAP-2," "GTPAP-3,"
"GTPAP-4," "GTPAP-5," "GTPAP-6," "GTPAP-7," "GTPAP-8," "GTPAP-9," "GTPAP-10,"
"GTPAP-11," "GTPAP-12," "GTPAP-13," "GTPAP-14," "GTPAP-15," "GTPAP-16," "GTPAP-17,"
"GTPAP-18," "GTPAP-19," "GTPAP-20," "GTPAP-21," "GTPAP-22," "GTPAP-23," "GTPAP-24,"
"GTPAP-25," "GTPAP-26," "GTPAP-27," "GTPAP-28," and "GTPAP-29." In one aspect, the
20 invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also includes a polypeptide comprising an amino acid sequence that differs by one or more conservative amino acid substitutions from an amino acid sequence selected from the group consisting of SEQ ID NO:1-29.

The invention further provides a substantially purified variant having at least 90% amino acid
25 identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide
30 encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The

invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

5 The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

10 The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof. The invention also provides an isolated and
15 purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group
20 consisting of SEQ ID NO:1-29. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing a polynucleotide of the invention under conditions suitable for the expression of the polypeptide; and (b) recovering the
25 polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from
30 the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially

purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding GTPAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of GTPAP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding GTPAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze GTPAP, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same

meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"GTPAP" refers to the amino acid sequences of substantially purified GTPAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GTPAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GTPAP either by directly interacting with GTPAP or by acting on components of the biological pathway in which GTPAP participates.

An "allelic variant" is an alternative form of the gene encoding GTPAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GTPAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GTPAP or a polypeptide with at least one functional characteristic of GTPAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GTPAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GTPAP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GTPAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GTPAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged -

amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

5 The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

10 "Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

15 The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GTPAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GTPAP either by directly interacting with GTPAP or by acting on components of the biological pathway in which GTPAP participates.

20 The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GTPAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.

25 Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

30 The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

 The term "antisense" refers to any composition containing a nucleic acid sequence which is

complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic GTPAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GTPAP or fragments of GTPAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the

protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

| | Original Residue | Conservative Substitution |
|----|------------------|---------------------------|
| 5 | Ala | Gly, Ser |
| | Arg | His, Lys |
| | Asn | Asp, Gln, His |
| | Asp | Asn, Glu |
| | Cys | Ala, Ser |
| 10 | Gln | Asn, Glu, His |
| | Glu | Asp, Gln, His |
| | Gly | Ala |
| | His | Asn, Arg, Gln, Glu |
| | Ile | Leu, Val |
| 15 | Leu | Ile, Val |
| | Lys | Arg, Gln, Glu |
| | Met | Leu, Ile |
| | Phe | His, Met, Leu, Trp, Tyr |
| | Ser | Cys, Thr |
| 20 | Thr | Ser, Val |
| | Trp | Phe, Tyr |
| | Tyr | His, Phe, Trp |
| | Val | Ile, Leu, Thr |

25 Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the
30 absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function
35 of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of GTPAP or the polynucleotide encoding GTPAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up
40 to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment

used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:30-58 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:30-58, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:30-58 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:30-58 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:30-58 and the region of SEQ ID NO:30-58 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-29 is encoded by a fragment of SEQ ID NO:30-58. A fragment of SEQ ID NO:1-29 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-29. For example, a fragment of SEQ ID NO:1-29 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-29. The precise length of a fragment of SEQ ID NO:1-29 and the region of SEQ ID NO:1-29 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the

substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

30 *Matrix: BLOSUM62*
 Reward for match: 1
 Penalty for mismatch: -2
 Open Gap: 5 and Extension Gap: 2 penalties
 Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example,
5 as defined by a particular SEQ ID number, or may be measured over a shorter length, for example,
over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at
least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous
nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported
by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a
10 length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode
similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes
in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid
sequences that all encode substantially the same protein.

15 The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to
the percentage of residue matches between at least two polypeptide sequences aligned using a
standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some
alignment methods take into account conservative amino acid substitutions. Such conservative
substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the
20 site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default
parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e
sequence alignment program (described and referenced above). For pairwise alignments of
polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap
25 penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default
residue weight table. As with polynucleotide alignments, the percent identity is reported by
CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise
comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9
30 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY;

specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration
5 may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to
10 those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A
15 hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide
20 sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

25 The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of GTPAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other
30 biological, functional, or immunological properties of GTPAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Probe" refers to nucleic acid sequences encoding GTPAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols. A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5. 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to

5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding GTPAP, or fragments thereof, or GTPAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA,-

RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may

have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2-Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human GTPase associated proteins (GTPAP), the polynucleotides encoding GTPAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, and immune system disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding GTPAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each GTPAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each GTPAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical

methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding GTPAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:30-58 and to distinguish between SEQ ID NO:30-58 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express GTPAP as a fraction of total tissues expressing GTPAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing GTPAP as a fraction of total tissues expressing GTPAP. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the specific expression of SEQ ID NO:43 in only one library, a human testis tissue library; the specific expression of SEQ ID NO:49 in only 4 libraries, one of which is associated with cell proliferation and 3 of which are associated with inflammation; and the specific expression of SEQ ID NO:40 in only 5 libraries, 3 of which are associated with cell proliferation and one of which is associated with inflammation.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding GTPAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses GTPAP variants. A preferred GTPAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GTPAP amino acid sequence, and which contains at least one functional or structural characteristic of GTPAP.

The invention also encompasses polynucleotides which encode GTPAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:30-58, which encodes GTPAP.

The invention also encompasses a variant of a polynucleotide sequence encoding GTPAP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GTPAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:30-58 which has at least about 70%, or alternatively at least about 90%, or even at least about

95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:30-58. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GTPAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GTPAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GTPAP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GTPAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GTPAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GTPAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GTPAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GTPAP and GTPAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GTPAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:30-58 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment

of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding GTPAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been

size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

5 Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate
10 software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

 In another embodiment of the invention, polynucleotide sequences or fragments thereof
15 which encode GTPAP may be cloned in recombinant DNA molecules that direct expression of GTPAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GTPAP.

 The nucleotide sequences of the present invention can be engineered using methods generally
20 known in the art in order to alter GTPAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction
25 sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

 In another embodiment, sequences encoding GTPAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, GTPAP itself or a fragment thereof may be synthesized using chemical methods. For
30 example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of GTPAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active GTPAP, the nucleotide sequences encoding GTPAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GTPAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GTPAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GTPAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GTPAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GTPAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or

tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GTPAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GTPAP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GTPAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of GTPAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of GTPAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GTPAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of GTPAP. Transcription of sequences encoding GTPAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., *The McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GTPAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader

sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GTPAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of GTPAP in cell lines is preferred. For example, sequences encoding GTPAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.

(See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GTPAP is inserted within a marker gene sequence, transformed cells containing sequences encoding GTPAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GTPAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GTPAP and that express GTPAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GTPAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GTPAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GTPAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GTPAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for

ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GTPAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein
5 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GTPAP may be designed to contain signal sequences which direct secretion of GTPAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the
10 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for
15 post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and W138) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GTPAP may be ligated to a heterologous sequence resulting in translation of a
20 fusion protein in any of the aforementioned host systems. For example, a chimeric GTPAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GTPAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),
25 maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity
30 purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GTPAP encoding sequence and the heterologous protein sequence, so that GTPAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10).

A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GTPAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ^{35}S -methionine.

Fragments of GTPAP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of GTPAP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GTPAP and GTPase associated proteins. In addition, the expression of GTPAP is closely associated with proliferating tissues associated with cancer and fetal development, inflamed tissues, and tissues involved in the immune response. Therefore, GTPAP appears to play a role in cell proliferative, autoimmune/inflammatory, and immune system disorders. In the treatment of disorders associated with increased GTPAP expression or activity, it is desirable to decrease the expression or activity of GTPAP. In the treatment of disorders associated with decreased GTPAP expression or activity, it is desirable to increase the expression or activity of GTPAP.

Therefore, in one embodiment, GTPAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis,

autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis,

5 glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner
10 syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and an immune system disorder, such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobinemia of Bruton, common variable immunodeficiency (CVI), DiGeorge's syndrome (thymic hypoplasia), thymic dysplasia, isolated IgA deficiency, severe combined immunodeficiency disease (SCID),
15 immunodeficiency with thrombocytopenia and eczema (Wiskott-Aldrich syndrome), Chediak-Higashi syndrome, chronic granulomatous diseases, hereditary angioneurotic edema, and immunodeficiency associated with Cushing's disease, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease.

In another embodiment, a vector capable of expressing GTPAP or a fragment or derivative
20 thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified GTPAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP including, but not
25 limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GTPAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of GTPAP may be administered to a subject to treat or
30 prevent a disorder associated with increased expression or activity of GTPAP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, and immune system disorders described above. In one aspect, an antibody which specifically binds GTPAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for

bringing a pharmaceutical agent to cells or tissues which express GTPAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GTPAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GTPAP including, but not limited to, those described above.

5 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the
10 various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GTPAP may be produced using methods which are generally known in the art. In particular, purified GTPAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GTPAP. Antibodies to GTPAP may
15 also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans,
20 and others may be immunized by injection with GTPAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in
25 humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GTPAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the
30 entire amino acid sequence of a small, naturally occurring molecule. Short stretches of GTPAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GTPAP may be prepared using any technique which provides for

the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and
5 Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda,
10 S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GTPAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

15 Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for GTPAP may also be generated.
20 For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

25 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GTPAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies
30 reactive to two non-interfering GTPAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GTPAP. Affinity is expressed as an

association constant, K_a , which is defined as the molar concentration of GTPAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GTPAP epitopes, represents the average affinity, or avidity, of the antibodies for GTPAP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular GTPAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the GTPAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GTPAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies. Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GTPAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GTPAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding GTPAP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding GTPAP. Thus, complementary molecules or fragments may be used to modulate GTPAP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GTPAP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides

encoding GTPAP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding GTPAP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding GTPAP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in
5 the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing
10 complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding GTPAP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for
15 the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

20 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GTPAP.

25 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of
30 candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques

for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GTPAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA
5 constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase
10 linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.
15 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical
25 or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of GTPAP, antibodies to GTPAP, and mimetics, agonists, antagonists, or inhibitors of GTPAP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical
30 carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial,

intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration.

Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's

solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of GTPAP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GTPAP or fragments thereof, antibodies of GTPAP, and agonists, antagonists or inhibitors of GTPAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be

determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind GTPAP may be used for the diagnosis of disorders characterized by expression of GTPAP, or in assays to monitor patients being treated with GTPAP or agonists, antagonists, or inhibitors of GTPAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GTPAP include methods which utilize the antibody and a label to detect GTPAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GTPAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GTPAP expression. Normal or standard values for GTPAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to GTPAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GTPAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GTPAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GTPAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GTPAP, and to monitor regulation of GTPAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GTPAP or closely related molecules may be used to identify nucleic acid sequences which encode GTPAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GTPAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GTPAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:30-58 or from genomic sequences including promoters, enhancers, and introns of the GTPAP gene.

Means for producing specific hybridization probes for DNAs encoding GTPAP include the cloning of polynucleotide sequences encoding GTPAP or GTPAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GTPAP may be used for the diagnosis of disorders associated with expression of GTPAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and an immune system disorder, such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobinemia of Bruton, common variable immunodeficiency (CVI), DiGeorge's syndrome (thymic hypoplasia), thymic dysplasia, isolated IgA deficiency, severe combined immunodeficiency disease (SCID), immunodeficiency with thrombocytopenia and eczema (Wiskott-Aldrich syndrome), Chediak-Higashi syndrome, chronic granulomatous diseases, hereditary angioneurotic edema, and immunodeficiency associated with Cushing's disease, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease. The polynucleotide sequences encoding GTPAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GTPAP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GTPAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GTPAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GTPAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GTPAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GTPAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding GTPAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a

polynucleotide encoding GTPAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding GTPAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

5 Methods which may also be used to quantify the expression of GTPAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is
10 presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

 In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify
15 genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

 Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)
20

 In another embodiment of the invention, nucleic acid sequences encoding GTPAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence.
25 The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

30 Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the

location of the gene encoding GTPAP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

5 In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides
10 valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention
15 may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GTPAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a
20 solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GTPAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are
25 synthesized on a solid substrate. The test compounds are reacted with GTPAP, or fragments thereof, and washed. Bound GTPAP is then detected by methods well known in the art. Purified GTPAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

30 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GTPAP specifically compete with a test compound for binding GTPAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GTPAP.

In additional embodiments, the nucleotide sequences which encode GTPAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

5 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

10 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. Nos. 60/109,592, 60/118,610, and 60/127,990 are hereby expressly incorporated
15 by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some
20 tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

25 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A⁺) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA
30 purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the

recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-
5 1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli
10 cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a
15 Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

20 Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence
25 scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific)
30 or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled

polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene

families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:30-58. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding GTPAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of GTPAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:30-58 were produced by extension of

an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham

Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

5 The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
10 recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:30-58 are used to obtain 5'
15 regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:30-58 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base
20 pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a
25 SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon
30 membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and

compared.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

VIII. Complementary Polynucleotides

Sequences complementary to the GTPAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GTPAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GTPAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GTPAP-encoding transcript.

IX. Expression of GTPAP

Expression and purification of GTPAP is achieved using bacterial or virus-based expression

systems. For expression of GTPAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GTPAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GTPAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GTPAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GTPAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GTPAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GTPAP obtained by these methods can be used directly in the following activity assay.

X. Demonstration of GTPAP Activity

The role of GTPAP can be assayed in vitro by monitoring the mobilization of Ca^{++} as part of the signal transduction pathway. (See, e.g., Grynkiewicz, G. et al. (1985) J. Biol. Chem. 260:3440; McColl, S. et al. (1993) J. Immunol. 150:4550-4555; and Aussel, C. et al. (1988) J. Immunol. 140:215.) The assay requires preloading neutrophils or T cells with a fluorescent dye such as FURA-2.

Upon binding Ca^{++} , FURA-2 exhibits an absorption shift that can be observed by scanning the excitation spectrum between 300 and 400 nm, while monitoring the emission at 510 nm. When the cells are exposed to one or more activating stimuli artificially (i.e., anti-CD3 antibody ligation of the T cell receptor) or physiologically (i.e., by allogeneic stimulation), Ca^{++} flux takes place. Ca^{++} flux results from the release of Ca^{++} from intracellular organelles or from Ca^{++} entry into the cell through activated Ca^{++} channels. This flux can be observed and quantified by assaying the cells in a fluorometer or fluorescence activated cell sorter. Measurements of Ca^{++} flux are compared between cells in their normal state and those preloaded with GTPAP. Increased mobilization attributable to increased GTPAP availability results in increased emission.

Alternatively, GTPAP activity is measured by quantifying the amount of a non-hydrolyzable GTP analogue, GTP γ S, bound over a 10 minute incubation period. Varying amounts of GTPAP are incubated at 30°C in 50mM Tris buffer, pH 7.5, containing 1mM dithiothreitol, 1mM EDTA and 1 μ M [^{35}S]GTP γ S. Samples are passed through nitrocellulose filters and washed twice with a buffer consisting of 50mM Tris-HCl, pH 7.8, 1mM NaN_3 , 10mM MgCl_2 , 1mM EDTA, 0.5mM dithiothreitol, 0.01mM PMSF, and 200mM NaCl. The filter-bound counts are measured by liquid scintillation to quantify the amount of bound [^{35}S]GTP γ S. GTPAP activity may also be measured as the amount of GTP hydrolysed over a 10 minute incubation period at 37°C. GTPAP is incubated in 50mM Tris-HCl buffer, pH 7.8, containing 1mM dithiothreitol, 2mM EDTA, 10 μ M [α - ^{32}P]GTP, and 1 μ M H-rab protein. GTPase activity is initiated by adding MgCl_2 to a final concentration of 10 mM. Samples are removed at various time points, mixed with an equal volume of ice-cold 0.5mM EDTA, and frozen. Aliquots are spotted onto polyethyleneimine-cellulose thin layer chromatography plates, which are developed in 1M LiCl, dried, and autoradiographed. The signal detected is proportional to GTPAP activity.

Alternatively, GTPAP activity may be demonstrated as the ability to interact with its associated G α or LMW GTPase in an in vitro binding assay. The candidate GTPases are expressed as fusion proteins with glutathione S-transferase (GST), and purified by affinity chromatography on glutathione-Sepharose. The GTPases are loaded with GDP by incubating 20 mM Tris buffer, pH 8.0, containing 100 mM NaCl, 2 mM EDTA, 5 mM MgCl_2 , 0.2 mM DTT, 100 μ M AMP-PNP and 10 μ M GDP at 30°C for 20 minutes. GTPAP is expressed as a FLAG fusion proteins in a baculovirus system. Extracts of these baculovirus cells containing GTPAP-FLAG fusion proteins are precleared with GST beads, then incubated with GST-GTPase fusion proteins. The complexes formed are precipitated by glutathione-Sepharose and separated by SDS-polyacrylamide gel electrophoresis. The separated proteins are blotted onto nitrocellulose membranes and probed with commercially available anti-

FLAG antibodies. GTPAP activity is proportional to the amount of GTPAP-FLAG fusion protein detected in the complex.

XI. Functional Assays

GTPAP function is assessed by expressing the sequences encoding GTPAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GTPAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GTPAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding GTPAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of GTPAP Specific Antibodies

GTPAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GTPAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GTPAP activity by, for example, binding the peptide or GTPAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring GTPAP Using Specific Antibodies

Naturally occurring or recombinant GTPAP is substantially purified by immunoaffinity chromatography using antibodies specific for GTPAP. An immunoaffinity column is constructed by covalently coupling anti-GTPAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GTPAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GTPAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GTPAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GTPAP is collected.

XIV. Identification of Molecules Which Interact with GTPAP

GTPAP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GTPAP, washed, and any wells with labeled GTPAP complex are assayed. Data obtained using different concentrations of GTPAP are used to calculate values for the number, affinity, and association of

GTPAP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.

Although the invention has been described in connection with certain embodiments, it should be

5 understood that the invention as claimed should not be unduly limited to such specific embodiments.

Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

| Polypeptide SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|---------------------------|--------------------------|-------------|-----------|---|
| 1 | 30 | 708398 | SYNORAT04 | 568987X31 (MMLR3DT01), 708398H1, 708398X11, 708398X15, 708398X16, 708398X17, and 708398X21 (SYNORAT04), 2170523F6 (ENDCNOT03), 3374750H1 (CONNTUT05) |
| 2 | 31 | 1259937 | MENITUT03 | 913652R6 (STOMNOT02), 1259937F6 and 1259937H1 (MENITUT03), 1476721F1 (CORPNOT02), 1729248F6 (BRSTTUT08), 2191963H1 (THYRTUT03), 3129757F6 (LUNGUTUT12), 3268746X15F1 (BRAINOT20), 3428891F6 (SKINNOT04) |
| 3 | 32 | 1452285 | PENITUT01 | 1452285F6 and 1452285H1 (PENITUT01), 2605011H1 (LUNGUTUT07), 3505135H1 (ADRENOT11) |
| 4 | 33 | 1812894 | PROSTUT12 | 1812894H1, 1812894X12 and 1809113T6 (PROSTUT12), 1904479F6 (OVARNOT07), 2232535X15F1 and 2232535X18F1 (PROSNOT16), 2267486X16C1 (UTRSNOT02), 2508562F6 (CONUTUT01) |
| 5 | 34 | 3074884 | BONEUNT01 | 225362F1 (PANCNOT01), 900707R1 (BRSTTUT03), 1339234F6 (COLNTUT03), 1759046R6 (PITUNOT03), 3074884H1 (BONEUNT01), SBDA02767F1 |
| 6 | 35 | 3452277 | UTRSNON03 | 1684553F6 (PROSNOT15), 1951534H1 (PITUNOT01), 3452277H1 (UTRSNON03), 4092781T6 (BSCNSZT01), SBFA01413F1, SBFA03044F1, SBFA01805F1 |
| 7 | 36 | 4203832 | BRAITUT29 | 723394F1 (SYNOOAT01), 862290R1, and 862290T1 (BRAITUT03), 1560918F1 (SPLNNOT04), 3509241H1 (CONCNOT01), 4203832H1 (BRAITUT29) |
| 8 | 37 | 104368 | BMARNOT02 | 104368H1 (BMARNOT02), SAEA03574F1, SAEA01063F1, SAEA00392F1, SAEA02287F1 |
| 9 | 38 | 1441680 | THYRNOT03 | 1441680F6, 1441680H1, and 1441680T6 (THYRNOT03), 1904222F6 (OVARNOT07), 2477983F6 (SMCANOT01) |
| 10 | 39 | 1494955 | PROSNON01 | 965986R1 (BRSTNOT05), 1429037F1 and 1429037T1 (SINTBST01), 1453487F6 (PENITUT01), 1486114H1 (CORPNOT02), 1494955H1 (PROSNON01), 1995426R6 (BRSTTUT03), 2112074X18F1 and 2112348R6 (BRAITUT03) |
| 11 | 40 | 1508161 | LUNGNOT14 | 1508161F6 and 1508161H1 (LUNGNOT14), 3334303H1 (BRAIFET01), 4755656H1 (BRAHNOT01) |
| 12 | 41 | 1811877 | PROSTUT12 | 493795H1 (HNT2NOT01), 1573136H1 (LNODNOT03), 1811877F6 and 1811877H1 (PROSTUT12), 1825223F6 (LSUBNOT03), 2454143H1 (ENDANOT01), 2651022H1 (BLADTUT08), 3487062H1 (EPIGNOT01), 4536531H1 (OVARNOT12), 4795253H1 (LIVRTUT09), 4854087H1 (TESTNOT10), 4906149H2 (TLYMNOT08), 5196386H1 (LUNLTUT04) |

Table 1 (cont.)

| Polypeptide SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|---------------------------|--------------------------|-------------|-----------|--|
| 13 | 42 | 1848674 | LUNGFET03 | 1574127F6, 3857867X306F1, and 3857867X313F1 (LNODNOT03), 1848674H1 (LUNGFET03), 1877170F6 (LEUKNOT03), 2695307H1 (UTRSNOT12), 4148654H1 (SINITUT04), 4984182H1 (HELATXT05), 5288671H1 (LIVRTUS02) |
| 14 | 43 | 2012970 | TESTNOT03 | 2012970H1, 2012970R6, 2012970X11F (TESTNOT03) |
| 15 | 44 | 2254315 | OVARTUT01 | 022341F1 (ADENINB01), 198476R6 (KIDNNOT02), 2254315H1 (OVARTUT01), 2370170F6 (ADRENOT07), 2451278F6 (ENDANOT01) |
| 16 | 45 | 2415545 | HNT3AZT01 | 775722H1 (COLNNOT05), 870320R6 (LUNGAST01), 889023R1 (STOMTUT01), 895724R1 (BRSTNOT05), 1398541F1 (BRAITUT08), 1662585F6 (BRSTNOT09), 2415545H1 (HNT3AZT01), 2985066H1 (CARGDIT01), 3462702H1 (293TF2T01) |
| 17 | 46 | 2707969 | PONSAZT01 | 282552R1, 282552X23, and 282552X7 (CARDNOT01), 889783R1 (STOMTUT01), 1995451R6 (BRSTTUT03), 2707969H1 (PONSAZT01), SAAC00359R1.comp, SAAB00136R1, SAAC00330R1 |
| 18 | 47 | 2817769 | BRSTNOT14 | 041660R1 (TBLYNOT01), 077378R1 (SYNORAB01), 740028R1 (PANCNOT04), 1593201F6 (BRAINOT14), 1924025R6 (BRSTTUT01), 2817769H1 (BRSTNOT14) |
| 19 | 48 | 2917557 | THYMFET03 | 473002F1 and 473002R1 (MMLR1DT01), 690999R6 (LUNGUT02), 997483R1 (KIDNTUT01), 1430662F6 (SINTBST01), 1514017F1 (PANCUTUT01), 1740475R6 (HIPONON01), 2109547H1 (BRAITUT03), 2917557H1 (THYMFET03), 4309528H1 (BRAUNOT01), 4990135H1 (LIVRTUT11) |
| 20 | 49 | 3421335 | UCMCNOT04 | 777588R6 and 777588T6 (COLNNOT05), 3421335H1 (UCMCNOT04) |
| 21 | 50 | 605761 | BRSTTUT01 | 605761F1, 605761H1, and 605761R6 (BRSTTUT01), 1271131X15 (TESTTUT02), 1516985F1 (PANCUTUT01), 1524935H1 (UCMCL5T01), 2234846F6 (PANCUTUT02) |
| 22 | 51 | 483862 | HNT2RAT01 | 483862H1 and 483862R1 (HNT2RAT01), 1750781X305F1, 1750781X307D2 (LIVRTUT01) |
| 23 | 52 | 1256777 | MENITUT03 | 264041R6 (HNT2AGT01), 826449R1 (PROSNOT06), 1256777H1 (MENITUT03), 2276061R6 (PROSNON01), 4614049H1 (BRAHNOT01) |
| 24 | 53 | 2198779 | SPLNFET02 | 1557708F6 (BLADTUT04), 1922490R6 (BRSTTUT01), 2198779H1 (SPLNFET02), 2541193F7 (BONRTUT01), 3039254F6 (BRSTNOT16), 3057079H1 (LNODNOT08), 3105017H1 (COLNUCT03), 4239592H1 (SYNWDIT01), 5064513H1 (ARTFTDT01) |

Table 1 (cont.)

| Polypeptide SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|---------------------------|--------------------------|-------------|-----------|---|
| 25 | 54 | 2226116 | SEMVNOT01 | 1662607F6 (BRSTNOT09), 1662607T6 (BRSTNOT09), 2226116F6 (SEMVNOT01), 2226116H1 (SEMVNOT01), 2930011F6 (TLYMNOT04), 3015747T6 (MUSCNOT07), 4087670H1 (LIVRNOT06) |
| 26 | 55 | 2504472 | CONUTUT01 | 420365F1 (BRSTNOT01), 762246R1 (BRAITUT02), 907754R2 (COLNNOT09), 1007508H1 (HEALDIT02), 1302342F6 (PLACNOT02), 1913887H1 (PROSTUT04), 2023822F6 (CONNNOT01), 2023822X11R1 (CONNNOT01), 2504472H1 (CONUTUT01), 2951618F6 (KIDNFET01) |
| 27 | 56 | 3029920 | HEARFET02 | 354846T6 (RATRNOT01), 418533R6 (BRSTNOT01), 935073R1 (CERVNOT01), 1340722F1 (COLNUTUT03), 1416203T6 (BRAINOT12), 1524567F1 (UCMCL5T01), 1773043H1 (MENTUNON3), 2590310H2 (LUNGNOT22), 3029920H1 (HEARFET02), 4873053H1 (COLDNOT01), 5687696H1 (BRAIUNT01) |
| 28 | 57 | 3332415 | BRAIFET01 | 118166R1 (MUSCNOT01), 1257348H1 (MENITUT03), 1288237T6 (BRAINOT11), 1335936F6 (COLNNOT13), 1452268H1 (PENITUT01), 1996016R6 (BRSTTUT03), 2116665R6 (BRSTTUT02), 2206894F6 (SINTFET03), 2540063H1 (BONRTUT01), 2808268H1 (BLADTUT08), 3086221H1 (HEAONOT03), 3127508H1 (LUNGTUT12), 3295812H1 (TLYJINT01), 3332415H1 (BRAIFET01), 3604705H1 (LUNGNOT30), 4821203H1 (PROSTUT17), 4970353H1 (KIDEUNC10), 5055775H1 (COLATMT01) |
| 29 | 58 | 4031536 | BRAINOT23 | 029167X3 (SPLNFET01), 350137R1 (LVENNOT01), 408825X1 (EOSTHET02), 689446X23 (LUNGTUT02), 1963062R6 (BRSTNOT04), 2288043R6 (BRAINON01), 4031536H1 (BRAINOT23) |

Table 2

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Motifs, and Domains | Homologous Sequences | Analytical Methods and Databases |
|---------------------------|---------------------------|---|-------------------------------------|--|---|---|
| 1 | 1002 | T30 S224 T405 S499 T533 S558 S701 T737 T845 S864 S6 T152 T268 T412 T442 T464 T514 T528 T693 S814 S815 S823 T880 Y117 Y842 | N446 | G524-T531: ATP/GTP- binding site motif | GTP-binding protein [Mus musculus] g53169 | BLAST MOTIFS |
| 2 | 338 | S21 S77 T86 S200 T246 T299 S77 S306 Y131 | N244 | | cAMP- regulated Guanine nucleotide exchange factor [Rattus norvegicus] g4079657 | BLAST |
| 3 | 211 | S159 S199 | N33 N74 | G16-T23: ATP/GTP- binding site motif | GTP-binding protein [Rattus norvegicus] g206543 | BLAST MOTIFS PFAM BLOCKS PRINTS |
| 4 | 516 | T14 S42 T237 S270 S347 S360 T371 T395 T433 S500 T3 S13 S96 T316 S430 | | | Fos-related antigen [Rattus norvegicus] g1016712 Rabaptin-4 [H. sapiens] g3832516 | BLAST MOTIFS |
| 5 | 445 | T44 T114 T219 T297 S314 S341 S356 T412 T24 S72 T91 T328 T388 T394 | | G230-T237: ATP/GTP- binding site motif | GTP-binding protein [H. sapiens] g2765411 | BLAST MOTIFS |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Motifs, and Domains | Homologous Sequences | Analytical Methods and Databases |
|---------------------------|---------------------------|--|-------------------------------------|--|---|--|
| 6 | 445 | S174 S202 S289 S29 S305 S323 T434 T11 T147 T197 T198 S270 S273 S371 S397 Y125 | N73 | | Regulator of G-protein signaling-9 [H. sapiens] g3284012 | BLAST |
| 7 | 281 | S182 S210 S254 S13 T56 S110 S182 S32 T46 S66 S177 | N130 N181 | G31-T38: ATP/GTP- binding site motif | Putative ras- like protein [H. sapiens] g4092830 | MOTIFS PRINTS BLAST PFAM |
| 8 | 301 | S92 T2 T3 Y15 S18 S19 S20 S25 S97 T120 S165 S296 T94 S116 T120 S284 | | E47-G66, S116-E178, Y188-G272: Phosducin signature | Phosducin- like protein [Rattus rattus] g1323727 | MOTIFS BLAST PRINTS |
| 9 | 485 | T6 Y57 S82 T91 S112 S187 T231 T257 S309 T6 T81 S132 S157 S210 S241 T462 | N460 | L49-S82: Beta G protein | Similar to WD domain Beta transducin- like protein [C. elegans] g5596646 | MOTIFS BLAST PRINTS |
| 10 | 447 | S420 S94 T107 S118 T167 T179 T308 S390 S39 S58 T78 T113 S129 T160 T167 Y174 T199 S216 S291 T302 T323 T359 T384 S423 T438 | N76 N92 N231 N289 N378 N421 | M294-T308: Beta transducin | WS beta- transducin repeat protein [Homo sapiens] g4704417 | MOTIFS BLAST |
| 11 | 199 | S90 T55 T140 S190 | | K6-E130: Ras Guanine exchange factor | Putative guanine nucleotide releasing factor [Drosophila affinis] g2981229 | MOTIFS BLAST PFAM |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Motifs, and Domains | Homologous Sequences | Analytical Methods and Databases |
|---------------------------|---------------------------|--|-------------------------------------|--|--|--|
| 12 | 694 | S57 S67 S99 T150 T346 S416 S467 S500 T522 T684 S99 T156 S209 S285 T331 T360 T388 T430 T477 T650 T688 | | L10-I24, M96-L110: Beta transducin | Transducin- like protein [H. sapiens] g414536 | MOTIFS BLAST |
| 13 | 654 | T10 S15 T49 S97 S102 S104 S112 S113 S377 S432 S638 T46 S54 S84 S97 T177 S217 T307 S401 S450 S504 T515 S546 T547 S561 Y618 | N353 N362 N502 | L197-F211: Beta transducin | Similar to the beta transducin family [C. elegans] g2315521 | MOTIFS BLAST |
| 14 | 180 | S14 | | G23-S30: ATP-GTP binding site | Rab7C (small GTP binding protein) [Lotus japonicus] g1370186 | MOTIFS BLAST |
| 15 | 374 | T100 T249 S260 T308 T328 S338 S351 S30 T73 T157 S237 T308 | N114 N189 N222 | G26-T33: ATP-GTP binding site | ATP(GTP) - binding protein [H. sapiens] g3646130 | MOTIFS BLAST |
| 16 | 649 | S67 T344 S366 S63 S68 S75 S122 S177 S265 T282 T332 S373 S380 S563 T569 S634 S20 T94 S128 S314 T382 T385 T458 T559 | | F307-S544: Probable rabGAP domain | Similar to probable rabGAP [C. elegans] g3925265 | MOTIFS BLAST PFAM |
| 17 | 698 | T244 S262 S17 T41 T42 T196 S206 S317 S479 S522 S556 T586 T680 T31 S95 T99 T140 T173 S257 T322 S374 T450 S568 T619 | N171 N194 N685 | | Small GTP- binding protein associated protein [Mus musculus] g725274 | MOTIFS BLAST |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Motifs, and Domains | Homologous Sequences | Analytical Methods and Databases |
|---------------------------|---------------------------|--|-------------------------------------|--|--|--|
| 18 | 396 | T325 S115 T133 S232 S275 T336 S22 T221 S232 T320 | N60 N230 N286 | G29-S36: ATP-GTP binding site | Putative GTP- binding protein [C. elegans] g3880615 | MOTIFS BLAST |
| 19 | 634 | T197 S3 S5 S9 T14 S132 T197 T285 T553 T40 T56 S160 T189 S261 S582 Y20 Y396 Y419 | | G52-T59: ATP-GTP binding site | Putative GTP- binding protein [H. sapiens] g3169010 | MOTIFS BLAST |
| 20 | 196 | T60 S73 S90 S99 S73 S193 | | G19-T26: ATP-GTP binding site | Kidney injury associated protein HW052 Acc No W86322 ADP- ribosylation factor-like protein 3 [Rattus norvegicus] g560006 | MOTIFS BLAST |
| 21 | 446 | T10 T24 T93 S122 T243 S263 S270 T305 S317 S325 T357 S372 T379 S100 S170 S223 T227 S285 T348 | N79 | L323-L337: Beta transducin | Putative WD40 repeat protein [A. thaliana] g4191784 | MOTIFS BLAST |
| 22 | 265 | T184 T76 T137 S139 T161 T174 T183 S213 | N159 | L141, L148, L155 L: zipper gene regulatory motif | TipD; similar to beta transducin family [D. discoideum] g2407788 | MOTIFS BLAST |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Motifs, and Domains | Homologous Sequences | Analytical Methods and Databases |
|---------------------------|---------------------------|---|-------------------------------------|---|--|---|
| 23 | 185 | T55 S111 S127 S148 S171 S14 S94 Y103 | | G10-T17: ATP/GTP binding site (P- loop) A4-S72: Ras domain | | MOTIFS PFAM PRINTS |
| 24 | 554 | S388 T488 S30 S75 T111 S149 S220 S237 T255 S305 S325 T339 T359 S363 S509 S172 T195 S211 T378 T438 T470 Y203 | N5 | N297-D336, P345- D383, G481-Q519: Beta-transducin WD40 repeats | WD-repeat protein [Arabidopsis thaliana] g3924603 | BLAST MOTIFS PFAM PRINTS |
| 25 | 434 | S164 S341 T347 S36 S68 S92 T286 S364 | N22 N383 | G259-S266: ATP/GTP binding site (P- loop): G113-R433: GTP1/OBG domain | Predicted GTP binding protein [C. elegans] g3878629 | BLAST MOTIFS PFAM BLOCKS PRINTS |
| 26 | 826 | S122 T243 T247 T427 S454 S519 T528 S623 S701 S715 S809 T58 S143 S266 T411 S505 S577 S603 T661 S735 T753 S791 T815 | N23 N264 N576 N600 N789 | R48-E91, L97-S143, F197 K237, V273- W319, W378-A416, W604 K642, A659- G697: Beta- transducin WD40 repeats | Predicted WD repeat protein [S. cerevesiae] P42935 | BLAST MOTIFS PFAM PRINTS |
| 27 | 618 | T414 S59 T105 S126 T139 T143 S196 T203 S311 S325 T370 T390 S477 T483 S541 T583 T94 S148 T247 Y160 Y383 Y456 | N118 N154 N346 | G11-T18, G425-S432: ATP/GTP binding site (P-loop) R6-K187: Ras domain | GTP-binding protein APD08 [H.sapiens] Accession W75771 | BLAST MOTIFS PFAM PRINTS |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Motifs, and Domains | Homologous Sequences | Analytical Methods and Databases |
|---------------------------|---------------------------|---|-------------------------------------|--|---|--|
| 28 | 596 | S17 S21 S50 S152 S153 T533 S539 T594 S36 S38 S80 T163 T169 S183 S211 T240 S306 T329 T417 S457 S508 T545 S45 T64 S88 T124 S139 S299 S451 S459 S528 S568 Y180 Y364 | | A178-L355: Rho- family guanine nucleotide exchange factor (RhoGEF) domain | Guanine nucleotide regulatory protein (NET1 homologue) [Mus musculus] g3834631 | BLAST MOTIFS PFAM BLOCKS |
| 29 | 589 | T108 S20 T90 S127 S176 S278 S467 T521 S522 T189 S254 T284 T292 T321 T324 T345 T364 T423 S444 T484 T527 | N572 | L252-S289, G293- N329, G333-D369, G373-D409, E413- D449, G453-D489, G493-D532: Beta- transducin WD40 repeats R160-K206: F-box domain | SEL-10 [C.elegans] g2677836 | BLAST MOTIFS PFAM PRINTS |

Table 3

| Nucleotide Seq ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|--------------------|---|--|---------|
| 30 | 628-711 | Reproductive (0.256) Nervous (0.154) Gastrointestinal (0.154) | Cell Proliferation (0.692) Inflammation (0.372) | PSPORT1 |
| 31 | 1094-1129 | Reproductive (0.268) Cardiovascular (0.146) Nervous (0.146) | Cell Proliferation (0.731) Inflammation (0.219) Neurological (0.049) | pINCY |
| 32 | 652-703 | Cardiovascular (0.375) Reproductive (0.375) Dermatologic (0.125) Endocrine (0.125) | Cell Proliferation (0.875) Trauma (0.125) | pINCY |
| 33 | 1224-1292 | Reproductive (0.412) Gastrointestinal (0.147) Hematopoietic/Immune (0.147) | Cell Proliferation (0.647) Inflammation (0.264) | pINCY |
| 34 | 16-65 | Nervous (0.211) Reproductive (0.197) Gastrointestinal (0.169) | Cell Proliferation (0.507) Inflammation (0.352) | pINCY |
| 35 | 947-1043 | Reproductive (0.444) Nervous (0.333) Gastrointestinal (0.111) Urologic (0.111) | Cell Proliferation (0.667) Inflammation (0.111) Neurological (0.111) | pINCY |
| 36 | 840-1001 | Nervous (0.340) Reproductive (0.208) Gastrointestinal (0.151) | Cell Proliferation (0.641) Inflammation (0.302) Neurological (0.038) | pINCY |

Table 3 (cont.)

| Nucleotide Seq ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|--------------------|--|--|-------------|
| 37 | 507-551 | Hematopoietic/Immune (0.269) Nervous (0.269) Reproductive (0.154) | Inflammation (0.423) Cell Proliferation (0.269) | PBLUESCRIPT |
| 38 | 218-262 | Cardiovascular (0.357) Nervous (0.214) Gastrointestinal (0.143) | Cell Proliferation (0.572) Inflammation (0.214) | pINCY |
| 39 | 164-208 | Nervous (0.280) Reproductive (0.260) Developmental (0.120) | Cell Proliferation (0.740) Inflammation (0.180) | PSPORT1 |
| 40 | 369-411 | Cardiovascular (0.250) Developmental (0.250) Gastrointestinal (0.250) | Cell Proliferation (0.500) Inflammation (0.250) | pINCY |
| 41 | 272-316 | Reproductive (0.392) Gastrointestinal (0.118) Hematopoietic/Immune (0.118) | Cell Proliferation (0.626) Inflammation (0.137) | pINCY |
| 42 | 664-708 | Nervous (0.211) Reproductive (0.211) Cardiovascular (0.158) | Cell Proliferation (0.614) Inflammation (0.281) | pINCY |
| 43 | 226-270 | Reproductive (1.000) | Inflammation (1.000) | PBLUESCRIPT |
| 44 | 11-55 | Reproductive (0.254) Gastrointestinal (0.206) Cardiovascular (0.159) | Cell Proliferation (0.698) Inflammation (0.206) | PSPORT1 |

Table 3 (cont.)

| Nucleotide Seq ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|--------------------|--|--|-------------|
| 45 | 637-681 | Reproductive (0.281) Nervous (0.188) Gastrointestinal (0.156) | Cell Proliferation (0.781) Inflammation (0.234) | pINCY |
| 46 | 1016-1060 | Nervous (0.330) Reproductive (0.183) Hematopoietic/Immune (0.122) | Cell Proliferation (0.582) Inflammation (0.235) | pINCY |
| 47 | 737-781 | Nervous (0.218) Reproductive (0.188) Gastrointestinal (0.158) | Cell Proliferation (0.655) Inflammation (0.211) | pINCY |
| 48 | 469-513 | Reproductive (0.222) Hematopoietic/Immune (0.160) Nervous (0.160) | Cell Proliferation (0.543) Inflammation (0.272) | pINCY |
| 49 | 226-270 | Gastrointestinal (0.333) Hematopoietic/Immune (0.333) Reproductive (0.333) | Inflammation (1.000) | pINCY |
| 50 | 456-500 | Reproductive (0.289) Gastrointestinal (0.133) Hematopoietic/Immune (0.133) | Cell Proliferation (0.778) Inflammation (0.156) | PSPORT1 |
| 51 | 252-296 | Nervous (0.500) Gastrointestinal (0.200) Cardiovascular (0.100) | Cell Proliferation (1.000) Inflammation (0.200) | PBLUESCRIPT |
| 52 | 60-104 | Nervous (0.326) Reproductive (0.326) Cardiovascular (0.152) | Cell proliferation (0.565) Inflammation (0.369) | pINCY |

Table 3 (cont.)

| Nucleotide Seq ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|----------------------|---|--|--------|
| 53 | 488-532 | Reproductive (0.232) Nervous (0.195) Hematopoietic/Immune (0.146) | Cell proliferation (0.622) Inflammation (0.427) | pINCY |
| 54 | 686-730 | Reproductive (0.250) Gastrointestinal (0.150) Hematopoietic/Immune (0.150) | Cell proliferation (0.700) Inflammation (0.400) | pINCY |
| 55 | 543-587 1299-1343 | Reproductive (0.282) Nervous (0.155) Gastrointestinal (0.146) | Cell proliferation (0.592) Inflammation (0.359) | pINCY |
| 56 | 345-389 792-836 | Nervous (0.268) Reproductive (0.169) Cardiovascular (0.113) Hematopoietic/Immune (0.113) | Cell proliferation (0.606) Inflammation (0.296) | pINCY |
| 57 | 163-207 | Reproductive (0.270) Gastrointestinal (0.189) Nervous (0.156) | Cell proliferation (0.705) Inflammation (0.254) | pINCY |
| 58 | 381-425 726-770 | Nervous (0.317) Reproductive (0.250) Gastrointestinal (0.117) | Cell proliferation (0.450) Inflammation (0.283) | pINCY |

Table 4

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|--|
| 30 | SYNORAT04 | This library was constructed using RNA isolated from the wrist synovial membrane tissue of a 62-year-old female with rheumatoid arthritis. |
| 31 | MENITUT03 | This library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer. |
| 32 | PENITUT01 | This library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease. |
| 33 | PROSTUT12 | This library was constructed using RNA isolated from prostate tumor tissue removed from a 65-year-old male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). |
| 34 | BONEUNT01 | This library was constructed using RNA isolated from Saos-2, a primary osteogenic sarcoma cell line (ATCC HTB-85) derived from an 11-year-old Caucasian female. |
| 35 | UTRSNON03 | This library was constructed from 6.4 million independent clones from a uterine library. RNA for these libraries was isolated from uterine myometrial tissue removed from a 41-year-old female during a vaginal hysterectomy with dilation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. The normalization and hybridization conditions were adapted from Soares et al. (Proc.Natl.Acad.Sci. USA (1994) 91:9928). |
| 36 | BRAITUT29 | This library was constructed using RNA isolated from brain tumor tissue removed from the parietal lobe of a 43-year-old female during excision of a cerebral meningeal lesion. Pathology indicated high grade glioma. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia. |
| 37 | BMARNOT02 | This library was constructed using RNA isolated from the bone marrow of 24 male and female Caucasian donors, 16 to 70 years old. (RNA came from Clontech.) |

Table 4 (cont.)

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|--|
| 38 | THYRNOT03 | This library was constructed using RNA isolated from thyroid tissue removed from the left thyroid of a 28-year-old Caucasian female during a complete thyroidectomy. Pathology indicated a small nodule of adenomatous hyperplasia present in the left thyroid. Pathology for the associated tumor tissue indicated dominant follicular adenoma, forming a well-encapsulated mass in the left thyroid. |
| 39 | PROSNON01 | This normalized library was constructed from 4.4 million independent clones from a prostate library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a self-inflicted gunshot wound. The normalization and hybridization conditions were adapted from Soares, M.B. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228-9232, using a longer (19 hour) reannealing hybridization period. |
| 40 | LUNGNOT14 | This library was constructed using RNA isolated from lung tissue removed from the left lower lobe of a 47-year-old Caucasian male during a segmental lung resection. Pathology for the associated tumor tissue indicated a grade 4 adenocarcinoma, and the parenchyma showed calcified granuloma. Patient history included benign hypertension and chronic obstructive pulmonary disease. Family history included type II diabetes and acute myocardial infarction. |
| 41 | PROSTUT12 | This library was constructed using RNA isolated from prostate tumor tissue removed from a 65-year-old Caucasian male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). |
| 42 | LUNGFET03 | This library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus who died at 20 weeks' gestation. |
| 43 | TESTNOT03 | This library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure. |
| 44 | OVARTUT01 | This library was constructed using RNA isolated from ovarian tumor tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology indicated grade 2 mucinous cystadenocarcinoma involving the entire left ovary. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer. |
| 45 | HNT3AZT01 | This library was constructed using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated for three days with 0.35 micromolar 5-aza-2'-deoxycytidine (AZ). |

Table 4 (cont.)

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|---|
| 46 | PONSAZT01 | This library was constructed using RNA isolated from diseased pons tissue from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease. |
| 47 | BRSTNOT14 | This library was constructed using RNA isolated from breast tissue obtained from a 62-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma, ductal type. Patient history included a benign colon neoplasm, hyperlipidemia, cardiac dysrhythmia, and obesity. Family history included atherosclerotic coronary artery disease, myocardial infarction, colon cancer, ovarian cancer, lung cancer, and cerebrovascular disease. |
| 48 | THYMFET03 | This library was constructed using RNA isolated from thymus tissue removed from a Caucasian male fetus. |
| 49 | UCMCNOT04 | This library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of multiple individuals of mixed age and sex. The cells were treated with G-CSF. |
| 50 | BRSTTUT01 | This library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. Family history included benign hypertension, atherosclerotic coronary artery disease, cerebrovascular disease, and depressive disorder. |
| 51 | HNT2RAT01 | This library was constructed at Stratagene (STR937231), using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated with retinoic acid for 24 hours. |
| 52 | MENITUT03 | This library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer. |
| 53 | SPLNFET02 | This library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation. |
| 54 | SEMVNOT01 | This library was constructed using RNA isolated from seminal vesicle tissue removed from a 58-year-old Caucasian male during radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 3+2) of the prostate. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included a malignant breast neoplasm. |

Table 4 (cont.)

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|---|
| 55 | CONUTUT01 | This library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites. |
| 56 | HEARFET02 | This library was constructed using RNA isolated from heart tissue removed from a Caucasian male fetus, who was stillborn at 23 weeks' gestation with a hypoplastic left heart. |
| 57 | BRAIFET01 | This library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who was stillborn at 23 weeks' gestation with a hypoplastic left heart. |
| 58 | BRAINOT23 | This library was constructed using RNA isolated from right temporal lobe tissue removed from a 45-year-old Black male during a brain lobectomy. Pathology for the associated tumor tissue indicated dysembryoplastic neuroepithelial tumor of the right temporal lobe. The right temporal region dura was consistent with calcifying pseudotumor of the neuraxis. The patient presented with convulsive intractable epilepsy, partial epilepsy, and memory disturbance. Patient history included obesity, meningitis, backache, unspecified sleep apnea, acute stress reaction, acquired knee deformity, and chronic sinusitis. Family history included obesity, benign hypertension, cirrhosis of the liver, alcohol abuse, hyperlipidemia, cerebrovascular disease, and type II diabetes. |

Table 5

| Program | Description | Reference | Parameter Threshold |
|-------------------|---|--|--|
| ABI FACTURA | A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| ABI/PARACEL FDF | A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA. | Mismatch <50% |
| ABI AutoAssembler | A program that assembles nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| BLAST | A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx. | Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402. | ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less |
| FASTA | A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch. | Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489. | ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity=95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater |
| BLIMPS | A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions. | Henikoff, S. and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:38-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424. | Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less |
| HMMER | An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM. | Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322. | Score=10-50 bits for PFAM hits, depending on individual protein families |

Table 5 (cont.)

| Program | Description | Reference | Parameter Threshold |
|-------------|---|--|--|
| ProfileScan | An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite. | Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221. | Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1. |
| Phred | A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability. | Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194. | |
| Phrap | A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences. | Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA. | Score= 120 or greater; Match length= 56 or greater |
| Consed | A graphical tool for viewing and editing Phrap assemblies | Gordon, D. et al. (1998) Genome Res. 8:195-202. | |
| SPScan | A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides. | Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439. | Score=3.5 or greater |
| Motifs | A program that searches amino acid sequences for patterns that matched those defined in Prosite. | Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI. | |

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.
2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof.
10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

a) culturing the host cell of claim 13 under conditions suitable for the

expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.

18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

20. A method for treating or preventing a disorder associated with increased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
 HILLMAN, Jennifer L.
 TANG, Y. Tom
 BANDMAN, Olga
 LAL, Preeti
 YUE, Henry
 LU, Dyung Aina M.
 BAUGHN, Mariah R.
 YANG, Junming
 AZIMZAI, Yalda

<120> GTPASE ASSOCIATED PROTEINS

<130> PF-0629 PCT

<140> To Be Assigned
 <141> Herewith

<150> 60/109,592; 60/118,610; 60/127,990
 <151> 1998-11-23; 1999-02-04; 1999-04-06

<160> 58

<170> PERL Program

<210> 1
 <211> 1002
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 708398CD1

<400> 1
 Met Pro Ser Lys Phe Ser Cys Arg Gln Leu Arg Glu Ala Gly Gln
 1 5 10 15
 Cys Phe Glu Ser Phe Leu Val Val Arg Gly Leu Asp Met Glu Thr
 20 25 30
 Asp Arg Glu Arg Leu Arg Thr Ile Tyr Asn Arg Asp Phe Lys Ile
 35 40 45
 Ser Phe Gly Thr Pro Ala Pro Gly Phe Ser Ser Met Leu Tyr Gly
 50 55 60
 Met Lys Ile Ala Asn Leu Ala Tyr Val Thr Lys Thr Arg Val Arg
 65 70 75
 Phe Phe Arg Leu Asp Arg Trp Ala Asp Val Arg Phe Pro Glu Lys
 80 85 90
 Arg Arg Met Lys Leu Gly Ser Asp Ile Ser Lys His His Lys Ser
 95 100 105
 Leu Leu Ala Lys Ile Phe Tyr Asp Arg Ala Glu Tyr Leu His Gly
 110 115 120
 Lys His Gly Val Asp Val Glu Val Gln Gly Pro His Glu Ala Arg

| | | | |
|-----------------|---------------------|---------------------|-----|
| | 125 | 130 | 135 |
| Asp Gly Gln Leu | Leu Ile Arg Leu Asp | Leu Asn Arg Lys Glu | Val |
| | 140 | 145 | 150 |
| Leu Thr Leu Arg | Leu Arg Asn Gly Gly | Thr Gln Ser Val Thr | Leu |
| | 155 | 160 | 165 |
| Thr His Leu Phe | Pro Leu Cys Arg Thr | Pro Gln Phe Ala Phe | Tyr |
| | 170 | 175 | 180 |
| Asn Glu Asp Gln | Glu Leu Pro Cys Pro | Leu Gly Pro Gly Glu | Cys |
| | 185 | 190 | 195 |
| Tyr Glu Leu His | Val His Cys Lys Thr | Ser Phe Val Gly Tyr | Phe |
| | 200 | 205 | 210 |
| Pro Ala Thr Val | Leu Trp Glu Leu Leu | Gly Pro Gly Glu Ser | Gly |
| | 215 | 220 | 225 |
| Ser Glu Gly Ala | Gly Thr Phe Tyr Ile | Ala Arg Phe Leu Ala | Ala |
| | 230 | 235 | 240 |
| Val Ala His Ser | Pro Leu Ala Ala Gln | Leu Lys Pro Met Thr | Pro |
| | 245 | 250 | 255 |
| Phe Lys Arg Thr | Arg Ile Thr Gly Asn | Pro Val Val Thr Asn | Arg |
| | 260 | 265 | 270 |
| Ile Glu Glu Gly | Glu Arg Pro Asp Arg | Ala Lys Gly Tyr Asp | Leu |
| | 275 | 280 | 285 |
| Glu Leu Ser Met | Ala Leu Gly Thr Tyr | Tyr Pro Pro Pro Arg | Leu |
| | 290 | 295 | 300 |
| Arg Gln Leu Leu | Pro Met Leu Leu Gln | Gly Thr Ser Ile Phe | Thr |
| | 305 | 310 | 315 |
| Ala Pro Lys Glu | Ile Ala Glu Ile Lys | Ala Gln Leu Glu Thr | Ala |
| | 320 | 325 | 330 |
| Leu Lys Trp Arg | Asn Tyr Glu Val Lys | Leu Arg Leu Leu Leu | His |
| | 335 | 340 | 345 |
| Leu Glu Glu Leu | Gln Met Glu His Asp | Ile Arg His Tyr Asp | Leu |
| | 350 | 355 | 360 |
| Glu Ser Val Pro | Met Thr Trp Asp Pro | Val Asp Gln Asn Pro | Arg |
| | 365 | 370 | 375 |
| Leu Leu Thr Leu | Glu Val Pro Gly Val | Thr Glu Ser Arg Pro | Ser |
| | 380 | 385 | 390 |
| Val Leu Arg Gly | Asp His Leu Phe Ala | Leu Leu Ser Ser Glu | Thr |
| | 395 | 400 | 405 |
| His Gln Glu Asp | Pro Ile Thr Tyr Lys | Gly Phe Val His Lys | Val |
| | 410 | 415 | 420 |
| Glu Leu Asp Arg | Val Lys Leu Ser Phe | Ser Met Ser Leu Leu | Ser |
| | 425 | 430 | 435 |
| Arg Phe Val Asp | Gly Leu Thr Phe Lys | Val Asn Phe Thr Phe | Asn |
| | 440 | 445 | 450 |
| Arg Gln Pro Leu | Arg Val Gln His Arg | Ala Leu Glu Leu Thr | Gly |
| | 455 | 460 | 465 |
| Arg Trp Leu Leu | Trp Pro Met Leu Phe | Pro Val Ala Pro Arg | Asp |
| | 470 | 475 | 480 |
| Val Pro Leu Leu | Pro Ser Asp Val Lys | Leu Lys Leu Tyr Asp | Arg |
| | 485 | 490 | 495 |
| Ser Leu Glu Ser | Asn Pro Glu Gln Leu | Gln Ala Met Arg His | Ile |
| | 500 | 505 | 510 |
| Val Thr Gly Thr | Thr Arg Pro Ala Pro | Tyr Ile Ile Phe Gly | Pro |
| | 515 | 520 | 525 |
| Pro Gly Thr Gly | Lys Thr Val Thr Leu | Val Glu Ala Ile Lys | Gln |
| | 530 | 535 | 540 |

3/65

| | | | | | |
|---------------------|---|--|------|--|-----|
| | 950 | | 955 | | 960 |
| Leu Leu Gln Gly | Leu Ser Lys Leu Ser Pro Ser Thr Ser Gly Pro | | | | |
| | 965 | | 970 | | 975 |
| His Ser His Asp Tyr | Leu Pro Gln Glu Arg Glu Gly Glu Gly Gly | | | | |
| | 980 | | 985 | | 990 |
| Leu Ser Leu Gln Val | Glu Pro Glu Trp Arg Asn Glu | | | | |
| | 995 | | 1000 | | |

<210> 2

<211> 338

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1259937CD1

<400> 2

| | | |
|---------------------|---|---------|
| Met Ala Ala Leu Ala | Gln Glu Asp Gly Trp Thr Lys Gly Gln Val | |
| 1 | 5 | 10 15 |
| Leu Val Lys Val Asn | Ser Ala Gly Asp Ala Ile Gly Leu Gln Pro | |
| | 20 | 25 30 |
| Asp Ala Arg Gly Val | Ala Thr Ser Leu Gly Leu Asn Glu Arg Leu | |
| | 35 | 40 45 |
| Phe Val Val Asn Pro | Gln Glu Val His Glu Leu Ile Pro His Pro | |
| | 50 | 55 60 |
| Asp Gln Leu Gly Pro | Thr Val Gly Ser Ala Glu Gly Leu Asp Leu | |
| | 65 | 70 75 |
| Val Ser Ala Lys Asp | Leu Ala Gly Gln Leu Thr Asp His Asp Trp | |
| | 80 | 85 90 |
| Ser Leu Phe Asn Ser | Ile His Gln Val Glu Leu Ile His Tyr Val | |
| | 95 | 100 105 |
| Leu Gly Pro Gln His | Leu Arg Asp Val Thr Thr Ala Asn Leu Glu | |
| | 110 | 115 120 |
| Arg Phe Met Arg Arg | Phe Asn Glu Leu Gln Tyr Trp Val Ala Thr | |
| | 125 | 130 135 |
| Glu Leu Cys Leu Cys | Pro Val Pro Gly Pro Arg Ala Gln Leu Leu | |
| | 140 | 145 150 |
| Arg Lys Phe Ile Lys | Leu Ala Ala His Leu Lys Glu Gln Lys Asn | |
| | 155 | 160 165 |
| Leu Asn Ser Phe Phe | Ala Val Met Phe Gly Leu Ser Asn Ser Ala | |
| | 170 | 175 180 |
| Ile Ser Arg Leu Ala | His Thr Trp Glu Arg Leu Pro His Lys Val | |
| | 185 | 190 195 |
| Arg Lys Leu Tyr Ser | Ala Leu Glu Arg Leu Leu Asp Pro Ser Trp | |
| | 200 | 205 210 |
| Asn His Arg Val Tyr | Arg Leu Ala Leu Ala Lys Leu Ser Pro Pro | |
| | 215 | 220 225 |
| Val Ile Pro Phe Met | Pro Leu Leu Leu Lys Asp Met Thr Phe Ile | |
| | 230 | 235 240 |
| His Glu Gly Asn His | Thr Leu Val Glu Asn Leu Ile Asn Phe Glu | |
| | 245 | 250 255 |
| Lys Met Arg Met Met | Ala Arg Ala Ala Arg Met Leu His His Cys | |
| | 260 | 265 270 |

```

Arg Ser His Asn Pro Val Pro Leu Ser Pro Leu Arg Ser Arg Val
      275      280      285
Ser His Leu His Glu Asp Ser Gln Val Ala Arg Ile Ser Thr Cys
      290      295      300
Ser Glu Gln Ser Leu Ser Thr Arg Ser Pro Ala Ser Thr Trp Ala
      305      310      315
Tyr Val Gln Gln Leu Lys Val Ile Asp Asn Gln Arg Glu Leu Ser
      320      325      330
Arg Leu Ser Arg Glu Leu Glu Pro
      335

```

```

<210> 3
<211> 211
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1452285CD1

```

```

<400> 3
Met Gln Ala Pro His Lys Glu His Leu Tyr Lys Leu Leu Val Ile
  1      5      10      15
Gly Asp Leu Gly Val Gly Lys Thr Ser Ile Ile Lys Arg Tyr Val
      20      25      30
His Gln Asn Phe Ser Ser His Tyr Arg Ala Thr Ile Gly Val Asp
      35      40      45
Phe Ala Leu Lys Val Leu His Trp Asp Pro Glu Thr Val Val Arg
      50      55      60
Leu Gln Leu Trp Asp Ile Ala Gly Gln Glu Arg Phe Gly Asn Met
      65      70      75
Thr Arg Val Tyr Tyr Arg Glu Ala Met Gly Ala Phe Ile Val Phe
      80      85      90
Asp Val Thr Arg Pro Ala Thr Phe Glu Ala Val Ala Lys Trp Lys
      95      100      105
Asn Asp Leu Asp Ser Lys Leu Ser Leu Pro Asn Gly Lys Pro Val
      110      115      120
Ser Val Val Leu Leu Ala Asn Lys Cys Asp Gln Gly Lys Asp Val
      125      130      135
Leu Met Asn Asn Gly Leu Lys Met Asp Gln Phe Cys Lys Glu His
      140      145      150
Gly Phe Val Gly Trp Phe Glu Thr Ser Ala Lys Glu Asn Ile Asn
      155      160      165
Ile Asp Glu Ala Ser Arg Cys Leu Val Lys His Ile Leu Ala Asn
      170      175      180
Glu Cys Asp Leu Met Glu Ser Ile Glu Pro Asp Val Val Lys Pro
      185      190      195
His Leu Thr Ser Thr Lys Val Ala Ser Cys Ser Gly Cys Ala Lys
      200      205      210
Ser

```

```

<210> 4
<211> 516

```


<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1812894CD1

<400> 4

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Met | Glu | Thr | Met | Lys | Ala | Val | Ala | Glu | Val | Ser | Glu | Ser | Thr | Lys | 1 | 5 | 10 | 15 |
| Ala | Glu | Ala | Val | Ala | Ala | Val | Gln | Arg | Gln | Cys | Gln | Glu | Glu | Val | 20 | 25 | 30 | |
| Ala | Ser | Leu | Gln | Ala | Ile | Leu | Lys | Asp | Ser | Ile | Ser | Ser | Tyr | Glu | 35 | 40 | 45 | |
| Ala | Gln | Ile | Thr | Ala | Leu | Lys | Gln | Glu | Arg | Gln | Gln | Gln | Gln | Gln | 50 | 55 | 60 | |
| Asp | Cys | Glu | Glu | Lys | Glu | Arg | Glu | Leu | Gly | Arg | Leu | Lys | Gln | Leu | 65 | 70 | 75 | |
| Leu | Ser | Arg | Ala | Tyr | Pro | Leu | Asp | Ser | Leu | Glu | Lys | Gln | Met | Glu | 80 | 85 | 90 | |
| Lys | Ala | His | Glu | Asp | Ser | Glu | Lys | Leu | Arg | Glu | Ile | Val | Leu | Pro | 95 | 100 | 105 | |
| Met | Glu | Lys | Glu | Ile | Glu | Glu | Leu | Lys | Ala | Lys | Leu | Leu | Arg | Ala | 110 | 115 | 120 | |
| Glu | Glu | Leu | Ile | Gln | Glu | Ile | Gln | Arg | Arg | Pro | Arg | His | Ala | Pro | 125 | 130 | 135 | |
| Ser | Leu | His | Gly | Ser | Thr | Glu | Leu | Leu | Pro | Leu | Ser | Arg | Asp | Pro | 140 | 145 | 150 | |
| Ser | Pro | Pro | Leu | Glu | Pro | Leu | Glu | Glu | Leu | Ser | Gly | Asp | Gly | Gly | 155 | 160 | 165 | |
| Pro | Ala | Ala | Glu | Ala | Phe | Ala | His | Asn | Cys | Asp | Asp | Ser | Ala | Ser | 170 | 175 | 180 | |
| Ile | Ser | Ser | Phe | Ser | Leu | Gly | Gly | Gly | Val | Gly | Ser | Ser | Ser | Ser | 185 | 190 | 195 | |
| Leu | Pro | Gln | Ser | Arg | Gln | Gly | Leu | Ser | Pro | Glu | Gln | Glu | Glu | Thr | 200 | 205 | 210 | |
| Ala | Ser | Leu | Val | Ser | Thr | Gly | Thr | Leu | Val | Pro | Glu | Gly | Ile | Tyr | 215 | 220 | 225 | |
| Leu | Pro | Pro | Pro | Gly | Tyr | Gln | Leu | Val | Pro | Asp | Thr | Gln | Trp | Glu | 230 | 235 | 240 | |
| Gln | Leu | Gln | Thr | Glu | Gly | Arg | Gln | Leu | Gln | Lys | Asp | Leu | Glu | Ser | 245 | 250 | 255 | |
| Val | Ser | Arg | Glu | Arg | Asp | Glu | Leu | Gln | Glu | Gly | Leu | Arg | Arg | Ser | 260 | 265 | 270 | |
| Asn | Glu | Asp | Cys | Ala | Lys | Gln | Met | Gln | Val | Leu | Leu | Ala | Gln | Val | 275 | 280 | 285 | |
| Gln | Asn | Ser | Glu | Gln | Leu | Leu | Arg | Thr | Leu | Gln | Gly | Thr | Val | Ser | 290 | 295 | 300 | |
| Gln | Ala | Gln | Glu | Arg | Val | Gln | Leu | Gln | Met | Ala | Glu | Leu | Val | Thr | 305 | 310 | 315 | |
| Thr | His | Lys | Cys | Leu | His | His | Glu | Val | Lys | Arg | Leu | Asn | Glu | Glu | 320 | 325 | 330 | |
| Asn | Gln | Gly | Leu | Arg | Ala | Glu | Gln | Leu | Pro | Ser | Ser | Ala | Pro | Gln | 335 | 340 | 345 | |
| Gly | Ser | Gln | Gln | Glu | Gln | Gly | Glu | Glu | Glu | Ser | Leu | Pro | Ser | Ser | | | | |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Pro | Glu | Leu | Gln | Gln | Leu | Leu | Cys | Cys | Thr | Arg | Gln | Glu | Ala | 350 | 355 | 360 |
| Arg | Ala | Arg | Leu | Gln | Ala | Gln | Glu | His | Gly | Ala | Glu | Arg | Leu | Arg | 365 | 370 | 375 |
| Ile | Glu | Ile | Val | Thr | Leu | Arg | Glu | Ala | Leu | Glu | Glu | Glu | Thr | Val | 380 | 385 | 390 |
| Ala | Arg | Ala | Ser | Leu | Glu | Gly | Gln | Leu | Arg | Val | Gln | Arg | Glu | Glu | 395 | 400 | 405 |
| Thr | Glu | Val | Leu | Glu | Ala | Ser | Leu | Cys | Ser | Leu | Arg | Thr | Glu | Met | 410 | 415 | 420 |
| Glu | Arg | Val | Gln | Gln | Glu | Gln | Ser | Lys | Ala | Gln | Leu | Pro | Asp | Leu | 425 | 430 | 435 |
| Leu | Ser | Glu | Gln | Arg | Ala | Lys | Val | Leu | Arg | Leu | Gln | Ala | Glu | Leu | 440 | 445 | 450 |
| Glu | Thr | Ser | Glu | Gln | Val | Gln | Arg | Asp | Phe | Val | Arg | Leu | Ser | Gln | 455 | 460 | 465 |
| Ala | Leu | Gln | Val | Arg | Leu | Glu | Arg | Ile | Arg | Gln | Ala | Glu | Thr | Leu | 470 | 475 | 480 |
| Glu | Gln | Val | Arg | Ser | Ile | Met | Asp | Glu | Ala | Pro | Leu | Thr | Asp | Val | 485 | 490 | 495 |
| Arg | Asp | Ile | Lys | Asp | Thr | | | | | | | | | | 500 | 505 | 510 |
| | | | | | | | | | | | | | | | 515 | | |

<210> 5
 <211> 445
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3074884CD1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---------|
| Met | Pro | Glu | Asp | Ala | Asp | Glu | Asn | Ala | Glu | Glu | Glu | Leu | Leu | Arg | <400> 5 |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Gly | Glu | Pro | Leu | Leu | Pro | Ala | Gly | Thr | Gln | Arg | Val | Cys | Leu | Val | |
| | | | | 20 | | | | | 25 | | | | | 30 | |
| His | Pro | Asp | Val | Lys | Trp | Gly | Pro | Gly | Lys | Ser | Gln | Met | Thr | Arg | |
| | | | | 35 | | | | | 40 | | | | | 45 | |
| Ala | Glu | Trp | Gln | Val | Ala | Glu | Ala | Thr | Ala | Leu | Val | His | Thr | Leu | |
| | | | | 50 | | | | | 55 | | | | | 60 | |
| Asp | Gly | Trp | Ser | Val | Val | Gln | Thr | Met | Val | Val | Ser | Thr | Lys | Thr | |
| | | | | 65 | | | | | 70 | | | | | 75 | |
| Pro | Asp | Arg | Lys | Leu | Ile | Phe | Gly | Lys | Gly | Asn | Phe | Glu | His | Leu | |
| | | | | 80 | | | | | 85 | | | | | 90 | |
| Thr | Glu | Lys | Ile | Arg | Gly | Ser | Pro | Asp | Val | Thr | Cys | Val | Phe | Leu | |
| | | | | 95 | | | | | 100 | | | | | 105 | |
| Asn | Val | Glu | Arg | Met | Ala | Ala | Pro | Thr | Lys | Lys | Glu | Leu | Glu | Ala | |
| | | | | 110 | | | | | 115 | | | | | 120 | |
| Ala | Trp | Gly | Val | Glu | Val | Phe | Asp | Arg | Phe | Thr | Val | Val | Leu | His | |
| | | | | 125 | | | | | 130 | | | | | 135 | |
| Ile | Phe | Arg | Cys | Asn | Ala | Arg | Thr | Lys | Glu | Ala | Arg | Leu | Gln | Val | |
| | | | | 140 | | | | | 145 | | | | | 150 | |

```

Ala Leu Ala Glu Met Pro Leu His Arg Ser Asn Leu Lys Arg Asp
      155                      160                      165
Val Ala His Leu Tyr Arg Gly Val Gly Ser Arg Tyr Ile Met Gly
      170                      175                      180
Ser Gly Glu Ser Phe Met Gln Leu Gln Gln Arg Leu Leu Arg Glu
      185                      190                      195
Lys Glu Ala Lys Ile Arg Lys Ala Leu Asp Arg Leu Arg Lys Lys
      200                      205                      210
Arg His Leu Leu Arg Arg Gln Arg Thr Arg Arg Glu Phe Pro Val
      215                      220                      225
Ile Ser Val Val Gly Tyr Thr Asn Cys Gly Lys Thr Thr Leu Ile
      230                      235                      240
Lys Ala Leu Thr Gly Asp Ala Ala Ile Gln Pro Arg Asp Gln Leu
      245                      250                      255
Phe Ala Thr Leu Asp Val Thr Ala His Ala Gly Thr Leu Pro Ser
      260                      265                      270
Arg Met Thr Val Leu Tyr Val Asp Thr Ile Gly Phe Leu Ser Gln
      275                      280                      285
Leu Pro His Gly Leu Ile Glu Ser Phe Ser Ala Thr Leu Glu Asp
      290                      295                      300
Val Ala His Ser Asp Leu Ile Leu His Val Arg Asp Val Ser His
      305                      310                      315
Pro Glu Ala Glu Leu Gln Lys Cys Ser Val Leu Ser Thr Leu Arg
      320                      325                      330
Gly Leu Gln Leu Pro Ala Pro Leu Leu Asp Ser Met Val Glu Val
      335                      340                      345
His Asn Lys Val Asp Leu Val Pro Gly Tyr Ser Pro Thr Glu Pro
      350                      355                      360
Asn Val Val Pro Val Ser Ala Leu Arg Gly His Gly Leu Gln Glu
      365                      370                      375
Leu Lys Ala Glu Leu Asp Ala Ala Val Leu Lys Ala Thr Gly Arg
      380                      385                      390
Gln Ile Leu Thr Leu Arg Val Arg Leu Ala Gly Ala Gln Leu Ser
      395                      400                      405
Trp Leu Tyr Lys Glu Ala Thr Val Gln Glu Val Asp Val Ile Pro
      410                      415                      420
Glu Asp Gly Ala Ala Asp Val Arg Val Ile Ile Ser Asn Ser Ala
      425                      430                      435
Tyr Gly Lys Phe Arg Lys Leu Phe Pro Gly
      440                      445

```

<210> 6

<211> 445

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3452277CD1

<400> 6

```

Met Tyr Tyr Gln Gln Ala Leu Met Arg Ser Thr Val Lys Ser Ser
  1              5              10              15
Val Ser Leu Gly Gly Ile Val Lys Tyr Ser Glu Gln Phe Ser Ser

```

| | | | | | |
|---|-----|--|-----|--|-----|
| | 20 | | 25 | | 30 |
| Asn Asp Ala Ile Met Ser Gly Cys Leu Pro Ser Asn Pro Trp Ile | | | | | |
| | 35 | | 40 | | 45 |
| Thr Asp Asp Thr Gln Phe Trp Asp Leu Asn Ala Lys Leu Val Glu | | | | | |
| | 50 | | 55 | | 60 |
| Ile Pro Thr Lys Met Arg Val Glu Arg Trp Ala Phe Asn Phe Ser | | | | | |
| | 65 | | 70 | | 75 |
| Glu Leu Ile Arg Asp Pro Lys Gly Arg Gln Ser Phe Gln Tyr Phe | | | | | |
| | 80 | | 85 | | 90 |
| Leu Lys Lys Glu Phe Ser Gly Glu Asn Leu Gly Phe Trp Glu Ala | | | | | |
| | 95 | | 100 | | 105 |
| Cys Glu Asp Leu Lys Tyr Gly Asp Gln Ser Lys Val Lys Glu Lys | | | | | |
| | 110 | | 115 | | 120 |
| Ala Glu Glu Ile Tyr Lys Leu Phe Leu Ala Pro Gly Ala Arg Arg | | | | | |
| | 125 | | 130 | | 135 |
| Trp Ile Asn Ile Asp Gly Lys Thr Met Asp Ile Thr Val Lys Gly | | | | | |
| | 140 | | 145 | | 150 |
| Leu Lys His Pro His Arg Tyr Val Leu Asp Ala Ala Gln Thr His | | | | | |
| | 155 | | 160 | | 165 |
| Ile Tyr Met Leu Met Lys Lys Asp Ser Tyr Ala Arg Tyr Leu Lys | | | | | |
| | 170 | | 175 | | 180 |
| Ser Pro Ile Tyr Lys Asp Met Leu Ala Lys Ala Ile Glu Pro Gln | | | | | |
| | 185 | | 190 | | 195 |
| Glu Thr Thr Lys Lys Ser Ser Thr Leu Pro Phe Met Arg Arg His | | | | | |
| | 200 | | 205 | | 210 |
| Leu Arg Ser Ser Pro Ser Pro Val Ile Leu Arg Gln Leu Glu Glu | | | | | |
| | 215 | | 220 | | 225 |
| Glu Ala Lys Ala Arg Glu Ala Ala Asn Thr Val Asp Ile Thr Gln | | | | | |
| | 230 | | 235 | | 240 |
| Pro Gly Gln His Met Ala Pro Ser Pro His Leu Thr Val Tyr Thr | | | | | |
| | 245 | | 250 | | 255 |
| Gly Thr Cys Met Pro Pro Ser Pro Ser Ser Pro Phe Ser Ser Ser | | | | | |
| | 260 | | 265 | | 270 |
| Cys Arg Ser Pro Arg Lys Pro Phe Ala Ser Pro Ser Arg Phe Ile | | | | | |
| | 275 | | 280 | | 285 |
| Arg Arg Pro Ser Thr Thr Ile Cys Pro Ser Pro Ile Arg Val Ala | | | | | |
| | 290 | | 295 | | 300 |
| Leu Glu Ser Ser Ser Gly Leu Glu Gln Lys Gly Glu Cys Ser Gly | | | | | |
| | 305 | | 310 | | 315 |
| Ser Met Ala Pro Arg Gly Pro Ser Val Thr Glu Ser Ser Glu Ala | | | | | |
| | 320 | | 325 | | 330 |
| Ser Leu Asp Thr Ser Trp Pro Arg Ser Arg Pro Arg Ala Pro Pro | | | | | |
| | 335 | | 340 | | 345 |
| Lys Ala Arg Met Ala Leu Ser Phe Ser Arg Phe Leu Arg Arg Gly | | | | | |
| | 350 | | 355 | | 360 |
| Cys Leu Ala Ser Pro Val Phe Ala Arg Leu Ser Pro Lys Cys Pro | | | | | |
| | 365 | | 370 | | 375 |
| Ala Val Ser His Gly Arg Val Gln Pro Leu Gly Asp Val Gly Gln | | | | | |
| | 380 | | 385 | | 390 |
| Gln Leu Pro Arg Leu Lys Ser Lys Arg Val Ala Asn Phe Phe Gln | | | | | |
| | 395 | | 400 | | 405 |
| Ile Lys Met Asp Val Pro Thr Gly Ser Gly Thr Cys Leu Met Asp | | | | | |
| | 410 | | 415 | | 420 |
| Ser Glu Asp Ala Gly Thr Gly Glu Ser Gly Asp Arg Ala Thr Glu | | | | | |
| | 425 | | 430 | | 435 |

Lys Glu Val Ile Cys Pro Trp Glu Ser Leu
440 445

<210> 7
<211> 281
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4203832CD1

<400> 7
Met Lys Leu Ala Ala Met Ile Lys Lys Met Cys Pro Ser Asp Ser
1 5 10 15
Glu Leu Ser Ile Pro Ala Lys Asn Cys Tyr Arg Met Val Ile Leu
20 25 30
Gly Ser Ser Lys Val Gly Lys Thr Ala Ile Val Ser Arg Phe Leu
35 40 45
Thr Gly Arg Phe Glu Asp Ala Tyr Thr Pro Thr Ile Glu Asp Phe
50 55 60
His Arg Lys Phe Tyr Ser Ile Arg Gly Glu Val Tyr Gln Leu Asp
65 70 75
Ile Leu Asp Thr Ser Gly Asn His Pro Phe Pro Ala Met Arg Cys
80 85 90
Leu Ser Ile Leu Thr Gly Asp Val Phe Ile Leu Val Phe Ser Leu
95 100 105
Asp Asn Arg Asp Ser Phe Glu Glu Val Gln Arg Leu Arg Gln Gln
110 115 120
Ile Leu Asp Thr Lys Ser Cys Leu Lys Asn Lys Thr Lys Glu Asn
125 130 135
Val Asp Val Pro Leu Val Ile Cys Gly Asn Lys Gly Asp Arg Asp
140 145 150
Phe Tyr Arg Glu Val Asp Gln Arg Glu Ile Glu Gln Leu Val Gly
155 160 165
Asp Asp Pro Gln Arg Cys Ala Tyr Phe Glu Ile Ser Ala Lys Lys
170 175 180
Asn Ser Ser Leu Asp Gln Met Phe Arg Ala Leu Phe Ala Met Ala
185 190 195
Lys Leu Pro Ser Glu Met Ser Pro Asp Leu His Arg Lys Val Ser
200 205 210
Val Gln Tyr Cys Asp Val Leu His Lys Lys Ala Leu Arg Asn Lys
215 220 225
Lys Leu Leu Arg Ala Gly Ser Gly Gly Gly Gly Gly Asp Pro Gly
230 235 240
Asp Ala Phe Gly Ile Val Ala Pro Phe Ala Arg Arg Pro Ser Val
245 250 255
His Ser Asp Leu Met Tyr Ile Arg Glu Lys Ala Ser Ala Gly Ser
260 265 270
Gln Ala Lys Asp Lys Glu Arg Cys Val Ile Ser
275 280

<210> 8
<211> 301
<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 104368CD1

<400> 8

```

Met Thr Thr Leu Asp Asp Lys Leu Leu Gly Glu Lys Leu Gln Tyr
  1          5          10          15
Tyr Tyr Ser Ser Ser Glu Asp Glu Asp Ser Asp His Glu Asp Lys
          20          25          30
Asp Arg Gly Arg Cys Ala Pro Ala Ser Ser Ser Val Pro Ala Glu
          35          40          45
Ala Glu Leu Ala Gly Glu Gly Ile Ser Val Asn Thr Gly Pro Lys
          50          55          60
Gly Val Ile Asn Asp Trp Arg Arg Phe Lys Gln Leu Glu Thr Glu
          65          70          75
Gln Arg Glu Glu Gln Cys Arg Glu Met Glu Arg Leu Ile Lys Lys
          80          85          90
Leu Ser Met Thr Cys Arg Ser His Leu Asp Glu Glu Glu Glu Gln
          95          100          105
Gln Lys Gln Lys Asp Leu Gln Glu Lys Ile Ser Gly Lys Met Thr
          110          115          120
Leu Lys Glu Phe Ala Ile Met Asn Glu Asp Gln Asp Asp Glu Glu
          125          130          135
Phe Leu Gln Gln Tyr Arg Lys Gln Arg Met Glu Glu Met Arg Gln
          140          145          150
Gln Leu His Lys Gly Pro Gln Phe Lys Gln Val Phe Glu Ile Ser
          155          160          165
Ser Gly Glu Gly Phe Leu Asp Met Ile Asp Lys Glu Gln Lys Ser
          170          175          180
Ile Val Ile Met Val His Ile Tyr Glu Asp Gly Ile Pro Gly Thr
          185          190          195
Glu Ala Met Asn Gly Cys Met Ile Cys Leu Ala Ala Glu Tyr Pro
          200          205          210
Ala Val Lys Phe Cys Lys Val Lys Ser Ser Val Ile Gly Ala Ser
          215          220          225
Ser Gln Phe Thr Arg Asn Ala Leu Pro Ala Leu Leu Ile Tyr Lys
          230          235          240
Gly Gly Glu Leu Ile Gly Asn Phe Val Arg Val Thr Asp Gln Leu
          245          250          255
Gly Asp Asp Phe Phe Ala Val Asp Leu Glu Ala Phe Leu Gln Glu
          260          265          270
Phe Gly Leu Leu Pro Glu Lys Glu Val Leu Val Leu Thr Ser Val
          275          280          285
Arg Asn Ser Ala Thr Cys His Ser Glu Asp Ser Asp Leu Glu Ile
          290          295          300
Asp

```

<210> 9

<211> 485

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1441680CD1

<400> 9

```

Met Arg Ala Val Leu Thr Trp Arg Asp Lys Ala Glu His Cys Ile
 1          5          10          15
Asn Asp Ile Ala Phe Lys Pro Asp Gly Thr Gln Leu Ile Leu Ala
 20          25          30
Ala Gly Ser Arg Leu Leu Val Tyr Asp Thr Ser Asp Gly Thr Leu
 35          40          45
Leu Gln Pro Leu Lys Gly His Lys Asp Thr Val Tyr Cys Val Ala
 50          55          60
Tyr Ala Lys Asp Gly Lys Arg Phe Ala Ser Gly Ser Ala Asp Lys
 65          70          75
Ser Val Ile Ile Trp Thr Ser Lys Leu Glu Gly Ile Leu Lys Tyr
 80          85          90
Thr His Asn Asp Ala Ile Gln Cys Val Ser Tyr Asn Pro Ile Thr
 95          100         105
His Gln Leu Ala Ser Cys Ser Ser Ser Asp Phe Gly Leu Trp Ser
 110         115         120
Pro Glu Gln Lys Ser Val Ser Lys His Lys Ser Ser Ser Lys Ile
 125         130         135
Ile Cys Cys Ser Trp Thr Asn Asp Gly Gln Tyr Leu Ala Leu Gly
 140         145         150
Met Phe Asn Gly Ile Ile Ser Ile Arg Asn Lys Asn Gly Glu Glu
 155         160         165
Lys Val Lys Ile Glu Arg Pro Gly Gly Ser Leu Ser Pro Ile Trp
 170         175         180
Ser Ile Cys Trp Asn Pro Ser Arg Glu Glu Arg Asn Asp Ile Leu
 185         190         195
Ala Val Ala Asp Trp Gly Gln Lys Val Ser Phe Tyr Gln Leu Ser
 200         205         210
Gly Lys Gln Ile Gly Lys Asp Arg Ala Leu Asn Phe Asp Pro Cys
 215         220         225
Cys Ile Ser Tyr Phe Thr Lys Gly Glu Tyr Ile Leu Leu Gly Gly
 230         235         240
Ser Asp Lys Gln Val Ser Leu Phe Thr Lys Asp Gly Val Arg Leu
 245         250         255
Gly Thr Val Gly Glu Gln Asn Ser Trp Val Trp Thr Cys Gln Ala
 260         265         270
Lys Pro Asp Ser Asn Tyr Val Val Val Gly Cys Gln Asp Gly Thr
 275         280         285
Ile Ser Phe Tyr Gln Leu Ile Phe Ser Thr Val His Gly Val Tyr
 290         295         300
Lys Asp Arg Tyr Ala Tyr Arg Asp Ser Met Thr Asp Val Ile Val
 305         310         315
Gln His Leu Ile Thr Glu Gln Lys Val Arg Ile Lys Cys Lys Glu
 320         325         330
Leu Val Lys Lys Ile Ala Ile Tyr Arg Asn Arg Leu Ala Ile Gln
 335         340         345
Leu Pro Glu Lys Ile Leu Ile Tyr Glu Leu Tyr Ser Glu Asp Leu
 350         355         360

```

```

Ser Asp Met His Tyr Arg Val Lys Glu Lys Ile Ile Lys Lys Phe
      365                      370                      375
Glu Cys Asn Leu Leu Val Val Cys Ala Asn His Ile Ile Leu Cys
      380                      385                      390
Gln Glu Lys Arg Leu Gln Cys Leu Ser Phe Ser Gly Val Lys Glu
      395                      400                      405
Arg Glu Trp Gln Met Glu Ser Leu Ile Arg Tyr Ile Lys Val Ile
      410                      415                      420
Gly Gly Pro Pro Gly Arg Glu Gly Leu Leu Val Gly Leu Lys Lys
      425                      430                      435
Met Tyr Leu Leu Val Tyr Ser Phe Ile Leu Ile Val Lys Asp Tyr
      440                      445                      450
Phe Ser Leu Ser Thr Asp Val Leu Gly Asn Leu Thr Trp Lys His
      455                      460                      465
Val Cys Lys Lys His Tyr Trp Val Phe His Leu Phe Ser Trp Tyr
      470                      475                      480
Tyr Ile Phe Val Gln
      485

```

<210> 10

<211> 447

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1494955CD1

<400> 10

```

Met Glu Leu Ser Gln Met Ser Glu Leu Met Gly Leu Ser Val Leu
  1          5          10          15
Leu Gly Leu Leu Ala Leu Met Ala Thr Ala Ala Val Ala Arg Gly
      20          25          30
Trp Leu Arg Ala Gly Glu Glu Arg Ser Gly Arg Pro Ala Cys Gln
      35          40          45
Lys Ala Asn Gly Phe Pro Pro Asp Lys Ser Ser Gly Ser Lys Lys
      50          55          60
Gln Lys Gln Tyr Gln Arg Ile Arg Lys Glu Lys Pro Gln Gln His
      65          70          75
Asn Phe Thr His Arg Leu Leu Ala Ala Ala Leu Lys Ser His Ser
      80          85          90
Gly Asn Ile Ser Cys Met Asp Phe Ser Ser Asn Gly Lys Tyr Leu
      95          100         105
Ala Thr Cys Ala Asp Asp Arg Thr Ile Arg Ile Trp Ser Thr Lys
      110         115         120
Asp Phe Leu Gln Arg Glu His Arg Ser Met Arg Ala Asn Val Glu
      125         130         135
Leu Asp His Ala Thr Leu Val Arg Phe Ser Pro Asp Cys Arg Ala
      140         145         150
Phe Ile Val Trp Leu Ala Asn Gly Asp Thr Leu Arg Val Phe Lys
      155         160         165
Met Thr Lys Arg Glu Asp Gly Gly Tyr Thr Phe Thr Ala Thr Pro
      170         175         180
Glu Asp Phe Pro Lys Lys His Lys Ala Pro Val Ile Asp Ile Gly

```


| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ala | Asn | Thr | Gly | Lys | Phe | Ile | Met | Thr | Ala | Ser | Ser | Asp | Thr | 185 | 190 | 195 |
| Thr | Val | Leu | Ile | Trp | Ser | Leu | Lys | Gly | Gln | Val | Leu | Ser | Thr | Ile | 200 | 205 | 210 |
| Asn | Thr | Asn | Gln | Met | Asn | Asn | Thr | His | Ala | Ala | Val | Ser | Pro | Cys | 215 | 220 | 225 |
| Gly | Arg | Phe | Val | Ala | Ser | Cys | Gly | Phe | Thr | Pro | Asp | Val | Lys | Val | 230 | 235 | 240 |
| Trp | Glu | Val | Cys | Phe | Gly | Lys | Lys | Gly | Glu | Phe | Gln | Glu | Val | Val | 245 | 250 | 255 |
| Arg | Ala | Phe | Glu | Leu | Lys | Gly | His | Ser | Ala | Ala | Val | His | Ser | Phe | 260 | 265 | 270 |
| Ala | Phe | Ser | Asn | Asp | Ser | Arg | Arg | Met | Ala | Ser | Val | Ser | Lys | Asp | 275 | 280 | 285 |
| Gly | Thr | Trp | Lys | Leu | Trp | Asp | Thr | Asp | Val | Glu | Tyr | Lys | Lys | Lys | 290 | 295 | 300 |
| Gln | Asp | Pro | Tyr | Leu | Leu | Lys | Thr | Gly | Arg | Phe | Glu | Glu | Ala | Ala | 305 | 310 | 315 |
| Gly | Ala | Ala | Pro | Cys | Arg | Leu | Ala | Leu | Ser | Pro | Asn | Ala | Gln | Val | 320 | 325 | 330 |
| Leu | Ala | Leu | Ala | Ser | Gly | Ser | Ser | Ile | His | Leu | Tyr | Asn | Thr | Arg | 335 | 340 | 345 |
| Arg | Gly | Glu | Lys | Glu | Glu | Cys | Phe | Glu | Arg | Val | His | Gly | Glu | Cys | 350 | 355 | 360 |
| Ile | Ala | Asn | Leu | Ser | Phe | Asp | Ile | Thr | Gly | Arg | Phe | Leu | Ala | Ser | 365 | 370 | 375 |
| Cys | Gly | Asp | Arg | Ala | Val | Arg | Leu | Phe | His | Asn | Thr | Pro | Gly | His | 380 | 385 | 390 |
| Arg | Ala | Met | Val | Glu | Glu | Met | Gln | Gly | His | Leu | Lys | Arg | Ala | Ser | 395 | 400 | 405 |
| Asn | Glu | Ser | Thr | Arg | Gln | Arg | Leu | Gln | Gln | Gln | Leu | Thr | Gln | Ala | 410 | 415 | 420 |
| Gln | Glu | Thr | Leu | Lys | Ser | Leu | Gly | Ala | Leu | Lys | Lys | | | | 425 | 430 | 435 |
| | | | | | | | | | | | | | | | 440 | 445 | |

<210> 11

<211> 199

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1508161CD1

<400> 11

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----|----|----|
| Met | Pro | Val | Lys | Lys | Lys | His | Arg | Ala | Arg | Met | Ile | Glu | Tyr | Phe | 1 | 5 | 10 | 15 |
| Ile | Asp | Val | Ala | Arg | Glu | Cys | Phe | Asn | Ile | Gly | Asn | Phe | Asn | Ser | 20 | 25 | 30 | 35 |
| Leu | Met | Ala | Ile | Ile | Ser | Gly | Met | Asn | Met | Ser | Pro | Val | Ser | Arg | 40 | 45 | 50 | 55 |
| Leu | Lys | Lys | Thr | Trp | Ala | Lys | Val | Lys | Thr | Ala | Lys | Phe | Asp | Ile | 60 | | | |

```

Leu Glu His Gln Met Asp Pro Ser Ser Asn Phe Tyr Asn Tyr Arg
      65              70              75
Thr Ala Leu Arg Gly Ala Ala Gln Arg Ser Leu Thr Ala His Ser
      80              85              90
Ser Arg Glu Lys Ile Val Ile Pro Phe Phe Ser Leu Leu Ile Lys
      95              100             105
Asp Ile Tyr Phe Leu Asn Glu Gly Cys Ala Asn Arg Leu Pro Asn
      110             115             120
Gly His Val Asn Phe Glu Lys Phe Trp Glu Leu Ala Lys Gln Val
      125             130             135
Ser Glu Phe Met Thr Trp Lys Gln Val Glu Cys Pro Phe Glu Arg
      140             145             150
Asp Arg Lys Ile Leu Gln Tyr Leu Leu Thr Val Pro Val Phe Ser
      155             160             165
Glu Asp Ala Leu Tyr Leu Ala Ser Tyr Glu Ser Glu Gly Pro Glu
      170             175             180
Asn His Ile Glu Lys Asp Arg Trp Lys Ser Leu Arg Ser Ser Leu
      185             190             195
Leu Gly Arg Val

```

<210> 12

<211> 694

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1811877CD1

<400> 12

```

Met Ala Phe Asp Pro Thr Ser Thr Leu Leu Ala Thr Gly Gly Cys
  1              5              10              15
Asp Gly Ala Val Arg Val Trp Asp Ile Val Arg His Tyr Gly Thr
      20              25              30
His His Phe Arg Gly Ser Pro Gly Val Val His Leu Val Ala Phe
      35              40              45
His Pro Asp Pro Thr Arg Leu Leu Leu Phe Ser Ser Ala Thr Asp
      50              55              60
Ala Ala Ile Arg Val Trp Ser Leu Gln Asp Arg Ser Cys Leu Ala
      65              70              75
Val Leu Thr Ala His Tyr Ser Ala Val Thr Ser Leu Ala Phe Ser
      80              85              90
Ala Asp Gly His Thr Met Leu Ser Ser Gly Arg Asp Lys Ile Cys
      95              100             105
Ile Ile Trp Asp Leu Gln Ser Cys Gln Ala Thr Arg Thr Val Pro
      110             115             120
Val Phe Glu Ser Val Glu Ala Ala Val Leu Leu Pro Glu Glu Pro
      125             130             135
Val Ser Gln Leu Gly Val Lys Ser Pro Gly Leu Tyr Phe Leu Thr
      140             145             150
Ala Gly Asp Gln Gly Thr Leu Arg Val Trp Glu Ala Ala Ser Gly
      155             160             165
Gln Cys Val Tyr Thr Gln Ala Gln Pro Pro Gly Pro Gly Gln Glu
      170             175             180

```

| | | | |
|---|-----|-----|-----|
| Leu Thr His Cys Thr Leu Ala His Thr Ala Gly Val Val Leu Thr | 185 | 190 | 195 |
| Ala Thr Ala Asp His Asn Leu Leu Leu Tyr Glu Ala Arg Ser Leu | 200 | 205 | 210 |
| Arg Leu Gln Lys Gln Phe Ala Gly Tyr Ser Glu Glu Val Leu Asp | 215 | 220 | 225 |
| Val Arg Phe Leu Gly Pro Glu Asp Ser His Val Val Val Ala Ser | 230 | 235 | 240 |
| Asn Ser Pro Cys Leu Lys Val Phe Glu Leu Gln Thr Ser Ala Cys | 245 | 250 | 255 |
| Gln Ile Leu His Gly His Thr Asp Ile Val Leu Ala Leu Asp Val | 260 | 265 | 270 |
| Phe Arg Lys Gly Trp Leu Phe Ala Ser Cys Ala Lys Asp Gln Ser | 275 | 280 | 285 |
| Val Arg Ile Trp Arg Met Asn Lys Ala Gly Gln Val Met Cys Val | 290 | 295 | 300 |
| Ala Gln Gly Ser Gly His Thr His Ser Val Gly Thr Val Cys Cys | 305 | 310 | 315 |
| Ser Arg Leu Lys Glu Ser Phe Leu Val Thr Gly Ser Gln Asp Cys | 320 | 325 | 330 |
| Thr Val Lys Leu Trp Pro Leu Pro Lys Ala Leu Leu Ser Lys Asn | 335 | 340 | 345 |
| Thr Ala Pro Asp Asn Gly Pro Ile Leu Leu Gln Ala Gln Thr Thr | 350 | 355 | 360 |
| Gln Arg Cys His Asp Lys Asp Ile Asn Ser Val Ala Ile Ala Pro | 365 | 370 | 375 |
| Asn Asp Lys Leu Leu Ala Thr Gly Ser Gln Asp Arg Thr Ala Lys | 380 | 385 | 390 |
| Leu Trp Ala Leu Pro Gln Cys Gln Leu Leu Gly Val Phe Ser Gly | 395 | 400 | 405 |
| His Arg Arg Gly Leu Trp Cys Val Gln Phe Ser Pro Met Asp Gln | 410 | 415 | 420 |
| Val Leu Ala Thr Ala Ser Ala Asp Gly Thr Ile Lys Leu Trp Ala | 425 | 430 | 435 |
| Leu Gln Asp Phe Ser Cys Leu Lys Thr Phe Glu Gly His Asp Ala | 440 | 445 | 450 |
| Ser Val Leu Lys Val Ala Phe Val Ser Arg Gly Thr Gln Leu Leu | 455 | 460 | 465 |
| Ser Ser Gly Ser Asp Gly Leu Val Lys Leu Trp Thr Ile Lys Asn | 470 | 475 | 480 |
| Asn Glu Cys Val Arg Thr Leu Asp Ala His Glu Asp Lys Val Trp | 485 | 490 | 495 |
| Gly Leu His Cys Ser Arg Leu Asp Asp His Ala Leu Thr Gly Ala | 500 | 505 | 510 |
| Ser Asp Ser Arg Val Ile Leu Trp Lys Asp Val Thr Glu Ala Glu | 515 | 520 | 525 |
| Gln Ala Glu Glu Gln Ala Arg Gln Glu Glu Gln Val Val Arg Gln | 530 | 535 | 540 |
| Gln Glu Leu Asp Asn Leu Leu His Glu Lys Arg Tyr Leu Arg Ala | 545 | 550 | 555 |
| Leu Gly Leu Ala Ile Ser Leu Asp Arg Pro His Thr Val Leu Thr | 560 | 565 | 570 |
| Val Ile Gln Ala Ile Arg Arg Asp Pro Glu Ala Cys Glu Lys Leu | 575 | 580 | 585 |
| Glu Ala Thr Met Leu Arg Leu Arg Arg Asp Gln Lys Glu Ala Leu | | | |

| | | | | | |
|-----------------|---------------------|---------------------|-----|--|-----|
| | 590 | | 595 | | 600 |
| Leu Arg Phe Cys | Val Thr Trp Asn Thr | Asn Ser Arg His Cys | His | | |
| | 605 | | 610 | | 615 |
| Glu Ala Gln Ala | Val Leu Gly Val Leu | Leu Arg Arg Glu Ala | Pro | | |
| | 620 | | 625 | | 630 |
| Glu Glu Leu Leu | Ala Tyr Glu Gly Val | Arg Ala Ala Leu Glu | Ala | | |
| | 635 | | 640 | | 645 |
| Leu Leu Pro Tyr | Thr Glu Arg His Phe | Gln Arg Leu Ser Arg | Thr | | |
| | 650 | | 655 | | 660 |
| Leu Gln Ala Ala | Ala Phe Leu Asp Phe | Leu Trp His Asn Met | Lys | | |
| | 665 | | 670 | | 675 |
| Leu Pro Val Pro | Ala Ala Ala Pro Thr | Pro Trp Glu Thr His | Lys | | |
| | 680 | | 685 | | 690 |
| Gly Ala Leu Pro | | | | | |

<210> 13

<211> 654

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1848674CD1

<400> 13

| | | | |
|---------------------|---------------------|---------------------|-----|
| Met Glu Arg Ser Gly | Pro Ser Glu Val Thr | Gly Ser Asp Ala Ser | |
| 1 | 5 | 10 | 15 |
| Gly Pro Asp Pro Gln | Leu Ala Val Thr Met | Gly Phe Thr Gly Phe | |
| | 20 | 25 | 30 |
| Gly Lys Lys Ala Arg | Thr Phe Asp Leu Glu | Ala Met Phe Glu Gln | |
| | 35 | 40 | 45 |
| Thr Arg Arg Thr Ala | Val Glu Arg Ser Arg | Lys Thr Leu Glu Ala | |
| | 50 | 55 | 60 |
| Arg Glu Lys Glu Glu | Glu Met Asn Arg Glu | Lys Glu Leu Arg Arg | |
| | 65 | 70 | 75 |
| Gln Asn Glu Asp Ile | Glu Pro Thr Ser Ser | Arg Ser Asn Val Val | |
| | 80 | 85 | 90 |
| Arg Asp Cys Ser Lys | Ser Ser Ser Arg Asp | Thr Ser Ser Ser Glu | |
| | 95 | 100 | 105 |
| Ser Glu Gln Ser Ser | Asp Ser Ser Asp Asp | Glu Leu Ile Gly Pro | |
| | 110 | 115 | 120 |
| Pro Leu Pro Pro Lys | Met Val Gly Lys Pro | Val Asn Phe Met Glu | |
| | 125 | 130 | 135 |
| Glu Asp Ile Leu Gly | Pro Leu Pro Pro Pro | Leu Asn Glu Glu Glu | |
| | 140 | 145 | 150 |
| Glu Glu Ala Glu Glu | Glu Glu Glu Glu Glu | Glu Glu Glu Glu Asn | |
| | 155 | 160 | 165 |
| Pro Val His Lys Ile | Pro Asp Ser His Glu | Ile Thr Leu Lys His | |
| | 170 | 175 | 180 |
| Gly Thr Lys Thr Val | Ser Ala Leu Gly Leu | Asp Pro Ser Gly Ala | |
| | 185 | 190 | 195 |
| Arg Leu Val Thr Gly | Gly Tyr Asp Tyr Asp | Val Lys Phe Trp Asp | |
| | 200 | 205 | 210 |
| Phe Ala Gly Met Asp | Ala Ser Phe Lys Ala | Phe Arg Ser Leu Gln | |

| | | | | | |
|-----------------|---------------------|-------------------------|-----|--|-----|
| | 215 | | 220 | | 225 |
| Pro Cys Glu Cys | His Gln Ile Lys Ser | Leu Gln Tyr Ser Asn Thr | | | |
| | 230 | | 235 | | 240 |
| Gly Asp Met Ile | Leu Val Val Ser Gly | Ser Ser Gln Ala Lys Val | | | |
| | 245 | | 250 | | 255 |
| Ile Asp Arg Asp | Gly Phe Glu Val Met | Glu Cys Ile Lys Gly Asp | | | |
| | 260 | | 265 | | 270 |
| Gln Tyr Ile Val | Asp Met Ala Asn Thr | Lys Gly His Thr Ala Met | | | |
| | 275 | | 280 | | 285 |
| Leu His Thr Gly | Ser Trp His Pro Lys | Ile Lys Gly Glu Phe Met | | | |
| | 290 | | 295 | | 300 |
| Thr Cys Ser Asn | Asp Ala Thr Val Arg | Thr Trp Glu Val Glu Asn | | | |
| | 305 | | 310 | | 315 |
| Pro Lys Lys Gln | Lys Ser Val Phe Lys | Pro Arg Thr Met Gln Gly | | | |
| | 320 | | 325 | | 330 |
| Lys Lys Val Ile | Pro Thr Thr Cys Thr | Tyr Ser Arg Asp Gly Asn | | | |
| | 335 | | 340 | | 345 |
| Leu Ile Ala Ala | Ala Cys Gln Asn Gly | Ser Ile Gln Ile Trp Asp | | | |
| | 350 | | 355 | | 360 |
| Arg Asn Leu Thr | Val His Pro Lys Phe | His Tyr Lys Gln Ala His | | | |
| | 365 | | 370 | | 375 |
| Asp Ser Gly Thr | Asp Thr Ser Cys Val | Thr Phe Ser Tyr Asp Gly | | | |
| | 380 | | 385 | | 390 |
| Asn Val Leu Ala | Ser Arg Gly Gly Asp | Asp Ser Leu Lys Leu Trp | | | |
| | 395 | | 400 | | 405 |
| Asp Ile Arg Gln | Phe Asn Lys Pro Leu | Phe Ser Ala Ser Gly Leu | | | |
| | 410 | | 415 | | 420 |
| Pro Thr Met Phe | Pro Met Thr Asp Cys | Cys Phe Ser Pro Asp Asp | | | |
| | 425 | | 430 | | 435 |
| Lys Leu Ile Val | Thr Gly Thr Ser Ile | Gln Arg Gly Cys Gly Ser | | | |
| | 440 | | 445 | | 450 |
| Gly Lys Leu Val | Phe Phe Glu Arg Arg | Thr Phe Gln Arg Val Tyr | | | |
| | 455 | | 460 | | 465 |
| Glu Ile Asp Ile | Thr Asp Ala Ser Val | Val Arg Cys Leu Trp His | | | |
| | 470 | | 475 | | 480 |
| Pro Lys Leu Asn | Gln Ile Met Val Gly | Thr Gly Asn Gly Leu Ala | | | |
| | 485 | | 490 | | 495 |
| Lys Val Tyr Tyr | Asp Pro Asn Lys Ser | Gln Arg Gly Ala Lys Leu | | | |
| | 500 | | 505 | | 510 |
| Cys Val Val Lys | Thr Gln Arg Lys Ala | Lys Gln Ala Glu Thr Leu | | | |
| | 515 | | 520 | | 525 |
| Thr Gln Asp Tyr | Ile Ile Thr Pro His | Ala Leu Pro Met Phe Arg | | | |
| | 530 | | 535 | | 540 |
| Glu Pro Arg Gln | Arg Ser Thr Arg Lys | Gln Leu Glu Lys Asp Arg | | | |
| | 545 | | 550 | | 555 |
| Leu Asp Pro Leu | Lys Ser His Lys Pro | Glu Pro Pro Val Ala Gly | | | |
| | 560 | | 565 | | 570 |
| Pro Gly Arg Gly | Gly Arg Val Gly Thr | His Gly Gly Thr Leu Ser | | | |
| | 575 | | 580 | | 585 |
| Ser Tyr Ile Val | Lys Asn Ile Ala Leu | Asp Lys Thr Asp Asp Ser | | | |
| | 590 | | 595 | | 600 |
| Asn Pro Arg Glu | Ala Ile Leu Arg His | Ala Lys Ala Ala Glu Asp | | | |
| | 605 | | 610 | | 615 |
| Ser Pro Tyr Trp | Val Ser Pro Ala Tyr | Ser Lys Thr Gln Pro Lys | | | |
| | 620 | | 625 | | 630 |

Thr Met Phe Ala Gln Val Glu Ser Asp Asp Glu Glu Ala Lys Asn
 635 640 645
 Glu Pro Glu Trp Lys Lys Arg Lys Ile
 650

<210> 14
 <211> 180
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2012970CD1

<400> 14
 Met Glu Ala Asn Met Pro Lys Arg Lys Glu Pro Gly Arg Ser Leu
 1 5 10 15
 Arg Ile Lys Val Ile Ser Met Gly Asn Ala Glu Val Gly Lys Ser
 20 25 30
 Cys Ile Ile Lys Arg Tyr Cys Glu Lys Arg Phe Val Ser Lys Tyr
 35 40 45
 Leu Ala Thr Ile Gly Ile Asp Tyr Gly Val Thr Lys Val His Val
 50 55 60
 Arg Asp Arg Glu Ile Lys Val Asn Ile Phe Asp Met Ala Gly His
 65 70 75
 Pro Phe Phe Tyr Glu Val Arg Asn Glu Phe Tyr Lys Asp Thr Gln
 80 85 90
 Gly Val Ile Leu Val Tyr Asp Val Gly Gln Lys Asp Ser Phe Asp
 95 100 105
 Ala Leu Asp Ala Trp Leu Ala Glu Met Lys Gln Glu Leu Gly Pro
 110 115 120
 His Gly Asn Met Glu Asn Ile Ile Phe Val Val Cys Ala Asn Lys
 125 130 135
 Ile Asp Cys Thr Lys His Arg Cys Val Asp Glu Ser Glu Gly Arg
 140 145 150
 Leu Trp Ala Glu Ser Lys Gly Phe Leu Tyr Phe Glu Thr Ser Ala
 155 160 165
 Gln Thr Gly Glu Gly Ile Asn Glu Met Phe Gln Ile His Leu Gly
 170 175 180

<210> 15
 <211> 374
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2254315CD1

<400> 15
 Met Ala Ala Ser Ala Ala Ala Ala Glu Leu Gln Ala Ser Gly Gly
 1 5 10 15
 Pro Arg His Pro Val Cys Leu Leu Val Leu Gly Met Ala Gly Ser

| | | | | | |
|---|-----|--|-----|--|-----|
| | 20 | | 25 | | 30 |
| Gly Lys Thr Thr Phe Val Gln Arg Leu Thr Gly His Leu His Ala | | | | | |
| | 35 | | 40 | | 45 |
| Gln Gly Thr Pro Pro Tyr Val Ile Asn Leu Asp Pro Ala Val His | | | | | |
| | 50 | | 55 | | 60 |
| Glu Val Pro Phe Pro Ala Asn Ile Asp Ile Arg Asp Thr Val Lys | | | | | |
| | 65 | | 70 | | 75 |
| Tyr Lys Glu Val Met Lys Gln Tyr Gly Leu Gly Pro Asn Gly Gly | | | | | |
| | 80 | | 85 | | 90 |
| Ile Val Thr Ser Leu Asn Leu Phe Ala Thr Arg Phe Asp Gln Val | | | | | |
| | 95 | | 100 | | 105 |
| Met Lys Phe Ile Glu Lys Ala Gln Asn Met Ser Lys Tyr Val Leu | | | | | |
| | 110 | | 115 | | 120 |
| Ile Asp Thr Pro Gly Gln Ile Glu Val Phe Thr Trp Ser Ala Ser | | | | | |
| | 125 | | 130 | | 135 |
| Gly Thr Ile Ile Thr Glu Ala Leu Ala Ser Ser Phe Pro Thr Val | | | | | |
| | 140 | | 145 | | 150 |
| Val Ile Tyr Val Met Asp Thr Ser Arg Ser Thr Asn Pro Val Thr | | | | | |
| | 155 | | 160 | | 165 |
| Phe Met Ser Asn Met Leu Tyr Ala Cys Ser Ile Leu Tyr Lys Thr | | | | | |
| | 170 | | 175 | | 180 |
| Lys Leu Pro Phe Ile Val Val Met Asn Lys Thr Asp Ile Ile Asp | | | | | |
| | 185 | | 190 | | 195 |
| His Ser Phe Ala Val Glu Trp Met Gln Asp Phe Glu Ala Phe Gln | | | | | |
| | 200 | | 205 | | 210 |
| Asp Ala Leu Asn Gln Glu Thr Thr Tyr Val Ser Asn Leu Thr Arg | | | | | |
| | 215 | | 220 | | 225 |
| Ser Met Ser Leu Val Leu Asp Glu Phe Tyr Ser Ser Leu Arg Val | | | | | |
| | 230 | | 235 | | 240 |
| Val Gly Val Ser Ala Val Leu Gly Thr Gly Leu Asp Glu Leu Phe | | | | | |
| | 245 | | 250 | | 255 |
| Val Gln Val Thr Ser Ala Ala Glu Glu Tyr Glu Arg Glu Tyr Arg | | | | | |
| | 260 | | 265 | | 270 |
| Pro Glu Tyr Glu Arg Leu Lys Lys Ser Leu Ala Asn Ala Glu Ser | | | | | |
| | 275 | | 280 | | 285 |
| Gln Gln Gln Arg Glu Gln Leu Glu Arg Leu Arg Lys Asp Met Gly | | | | | |
| | 290 | | 295 | | 300 |
| Ser Val Ala Leu Asp Ala Gly Thr Ala Lys Asp Ser Leu Ser Pro | | | | | |
| | 305 | | 310 | | 315 |
| Val Leu His Pro Ser Asp Leu Ile Leu Thr Arg Gly Thr Leu Asp | | | | | |
| | 320 | | 325 | | 330 |
| Glu Glu Asp Glu Glu Ala Asp Ser Asp Thr Asp Asp Ile Asp His | | | | | |
| | 335 | | 340 | | 345 |
| Arg Val Thr Glu Glu Ser His Glu Glu Pro Ala Phe Gln Asn Phe | | | | | |
| | 350 | | 355 | | 360 |
| Met Gln Glu Ser Met Ala Gln Tyr Trp Lys Arg Asn Asn Lys | | | | | |
| | 365 | | 370 | | |

<210> 16

<211> 649

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No. 2415545CD1

<400> 16

```

Met Glu Gly Ala Gly Tyr Arg Val Val Phe Glu Lys Gly Gly Val
  1          5          10          15
Tyr Leu His Thr Ser Ala Lys Lys Tyr Gln Asp Arg Asp Ser Leu
          20          25          30
Ile Ala Gly Val Ile Arg Val Val Glu Lys Asp Asn Asp Val Leu
          35          40          45
Leu His Trp Ala Pro Val Glu Glu Ala Gly Asp Ser Thr Gln Ile
          50          55          60
Leu Phe Ser Lys Lys Asp Ser Ser Gly Gly Asp Ser Cys Ala Ser
          65          70          75
Glu Glu Glu Pro Thr Phe Asp Pro Gly Tyr Glu Pro Asp Trp Ala
          80          85          90
Val Ile Ser Thr Val Arg Pro Gln Pro Cys His Ser Glu Pro Thr
          95          100          105
Arg Gly Ala Glu Pro Ser Cys Pro Gln Gly Ser Trp Ala Phe Ser
          110          115          120
Val Ser Leu Gly Glu Leu Lys Ser Ile Arg Arg Ser Lys Pro Gly
          125          130          135
Leu Ser Trp Ala Tyr Leu Val Leu Val Thr Gln Ala Gly Gly Ser
          140          145          150
Leu Pro Ala Leu His Phe His Arg Gly Gly Thr Arg Ala Leu Leu
          155          160          165
Arg Val Leu Ser Arg Tyr Leu Leu Leu Ala Ser Ser Pro Gln Asp
          170          175          180
Ser Arg Leu Tyr Leu Val Phe Pro His Asp Ser Ser Ala Leu Ser
          185          190          195
Asn Ser Phe His His Leu Gln Leu Phe Asp Gln Asp Ser Ser Asn
          200          205          210
Val Val Ser Arg Phe Leu Gln Asp Pro Tyr Ser Thr Thr Phe Ser
          215          220          225
Ser Phe Ser Arg Val Thr Asn Phe Phe Arg Gly Ala Leu Gln Pro
          230          235          240
Gln Pro Glu Gly Ala Ala Ser Asp Leu Pro Pro Pro Pro Asp Asp
          245          250          255
Glu Pro Glu Pro Gly Phe Glu Val Ile Ser Cys Val Glu Leu Gly
          260          265          270
Pro Arg Pro Thr Val Glu Arg Gly Pro Pro Val Thr Glu Glu Glu
          275          280          285
Trp Ala Arg His Val Gly Pro Glu Gly Arg Leu Gln Gln Val Pro
          290          295          300
Glu Leu Lys Asn Arg Ile Phe Ser Gly Gly Leu Ser Pro Ser Leu
          305          310          315
Arg Arg Glu Ala Trp Lys Phe Leu Leu Gly Tyr Leu Ser Trp Glu
          320          325          330
Gly Thr Ala Glu Glu His Lys Ala His Ile Arg Lys Lys Thr Asp
          335          340          345
Glu Tyr Phe Arg Met Lys Leu Gln Trp Lys Ser Val Ser Pro Glu
          350          355          360
Gln Glu Arg Arg Asn Ser Leu Leu His Gly Tyr Arg Ser Leu Ile
          365          370          375
Glu Arg Asp Val Ser Arg Thr Asp Arg Thr Asn Lys Phe Tyr Glu

```


| | | | | | |
|---|-----|--|-----|--|-----|
| | 380 | | 385 | | 390 |
| Gly Pro Glu Asn Pro Gly Leu Gly Leu Leu Asn Asp Ile Leu Leu | | | | | |
| | 395 | | 400 | | 405 |
| Thr Tyr Cys Met Tyr His Phe Asp Leu Gly Tyr Val Gln Gly Met | | | | | |
| | 410 | | 415 | | 420 |
| Ser Asp Leu Leu Ser Pro Ile Leu Tyr Val Ile Gln Asn Glu Val | | | | | |
| | 425 | | 430 | | 435 |
| Asp Ala Phe Trp Cys Phe Cys Gly Phe Met Glu Leu Val Gln Gly | | | | | |
| | 440 | | 445 | | 450 |
| Asn Phe Glu Glu Ser Gln Glu Thr Met Lys Arg Gln Leu Gly Arg | | | | | |
| | 455 | | 460 | | 465 |
| Leu Leu Leu Leu Leu Arg Val Leu Asp Pro Leu Leu Cys Asp Phe | | | | | |
| | 470 | | 475 | | 480 |
| Leu Asp Ser Gln Asp Ser Gly Ser Leu Cys Phe Cys Phe Arg Trp | | | | | |
| | 485 | | 490 | | 495 |
| Leu Leu Ile Trp Phe Lys Arg Glu Phe Pro Phe Pro Asp Val Leu | | | | | |
| | 500 | | 505 | | 510 |
| Arg Leu Trp Glu Val Leu Trp Thr Gly Leu Pro Gly Pro Asn Leu | | | | | |
| | 515 | | 520 | | 525 |
| His Leu Leu Val Ala Cys Ala Ile Leu Asp Met Glu Arg Asp Thr | | | | | |
| | 530 | | 535 | | 540 |
| Leu Met Leu Ser Gly Phe Gly Ser Asn Glu Ile Leu Lys His Ile | | | | | |
| | 545 | | 550 | | 555 |
| Asn Glu Leu Thr Met Lys Leu Ser Val Glu Asp Val Leu Thr Arg | | | | | |
| | 560 | | 565 | | 570 |
| Ala Glu Ala Leu His Arg Gln Leu Thr Ala Cys Thr Arg Ala Ala | | | | | |
| | 575 | | 580 | | 585 |
| Pro Gln Arg Ala Gly Asp Pro Gly Ala Gly Pro Ala Thr Gln Ser | | | | | |
| | 590 | | 595 | | 600 |
| Pro Thr Ala Pro Arg Pro Pro Pro Pro Arg Cys Leu Cys Thr Pro | | | | | |
| | 605 | | 610 | | 615 |
| Thr Arg Ala Pro Pro Thr Pro Pro Pro Ser Thr Asp Thr Ala Pro | | | | | |
| | 620 | | 625 | | 630 |
| Gln Pro Asp Ser Ser Leu Glu Ile Leu Pro Glu Glu Glu Asp Glu | | | | | |
| | 635 | | 640 | | 645 |
| Gly Ala Asp Ser | | | | | |

<210> 17

<211> 698

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2707969CD1

<400> 17

| | | | | | |
|---|----|--|----|--|----|
| Met Cys His Asp Asp Asp Asp Lys Asp Pro Val Leu Arg Val Phe | | | | | |
| 1 | 5 | | 10 | | 15 |
| Asp Ser Arg Val Asp Lys Ile Arg Leu Leu Asn Val Arg Thr Pro | | | | | |
| | 20 | | 25 | | 30 |
| Thr Leu Arg Thr Ser Met Tyr Gln Lys Cys Thr Thr Val Asp Glu | | | | | |
| | 35 | | 40 | | 45 |
| Ala Glu Lys Ala Ile Glu Leu Arg Leu Ala Lys Ile Asp His Thr | | | | | |

| | | | | | |
|-----|-----|-----|-----|-----|-----|
| | 50 | | 55 | | 60 |
| Ala | Ile | His | Pro | His | Leu |
| | 65 | | 70 | | 75 |
| Tyr | Glu | Pro | Gly | Phe | Phe |
| | 80 | | 85 | | 90 |
| Thr | Gly | Pro | Ala | Ser | Asn |
| | 95 | | 100 | | 105 |
| Gln | Trp | Arg | Arg | Lys | Asp |
| | 110 | | 115 | | 120 |
| Arg | Leu | Asp | Asn | Asp | Gln |
| | 125 | | 130 | | 135 |
| Thr | Met | Gly | Ser | Thr | Ile |
| | 140 | | 145 | | 150 |
| Pro | Ser | Val | Ile | Ala | Gln |
| | 155 | | 160 | | 165 |
| Leu | Lys | Glu | Cys | Arg | Asn |
| | 170 | | 175 | | 180 |
| Met | Gly | Arg | Glu | Ala | Val |
| | 185 | | 190 | | 195 |
| Thr | Gly | Val | Glu | Glu | Asn |
| | 200 | | 205 | | 210 |
| Leu | Glu | Arg | Ile | Trp | Ser |
| | 215 | | 220 | | 225 |
| Ser | Ala | Leu | Trp | Ser | His |
| | 230 | | 235 | | 240 |
| Arg | Lys | Leu | Thr | Ser | Gly |
| | 245 | | 250 | | 255 |
| Asp | Ser | Glu | Arg | Arg | Lys |
| | 260 | | 265 | | 270 |
| Leu | Arg | Ile | Ser | Leu | Ile |
| | 275 | | 280 | | 285 |
| Gly | Glu | Ile | Lys | Thr | Asp |
| | 290 | | 295 | | 300 |
| Leu | Ser | Met | Glu | Lys | Lys |
| | 305 | | 310 | | 315 |
| Leu | Ser | Asp | His | Glu | Leu |
| | 320 | | 325 | | 330 |
| Phe | Leu | Arg | Cys | Asp | Asp |
| | 335 | | 340 | | 345 |
| Leu | Ser | Phe | Asn | Ala | Val |
| | 350 | | 355 | | 360 |
| Thr | Thr | Ile | Leu | Ile | Pro |
| | 365 | | 370 | | 375 |
| Lys | Leu | Gly | Gly | Ser | Met |
| | 380 | | 385 | | 390 |
| Ser | Gly | Glu | Leu | Gly | Glu |
| | 395 | | 400 | | 405 |
| Val | Leu | Glu | Met | Thr | Phe |
| | 410 | | 415 | | 420 |
| Thr | Val | Gln | Ile | Gly | His |
| | 425 | | 430 | | 435 |
| Leu | Val | Glu | Tyr | Val | Met |
| | 440 | | 445 | | 450 |
| Tyr | Lys | Phe | Pro | Cys | Gly |
| | 455 | | 460 | | 465 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Gly | Ser | Leu | Glu | Arg | Ile | Leu | Val | Gly | Glu | Leu | Leu | Thr | Ser | Gln | |
| | | | | 470 | | | | | 475 | | | | | 480 | |
| Pro | Glu | Val | Asp | Glu | Arg | Pro | Cys | Arg | Thr | Pro | Pro | Leu | Gln | Gln | |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Ser | Pro | Ser | Val | Ile | Arg | Arg | Leu | Val | Thr | Ile | Ser | Pro | Asn | Asn | |
| | | | | 500 | | | | | 505 | | | | | 510 | |
| Lys | Pro | Lys | Leu | Asn | Thr | Gly | Gln | Ile | Gln | Glu | Ser | Ile | Gly | Glu | |
| | | | | 515 | | | | | 520 | | | | | 525 | |
| Ala | Val | Asn | Gly | Ile | Val | Lys | His | Phe | His | Lys | Pro | Glu | Lys | Glu | |
| | | | | 530 | | | | | 535 | | | | | 540 | |
| Arg | Gly | Ser | Leu | Thr | Leu | Leu | Leu | Cys | Gly | Glu | Cys | Gly | Leu | Val | |
| | | | | 545 | | | | | 550 | | | | | 555 | |
| Ser | Ala | Leu | Glu | Gln | Ala | Phe | Gln | His | Gly | Phe | Lys | Ser | Pro | Arg | |
| | | | | 560 | | | | | 565 | | | | | 570 | |
| Leu | Phe | Lys | Asn | Val | Phe | Ile | Trp | Asp | Phe | Leu | Glu | Lys | Ala | Gln | |
| | | | | 575 | | | | | 580 | | | | | 585 | |
| Thr | Tyr | Tyr | Glu | Thr | Leu | Glu | Lys | Asn | Glu | Val | Val | Pro | Glu | Glu | |
| | | | | 590 | | | | | 595 | | | | | 600 | |
| Asn | Trp | His | Thr | Arg | Ala | Arg | Asn | Phe | Cys | Arg | Phe | Val | Thr | Ala | |
| | | | | 605 | | | | | 610 | | | | | 615 | |
| Ile | Asn | Asn | Thr | Pro | Arg | Asn | Ile | Gly | Lys | Asp | Gly | Lys | Phe | Gln | |
| | | | | 620 | | | | | 625 | | | | | 630 | |
| Met | Leu | Val | Cys | Leu | Gly | Ala | Arg | Asp | His | Leu | Leu | His | His | Trp | |
| | | | | 635 | | | | | 640 | | | | | 645 | |
| Ile | Ala | Leu | Leu | Ala | Asp | Cys | Pro | Ile | Thr | Ala | His | Met | Tyr | Glu | |
| | | | | 650 | | | | | 655 | | | | | 660 | |
| Asp | Val | Ala | Leu | Ile | Lys | Asp | His | Thr | Leu | Val | Asn | Ser | Leu | Ile | |
| | | | | 665 | | | | | 670 | | | | | 675 | |
| Arg | Val | Leu | Gln | Thr | Leu | Gln | Glu | Phe | Asn | Ile | Thr | Leu | Glu | Thr | |
| | | | | 680 | | | | | 685 | | | | | 690 | |
| Ser | Leu | Val | Lys | Gly | Ile | Asp | Ile | | | | | | | | |
| | | | | 695 | | | | | | | | | | | |

<210> 18
 <211> 396
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2817769CD1

| | | | | | | | | | | | | | | | |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| <400> | 18 | | | | | | | | | | | | | | |
| Met | Pro | Pro | Lys | Lys | Gly | Gly | Asp | Gly | Ile | Lys | Pro | Pro | Pro | Ile | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Ile | Gly | Arg | Phe | Gly | Thr | Ser | Leu | Lys | Ile | Gly | Ile | Val | Gly | Leu | |
| | | | | 20 | | | | | 25 | | | | | 30 | |
| Pro | Asn | Val | Gly | Lys | Ser | Thr | Phe | Phe | Asn | Val | Leu | Thr | Asn | Ser | |
| | | | | 35 | | | | | 40 | | | | | 45 | |
| Gln | Ala | Ser | Ala | Glu | Asn | Phe | Pro | Phe | Cys | Thr | Ile | Asp | Pro | Asn | |
| | | | | 50 | | | | | 55 | | | | | 60 | |
| Glu | Ser | Arg | Val | Pro | Val | Pro | Asp | Glu | Arg | Phe | Asp | Phe | Leu | Cys | |
| | | | | 65 | | | | | 70 | | | | | 75 | |
| Gln | Tyr | His | Lys | Pro | Ala | Ser | Lys | Ile | Pro | Ala | Phe | Leu | Asn | Val | |
| | | | | 80 | | | | | 85 | | | | | 90 | |

```
<210> 19
<211> 634
<212> PRT
<213> Homo sapiens
```

<400> 19
Met Ser Ser Asp Ser Glu Tyr Asp Ser Asp Asp Asp Arg Thr Lys

| | | | |
|---|-----|-----|-----|
| 1 | 5 | 10 | 15 |
| Glu Glu Arg Ala Tyr Asp Lys Ala Lys Arg Arg Ile Glu Lys Arg | 20 | 25 | 30 |
| Arg Leu Glu His Ser Lys Asn Val Asn Thr Glu Lys Leu Arg Ala | 35 | 40 | 45 |
| Pro Ile Ile Cys Val Leu Gly His Val Asp Thr Gly Lys Thr Lys | 50 | 55 | 60 |
| Ile Leu Asp Lys Leu Arg His Thr His Val Gln Asp Gly Glu Ala | 65 | 70 | 75 |
| Gly Gly Ile Thr Gln Gln Ile Gly Ala Thr Asn Val Pro Leu Glu | 80 | 85 | 90 |
| Ala Ile Asn Glu Gln Thr Lys Met Ile Lys Asn Phe Asp Arg Glu | 95 | 100 | 105 |
| Asn Val Arg Ile Pro Gly Met Leu Ile Ile Asp Thr Pro Gly His | 110 | 115 | 120 |
| Glu Ser Phe Ser Asn Leu Arg Asn Arg Gly Ser Ser Leu Cys Asp | 125 | 130 | 135 |
| Ile Ala Ile Leu Val Val Asp Ile Met His Gly Leu Glu Pro Gln | 140 | 145 | 150 |
| Thr Ile Glu Ser Ile Asn Leu Leu Lys Ser Lys Lys Cys Pro Phe | 155 | 160 | 165 |
| Ile Val Ala Leu Asn Lys Ile Asp Arg Leu Tyr Asp Trp Lys Lys | 170 | 175 | 180 |
| Ser Pro Asp Ser Asp Val Ala Ala Thr Leu Lys Lys Gln Lys Lys | 185 | 190 | 195 |
| Asn Thr Lys Asp Glu Phe Glu Glu Arg Ala Lys Ala Ile Ile Val | 200 | 205 | 210 |
| Glu Phe Ala Gln Gln Gly Leu Asn Ala Ala Leu Phe Tyr Glu Asn | 215 | 220 | 225 |
| Lys Asp Pro Arg Thr Phe Val Ser Leu Val Pro Thr Ser Ala His | 230 | 235 | 240 |
| Thr Gly Asp Gly Met Gly Ser Leu Ile Tyr Leu Leu Val Glu Leu | 245 | 250 | 255 |
| Thr Gln Thr Met Leu Ser Lys Arg Leu Ala His Cys Glu Glu Leu | 260 | 265 | 270 |
| Arg Ala Gln Val Met Glu Val Lys Ala Leu Pro Gly Met Gly Thr | 275 | 280 | 285 |
| Thr Ile Asp Val Ile Leu Ile Asn Gly Arg Leu Lys Glu Gly Asp | 290 | 295 | 300 |
| Thr Ile Ile Val Pro Gly Val Glu Gly Pro Ile Val Thr Gln Ile | 305 | 310 | 315 |
| Arg Gly Leu Leu Leu Pro Pro Pro Met Lys Glu Leu Arg Val Lys | 320 | 325 | 330 |
| Asn Gln Tyr Glu Lys His Lys Glu Val Glu Ala Ala Gln Gly Val | 335 | 340 | 345 |
| Lys Ile Leu Gly Lys Asp Leu Glu Lys Thr Leu Ala Gly Leu Pro | 350 | 355 | 360 |
| Leu Leu Val Ala Tyr Lys Glu Asp Glu Ile Pro Val Leu Lys Asp | 365 | 370 | 375 |
| Glu Leu Ile His Glu Leu Lys Gln Thr Leu Asn Ala Ile Lys Leu | 380 | 385 | 390 |
| Glu Glu Lys Gly Val Tyr Val Gln Ala Ser Thr Leu Gly Ser Leu | 395 | 400 | 405 |
| Glu Ala Leu Leu Glu Phe Leu Lys Thr Ser Glu Val Pro Tyr Ala | 410 | 415 | 420 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Ile | Asn | Ile | Gly | Pro | Val | His | Lys | Lys | Asp | Val | Met | Lys | Ala |
| | | | | 425 | | | | | 430 | | | | | 435 |
| Ser | Val | Met | Leu | Glu | His | Asp | Pro | Gln | Tyr | Ala | Val | Ile | Leu | Ala |
| | | | | 440 | | | | | 445 | | | | | 450 |
| Phe | Asp | Val | Arg | Ile | Glu | Arg | Asp | Ala | Gln | Glu | Met | Ala | Asp | Ser |
| | | | | 455 | | | | | 460 | | | | | 465 |
| Leu | Gly | Val | Arg | Ile | Phe | Ser | Ala | Glu | Ile | Ile | Tyr | His | Leu | Phe |
| | | | | 470 | | | | | 475 | | | | | 480 |
| Asp | Ala | Phe | Thr | Lys | Tyr | Arg | Gln | Asp | Tyr | Lys | Lys | Gln | Lys | Gln |
| | | | | 485 | | | | | 490 | | | | | 495 |
| Glu | Glu | Phe | Lys | His | Ile | Ala | Val | Phe | Pro | Cys | Lys | Ile | Lys | Ile |
| | | | | 500 | | | | | 505 | | | | | 510 |
| Leu | Pro | Gln | Tyr | Ile | Phe | Asn | Ser | Arg | Asp | Pro | Ile | Val | Met | Gly |
| | | | | 515 | | | | | 520 | | | | | 525 |
| Val | Thr | Val | Glu | Ala | Gly | Gln | Val | Lys | Gln | Gly | Thr | Pro | Met | Cys |
| | | | | 530 | | | | | 535 | | | | | 540 |
| Val | Pro | Ser | Lys | Asn | Phe | Val | Asp | Ile | Gly | Ile | Val | Thr | Ser | Ile |
| | | | | 545 | | | | | 550 | | | | | 555 |
| Glu | Ile | Asn | His | Lys | Gln | Val | Asp | Val | Ala | Lys | Lys | Gly | Gln | Glu |
| | | | | 560 | | | | | 565 | | | | | 570 |
| Val | Cys | Val | Lys | Ile | Glu | Pro | Ile | Pro | Gly | Glu | Ser | Pro | Lys | Met |
| | | | | 575 | | | | | 580 | | | | | 585 |
| Phe | Gly | Arg | His | Phe | Glu | Ala | Thr | Asp | Ile | Leu | Val | Ser | Lys | Ile |
| | | | | 590 | | | | | 595 | | | | | 600 |
| Ser | Arg | Gln | Ser | Ile | Asp | Ala | Leu | Lys | Asp | Trp | Phe | Arg | Asp | Glu |
| | | | | 605 | | | | | 610 | | | | | 615 |
| Met | Gln | Lys | Ser | Asp | Trp | Gln | Leu | Ile | Val | Glu | Leu | Lys | Lys | Val |
| | | | | 620 | | | | | 625 | | | | | 630 |
| Phe | Glu | Ile | Ile | | | | | | | | | | | |

<210> 20

<211> 196

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3421335CD1

<400> 20

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Ser | Val | Asn | Ser | Arg | Gly | His | Lys | Ala | Glu | Ala | Gln | Val |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
| Val | Met | Met | Gly | Leu | Asp | Ser | Ala | Gly | Lys | Thr | Thr | Leu | Leu | Tyr |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Lys | Leu | Lys | Gly | His | Gln | Leu | Val | Glu | Thr | Leu | Pro | Thr | Val | Gly |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Phe | Asn | Val | Glu | Pro | Leu | Lys | Ala | Pro | Gly | His | Val | Ser | Leu | Thr |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Leu | Trp | Asp | Val | Gly | Gly | Gln | Ala | Pro | Leu | Arg | Ala | Ser | Trp | Lys |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Asp | Tyr | Leu | Glu | Gly | Thr | Asp | Ile | Leu | Val | Tyr | Val | Leu | Asp | Ser |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Thr | Asp | Glu | Ala | Arg | Leu | Pro | Glu | Ser | Ala | Ala | Glu | Leu | Thr | Glu |
| | | | | 95 | | | | | 100 | | | | | 105 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Leu | Asn | Asp | Pro | Asn | Met | Ala | Gly | Val | Pro | Phe | Leu | Val | Leu |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Ala | Asn | Lys | Gln | Glu | Ala | Pro | Asp | Ala | Leu | Pro | Leu | Leu | Lys | Ile |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Arg | Asn | Arg | Leu | Ser | Leu | Glu | Arg | Phe | Gln | Asp | His | Cys | Trp | Glu |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Leu | Arg | Gly | Cys | Ser | Ala | Leu | Thr | Gly | Glu | Gly | Leu | Pro | Glu | Ala |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Leu | Gln | Ser | Leu | Trp | Ser | Leu | Leu | Lys | Ser | Arg | Ser | Cys | Met | Cys |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Leu | Gln | Ala | Arg | Ala | His | Gly | Ala | Glu | Arg | Gly | Asp | Ser | Lys | Arg |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Ser | | | | | | | | | | | | | | |

<210> 21

<211> 446

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 605761CD1

<400> 21

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ala | Arg | Lys | Gly | Arg | Arg | Arg | Thr | Cys | Glu | Thr | Gly | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
| Pro | Met | Glu | Ala | Glu | Ser | Gly | Asp | Thr | Ser | Ser | Glu | Gly | Pro | Ala |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Gln | Val | Tyr | Leu | Pro | Gly | Arg | Gly | Pro | Pro | Leu | Arg | Glu | Gly | Glu |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Glu | Leu | Val | Met | Asp | Glu | Glu | Ala | Tyr | Val | Leu | Tyr | His | Arg | Ala |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Gln | Thr | Gly | Ala | Pro | Cys | Leu | Ser | Phe | Asp | Ile | Val | Arg | Asp | His |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Leu | Gly | Asp | Asn | Arg | Thr | Glu | Leu | Pro | Leu | Thr | Leu | Tyr | Leu | Cys |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Ala | Gly | Thr | Gln | Ala | Glu | Ser | Ala | Gln | Ser | Asn | Arg | Leu | Met | Met |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Leu | Arg | Met | His | Asn | Leu | His | Gly | Thr | Lys | Pro | Pro | Pro | Ser | Glu |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Gly | Ser | Asp | Glu | Glu | Glu | Glu | Glu | Glu | Asp | Glu | Glu | Asp | Glu | Glu |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Glu | Arg | Lys | Pro | Gln | Leu | Glu | Leu | Ala | Met | Val | Pro | His | Tyr | Gly |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Gly | Ile | Asn | Arg | Val | Arg | Val | Ser | Trp | Leu | Gly | Glu | Glu | Pro | Val |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Ala | Gly | Val | Trp | Ser | Glu | Lys | Gly | Gln | Val | Glu | Val | Phe | Ala | Leu |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Arg | Arg | Leu | Leu | Gln | Val | Val | Glu | Glu | Pro | Gln | Ala | Leu | Ala | Ala |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Phe | Leu | Arg | Asp | Glu | Gln | Ala | Gln | Met | Lys | Pro | Ile | Phe | Ser | Phe |
| | | | | 200 | | | | | 205 | | | | | 210 |
| Ala | Gly | His | Met | Gly | Glu | Gly | Phe | Ala | Leu | Asp | Trp | Ser | Pro | Arg |
| | | | | 215 | | | | | 220 | | | | | 225 |

```

Val Thr Gly Arg Leu Leu Thr Gly Asp Cys Gln Lys Asn Ile His
230 235 240
Leu Trp Thr Pro Thr Asp Gly Gly Ser Trp His Val Asp Gln Arg
245 250 255
Pro Phe Val Gly His Thr Arg Ser Val Glu Asp Leu Gln Trp Ser
260 265 270
Pro Thr Glu Asn Thr Val Phe Ala Ser Cys Ser Ala Asp Ala Ser
275 280 285
Ile Arg Ile Trp Asp Ile Arg Ala Ala Pro Ser Lys Ala Cys Met
290 295 300
Leu Thr Thr Ala Thr Ala His Asp Gly Asp Val Asn Val Ile Ser
305 310 315
Trp Ser Arg Arg Glu Pro Phe Leu Leu Ser Gly Gly Asp Asp Gly
320 325 330
Ala Leu Lys Ile Trp Asp Leu Arg Gln Phe Lys Ser Gly Ser Pro
335 340 345
Val Ala Thr Phe Lys Gln His Val Ala Pro Val Thr Ser Val Glu
350 355 360
Trp His Pro Gln Asp Ser Gly Val Phe Ala Ala Ser Gly Ala Asp
365 370 375
His Gln Ile Thr Gln Trp Asp Leu Ala Val Glu Arg Asp Pro Glu
380 385 390
Ala Gly Asp Val Glu Ala Asp Pro Gly Leu Ala Asp Leu Pro Gln
395 400 405
Gln Leu Leu Phe Val His Gln Gly Glu Thr Glu Leu Lys Glu Leu
410 415 420
His Trp His Pro Gln Cys Pro Gly Leu Leu Val Ser Thr Ala Leu
425 430 435
Ser Gly Phe Thr Ile Phe Arg Thr Ile Ser Val
440 445

```

<210> 22

<211> 265

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 483862CD1

<400> 22

```

Met Ser Ser Gly Leu Arg Ala Ala Asp Phe Pro Arg Trp Lys Arg
1 5 10 15
His Ile Ser Glu Gln Leu Arg Arg Arg Asp Arg Leu Gln Arg Gln
20 25 30
Ala Phe Glu Glu Ile Ile Leu Gln Tyr Asn Lys Leu Leu Glu Lys
35 40 45
Ser Asp Leu His Ser Val Leu Ala Gln Lys Leu Gln Ala Glu Lys
50 55 60
His Asp Val Pro Asn Arg His Glu Ile Ser Pro Gly His Asp Gly
65 70 75
Thr Trp Asn Asp Asn Gln Leu Gln Glu Met Ala Gln Leu Arg Ile
80 85 90
Lys His Gln Glu Glu Leu Thr Glu Leu His Lys Lys Arg Gly Glu

```


| | | | | | |
|---------------------|-----------------|---------------------|-----|--|-----|
| | 95 | | 100 | | 105 |
| Leu Ala Gln Leu Val | Ile Asp Leu Asn | Asn Gln Met Gln Arg | Lys | | |
| | 110 | | 115 | | 120 |
| Asp Arg Glu Met Gln | Met Asn Glu Ala | Lys Ile Ala Glu Cys | Leu | | |
| | 125 | | 130 | | 135 |
| Gln Thr Ile Ser Asp | Leu Glu Thr Glu | Cys Leu Asp Leu Arg | Thr | | |
| | 140 | | 145 | | 150 |
| Lys Leu Cys Asp Leu | Glu Arg Ala Asn | Gln Thr Leu Lys Asp | Glu | | |
| | 155 | | 160 | | 165 |
| Tyr Asp Ala Leu Gln | Ile Thr Phe Thr | Ala Leu Glu Gly Lys | Leu | | |
| | 170 | | 175 | | 180 |
| Arg Lys Thr Thr Glu | Glu Asn Gln Glu | Leu Val Thr Arg Trp | Met | | |
| | 185 | | 190 | | 195 |
| Ala Glu Lys Ala Gln | Glu Ala Asn Arg | Leu Asn Ala Glu Asn | Glu | | |
| | 200 | | 205 | | 210 |
| Lys Asp Ser Arg Arg | Arg Gln Ala Arg | Leu Gln Lys Glu Leu | Ala | | |
| | 215 | | 220 | | 225 |
| Glu Ala Ala Lys Glu | Pro Leu Pro Val | Glu Gln Asp Asp Asp | Ile | | |
| | 230 | | 235 | | 240 |
| Glu Val Ile Val Asp | Glu Thr Ser Asp | His Thr Glu Glu Thr | Ser | | |
| | 245 | | 250 | | 255 |
| Pro Val Arg Ala Ile | Ser Arg Ala Ala | Thr | | | |
| | 260 | | 265 | | |

<210> 23

<211> 185

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1256777CD1

<400> 23

| | | | |
|---------------------|-----------------|---------------------|-----|
| Met Leu Lys Ala Lys | Ile Leu Phe Val | Gly Pro Cys Glu Ser | Gly |
| 1 | 5 | 10 | 15 |
| Lys Thr Val Leu Ala | Asn Phe Leu Thr | Glu Ser Ser Asp Ile | Thr |
| | 20 | 25 | 30 |
| Glu Tyr Ser Pro Thr | Gln Gly Val Arg | Ile Leu Glu Phe Glu | Asn |
| | 35 | 40 | 45 |
| Pro His Val Thr Ser | Asn Asn Lys Gly | Thr Gly Cys Glu Phe | Glu |
| | 50 | 55 | 60 |
| Leu Trp Asp Cys Gly | Gly Asp Ala Lys | Phe Glu Ser Cys Trp | Pro |
| | 65 | 70 | 75 |
| Ala Leu Met Lys Asp | Ala His Gly Val | Val Ile Val Phe Asn | Ala |
| | 80 | 85 | 90 |
| Asp Ile Pro Ser His | Arg Lys Glu Met | Glu Met Trp Tyr Ser | Cys |
| | 95 | 100 | 105 |
| Phe Val Gln Gln Pro | Ser Leu Gln Asp | Thr Gln Cys Met Leu | Ile |
| | 110 | 115 | 120 |
| Ala His His Lys Pro | Gly Ser Gly Asp | Asp Lys Gly Ser Leu | Ser |
| | 125 | 130 | 135 |
| Leu Ser Pro Pro Leu | Asn Lys Leu Lys | Leu Val His Ser Asn | Leu |
| | 140 | 145 | 150 |

Glu Asp Asp Pro Glu Glu Ile Arg Met Glu Phe Ile Lys Tyr Leu
 155 160 165
 Lys Ser Ile Ile Asn Ser Met Ser Glu Ser Arg Asp Arg Glu Glu
 170 175 180
 Met Ser Ile Met Thr
 185

<210> 24
 <211> 554
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2198779CD1

<400> 24
 Met Gly Ser Arg Asn Ser Ser Ser Ala Gly Ser Gly Ser Gly Asp
 1 5 10 15
 Pro Ser Glu Gly Leu Pro Arg Arg Gly Ala Gly Leu Arg Arg Ser
 20 25 30
 Glu Glu Glu Glu Glu Glu Asp Glu Asp Val Asp Leu Ala Gln Val
 35 40 45
 Leu Ala Tyr Leu Leu Arg Arg Gly Gln Val Arg Leu Val Gln Gly
 50 55 60
 Gly Gly Ala Ala Asn Leu Gln Phe Ile Gln Ala Leu Leu Asp Ser
 65 70 75
 Glu Glu Glu Asn Asp Arg Ala Trp Asp Gly Arg Leu Gly Asp Arg
 80 85 90
 Tyr Asn Pro Pro Val Asp Ala Thr Pro Asp Thr Arg Glu Leu Glu
 95 100 105
 Phe Asn Glu Ile Lys Thr Gln Val Glu Leu Ala Thr Gly Gln Leu
 110 115 120
 Gly Leu Arg Arg Ala Ala Gln Lys His Ser Phe Pro Arg Met Leu
 125 130 135
 His Gln Arg Glu Arg Gly Leu Cys His Arg Gly Ser Phe Ser Leu
 140 145 150
 Gly Glu Gln Ser Arg Val Ile Ser His Phe Leu Pro Asn Asp Leu
 155 160 165
 Gly Phe Thr Asp Ser Tyr Ser Gln Lys Ala Phe Cys Gly Ile Tyr
 170 175 180
 Ser Lys Asp Gly Gln Ile Phe Met Ser Ala Cys Gln Asp Gln Thr
 185 190 195
 Ile Arg Leu Tyr Asp Cys Arg Tyr Gly Arg Phe Arg Lys Phe Lys
 200 205 210
 Ser Ile Lys Ala Arg Asp Val Gly Trp Ser Val Leu Asp Val Ala
 215 220 225
 Phe Thr Pro Asp Gly Asn His Phe Leu Tyr Ser Ser Trp Ser Asp
 230 235 240
 Tyr Ile His Ile Cys Asn Ile Tyr Gly Glu Gly Asp Thr His Thr
 245 250 255
 Ala Leu Asp Leu Arg Pro Asp Glu Arg Arg Phe Ala Val Phe Ser
 260 265 270
 Ile Ala Val Ser Ser Asp Gly Arg Glu Val Leu Gly Gly Ala Asn
 275 280 285

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Gly | Cys | Leu | Tyr | Val | Phe | Asp | Arg | Glu | Gln | Asn | Arg | Arg | Thr | 290 | 295 | 300 |
| Leu | Gln | Ile | Glu | Ser | His | Glu | Asp | Asp | Val | Asn | Ala | Val | Ala | Phe | 305 | 310 | 315 |
| Ala | Asp | Ile | Ser | Ser | Gln | Ile | Leu | Phe | Ser | Gly | Gly | Asp | Asp | Ala | 320 | 325 | 330 |
| Ile | Cys | Lys | Val | Trp | Asp | Arg | Arg | Thr | Met | Arg | Glu | Asp | Asp | Pro | 335 | 340 | 345 |
| Lys | Pro | Val | Gly | Ala | Leu | Ala | Gly | His | Gln | Asp | Gly | Ile | Thr | Phe | 350 | 355 | 360 |
| Ile | Asp | Ser | Lys | Gly | Asp | Ala | Arg | Tyr | Leu | Ile | Ser | Asn | Ser | Lys | 365 | 370 | 375 |
| Asp | Gln | Thr | Ile | Lys | Leu | Trp | Asp | Ile | Arg | Arg | Phe | Ser | Ser | Arg | 380 | 385 | 390 |
| Glu | Gly | Met | Glu | Ala | Ser | Arg | Gln | Ala | Ala | Thr | Gln | Gln | Asn | Trp | 395 | 400 | 405 |
| Asp | Tyr | Arg | Trp | Gln | Gln | Val | Pro | Lys | Lys | Gly | Phe | Thr | Leu | His | 410 | 415 | 420 |
| Pro | Tyr | Pro | Ala | Trp | Arg | Lys | Leu | Lys | Leu | Pro | Gly | Asp | Ser | Ser | 425 | 430 | 435 |
| Leu | Met | Thr | Tyr | Arg | Gly | His | Gly | Val | Leu | His | Thr | Leu | Ile | Arg | 440 | 445 | 450 |
| Cys | Arg | Phe | Ser | Pro | Ile | His | Ser | Thr | Gly | Gln | Gln | Phe | Ile | Tyr | 455 | 460 | 465 |
| Ser | Gly | Cys | Ser | Thr | Gly | Lys | Val | Val | Val | Tyr | Asp | Leu | Leu | Ser | 470 | 475 | 480 |
| Gly | His | Ile | Val | Lys | Lys | Leu | Thr | Asn | His | Lys | Ala | Cys | Val | Arg | 485 | 490 | 495 |
| Asp | Val | Ser | Trp | His | Pro | Phe | Glu | Glu | Lys | Ile | Val | Ser | Ser | Ser | 500 | 505 | 510 |
| Trp | Asp | Gly | Asn | Leu | Arg | Leu | Trp | Gln | Tyr | Arg | Gln | Ala | Glu | Tyr | 515 | 520 | 525 |
| Phe | Gln | Asp | Asp | Met | Pro | Glu | Ser | Glu | Glu | Cys | Ala | Ser | Ala | Pro | 530 | 535 | 540 |
| Ala | Pro | Val | Pro | Gln | Ser | Ser | Thr | Pro | Phe | Ser | Ser | Pro | Gln | | 545 | 550 | |

<210> 25

<211> 434

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2226116CD1

<400> 25

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----|----|----|
| Met | Arg | Pro | Ser | Ser | Ser | Val | Ser | Val | Ser | Cys | Pro | Ala | Leu | Asn | 1 | 5 | 10 | 15 |
| Gln | Val | Ser | His | Phe | Ala | Asn | Leu | Thr | Ser | Val | Gly | Ala | Met | Ala | 20 | 25 | 30 | |
| Pro | Ala | Arg | Cys | Phe | Ser | Ala | Arg | Leu | Arg | Thr | Val | Phe | Gln | Gly | 35 | 40 | 45 | |
| Val | Gly | His | Trp | Ala | Leu | Ser | Thr | Trp | Ala | Gly | Leu | Lys | Pro | Ser | | | | |

| | | | |
|---------------------|-----------------|---------------------|-----|
| Arg Leu Leu Pro Gln | Arg Ala Ser Pro | Arg Leu Leu Ser Val | Gly |
| 65 | 70 | | 75 |
| Arg Ala Asp Leu Ala | Lys His Gln Glu | Leu Pro Gly Lys Lys | Leu |
| 80 | 85 | | 90 |
| Leu Ser Glu Lys Lys | Leu Lys Arg Tyr | Phe Val Asp Tyr Arg | Arg |
| 95 | 100 | | 105 |
| Val Leu Val Cys Gly | Gly Asn Gly Gly | Ala Gly Ala Ser Cys | Phe |
| 110 | 115 | | 120 |
| His Ser Glu Pro Arg | Lys Glu Phe Gly | Pro Asp Gly Gly | Asp |
| 125 | 130 | | 135 |
| Gly Gly Asn Gly Gly | His Val Ile Leu | Arg Val Asp Gln Gln | Val |
| 140 | 145 | | 150 |
| Lys Ser Leu Ser Ser | Val Leu Ser Arg | Tyr Gln Gly Phe Ser | Gly |
| 155 | 160 | | 165 |
| Glu Asp Gly Gly Ser | Lys Asn Cys Phe | Gly Arg Ser Gly Ala | Val |
| 170 | 175 | | 180 |
| Leu Tyr Ile Arg Val | Pro Val Gly Thr | Leu Val Lys Glu Gly | Gly |
| 185 | 190 | | 195 |
| Arg Val Val Ala Asp | Leu Ser Cys Val | Gly Asp Glu Tyr Ile | Ala |
| 200 | 205 | | 210 |
| Ala Leu Gly Gly Ala | Gly Gly Lys Gly | Asn Arg Phe Phe Leu | Ala |
| 215 | 220 | | 225 |
| Asn Asn Asn Arg Ala | Pro Val Thr Cys | Thr Pro Gly Gln Pro | Gly |
| 230 | 235 | | 240 |
| Gln Gln Arg Val Leu | His Leu Glu Leu | Lys Thr Val Ala His | Ala |
| 245 | 250 | | 255 |
| Gly Met Val Gly Phe | Pro Asn Ala Gly | Lys Ser Ser Leu Leu | Arg |
| 260 | 265 | | 270 |
| Ala Ile Ser Asn Ala | Arg Pro Ala Val | Ala Ser Tyr Pro Phe | Thr |
| 275 | 280 | | 285 |
| Thr Leu Lys Pro His | Val Gly Ile Val | His Tyr Glu Gly His | Leu |
| 290 | 295 | | 300 |
| Gln Ile Ala Val Ala | Asp Ile Pro Gly | Ile Ile Arg Gly Ala | His |
| 305 | 310 | | 315 |
| Gln Asn Arg Gly Leu | Gly Ser Ala Phe | Leu Arg His Ile Glu | Arg |
| 320 | 325 | | 330 |
| Cys Arg Phe Leu Leu | Phe Val Val Asp | Leu Ser Gln Pro Glu | Pro |
| 335 | 340 | | 345 |
| Trp Thr Gln Val Asp | Asp Leu Lys Tyr | Glu Leu Glu Met Tyr | Glu |
| 350 | 355 | | 360 |
| Lys Gly Leu Ser Ala | Arg Pro His Ala | Ile Val Ala Asn Lys | Ile |
| 365 | 370 | | 375 |
| Asp Leu Pro Glu Ala | Gln Ala Asn Leu | Ser Gln Leu Arg Asp | His |
| 380 | 385 | | 390 |
| Leu Gly Gln Glu Val | Ile Val Leu Ser | Ala Leu Thr Gly Glu | Asn |
| 395 | 400 | | 405 |
| Leu Glu Gln Leu Leu | Leu His Leu Lys | Val Leu Tyr Asp Ala | Tyr |
| 410 | 415 | | 420 |
| Ala Glu Ala Glu Leu | Gly Gln Gly Arg | Gln Pro Leu Arg Trp | |
| 425 | 430 | | |

<210> 26

<211> 826

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2504472CD1

<400> 26

```

Met Val Ala Pro Val Leu Glu Thr Ser His Val Phe Cys Cys Pro
1          5          10          15
Asn Arg Val Arg Gly Val Leu Asn Trp Ser Ser Gly Pro Arg Gly
20          25          30
Leu Leu Ala Phe Gly Thr Ser Cys Ser Val Val Leu Tyr Asp Pro
35          40          45
Leu Lys Arg Val Val Val Thr Asn Leu Asn Gly His Thr Ala Arg
50          55          60
Val Asn Cys Ile Gln Trp Ile Cys Lys Gln Asp Gly Ser Pro Ser
65          70          75
Thr Glu Leu Val Ser Gly Gly Ser Asp Asn Gln Val Ile His Trp
80          85          90
Glu Ile Glu Asp Asn Gln Leu Leu Lys Ala Val His Leu Gln Gly
95          100         105
His Glu Gly Pro Val Tyr Ala Val His Ala Val Tyr Gln Arg Arg
110         115         120
Thr Ser Asp Pro Ala Leu Cys Thr Leu Ile Val Ser Ala Ala Ala
125         130         135
Asp Ser Ala Val Arg Leu Trp Ser Lys Lys Gly Pro Glu Val Met
140         145         150
Cys Leu Gln Thr Leu Asn Phe Gly Asn Gly Phe Ala Leu Ala Leu
155         160         165
Cys Leu Ser Phe Leu Pro Asn Thr Asp Val Pro Ile Leu Ala Cys
170         175         180
Gly Asn Asp Asp Cys Arg Ile His Ile Phe Ala Gln Gln Asn Asp
185         190         195
Gln Phe Gln Lys Val Leu Ser Leu Cys Gly His Glu Asp Trp Ile
200         205         210
Arg Gly Val Glu Trp Ala Ala Phe Gly Arg Asp Leu Phe Leu Ala
215         220         225
Ser Cys Ser Gln Asp Cys Leu Ile Arg Ile Trp Lys Leu Tyr Ile
230         235         240
Lys Ser Thr Ser Leu Glu Thr Gln Asp Asp Asp Asn Ile Arg Leu
245         250         255
Lys Glu Asn Thr Phe Thr Ile Glu Asn Glu Ser Val Lys Ile Ala
260         265         270
Phe Ala Val Thr Leu Glu Thr Val Leu Ala Gly His Glu Asn Trp
275         280         285
Val Asn Ala Val His Trp Gln Pro Val Phe Tyr Lys Asp Gly Val
290         295         300
Leu Gln Gln Pro Val Arg Leu Leu Ser Ala Ser Met Asp Lys Thr
305         310         315
Met Ile Leu Trp Ala Pro Asp Glu Glu Ser Gly Val Trp Leu Glu
320         325         330
Gln Val Arg Val Gly Glu Val Gly Gly Asn Thr Leu Gly Phe Tyr
335         340         345
Asp Cys Gln Phe Asn Glu Asp Gly Ser Met Ile Ile Ala His Ala

```

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | | | | 350 | | | | | 355 | | | | | 360 |
| Phe | His | Gly | Ala | Leu | His | Leu | Trp | Lys | Gln | Asn | Thr | Val | Asn | Pro |
| | | | | 365 | | | | | 370 | | | | | 375 |
| Arg | Glu | Trp | Thr | Pro | Glu | Ile | Val | Ile | Ser | Gly | His | Phe | Asp | Gly |
| | | | | 380 | | | | | 385 | | | | | 390 |
| Val | Gln | Asp | Leu | Val | Trp | Asp | Pro | Glu | Gly | Glu | Phe | Ile | Ile | Thr |
| | | | | 395 | | | | | 400 | | | | | 405 |
| Val | Gly | Thr | Asp | Gln | Thr | Thr | Arg | Leu | Phe | Ala | Pro | Trp | Lys | Arg |
| | | | | 410 | | | | | 415 | | | | | 420 |
| Lys | Asp | Gln | Ser | Gln | Val | Thr | Trp | His | Glu | Ile | Ala | Arg | Pro | Gln |
| | | | | 425 | | | | | 430 | | | | | 435 |
| Ile | His | Gly | Tyr | Asp | Leu | Lys | Cys | Leu | Ala | Met | Ile | Asn | Arg | Phe |
| | | | | 440 | | | | | 445 | | | | | 450 |
| Gln | Phe | Val | Ser | Gly | Ala | Asp | Glu | Lys | Val | Leu | Arg | Val | Phe | Ser |
| | | | | 455 | | | | | 460 | | | | | 465 |
| Ala | Pro | Arg | Asn | Phe | Val | Glu | Asn | Phe | Cys | Ala | Ile | Thr | Gly | Gln |
| | | | | 470 | | | | | 475 | | | | | 480 |
| Ser | Leu | Asn | His | Val | Leu | Cys | Asn | Gln | Asp | Ser | Asp | Leu | Pro | Glu |
| | | | | 485 | | | | | 490 | | | | | 495 |
| Gly | Ala | Thr | Val | Pro | Ala | Leu | Gly | Leu | Ser | Asn | Lys | Ala | Val | Phe |
| | | | | 500 | | | | | 505 | | | | | 510 |
| Gln | Gly | Asp | Ile | Ala | Ser | Gln | Pro | Ser | Asp | Glu | Glu | Glu | Leu | Leu |
| | | | | 515 | | | | | 520 | | | | | 525 |
| Thr | Ser | Thr | Gly | Phe | Glu | Tyr | Gln | Gln | Val | Ala | Phe | Gln | Pro | Ser |
| | | | | 530 | | | | | 535 | | | | | 540 |
| Ile | Leu | Thr | Glu | Pro | Pro | Thr | Glu | Asp | His | Leu | Leu | Gln | Asn | Thr |
| | | | | 545 | | | | | 550 | | | | | 555 |
| Leu | Trp | Pro | Glu | Val | Gln | Lys | Leu | Tyr | Gly | His | Gly | Tyr | Glu | Ile |
| | | | | 560 | | | | | 565 | | | | | 570 |
| Phe | Cys | Val | Thr | Cys | Asn | Ser | Ser | Lys | Thr | Leu | Leu | Ala | Ser | Ala |
| | | | | 575 | | | | | 580 | | | | | 585 |
| Cys | Lys | Ala | Ala | Lys | Lys | Glu | His | Ala | Ala | Ile | Ile | Leu | Trp | Asn |
| | | | | 590 | | | | | 595 | | | | | 600 |
| Thr | Thr | Ser | Trp | Lys | Gln | Val | Gln | Asn | Leu | Val | Phe | His | Ser | Leu |
| | | | | 605 | | | | | 610 | | | | | 615 |
| Thr | Val | Thr | Gln | Met | Ala | Phe | Ser | Pro | Asn | Glu | Lys | Phe | Leu | Leu |
| | | | | 620 | | | | | 625 | | | | | 630 |
| Ala | Val | Ser | Arg | Asp | Arg | Thr | Trp | Ser | Leu | Trp | Lys | Lys | Gln | Asp |
| | | | | 635 | | | | | 640 | | | | | 645 |
| Thr | Ile | Ser | Pro | Glu | Phe | Glu | Pro | Val | Phe | Ser | Leu | Phe | Ala | Phe |
| | | | | 650 | | | | | 655 | | | | | 660 |
| Thr | Asn | Lys | Ile | Thr | Ser | Val | His | Ser | Arg | Ile | Ile | Trp | Ser | Cys |
| | | | | 665 | | | | | 670 | | | | | 675 |
| Asp | Trp | Ser | Pro | Asp | Ser | Lys | Tyr | Phe | Phe | Thr | Gly | Ser | Arg | Asp |
| | | | | 680 | | | | | 685 | | | | | 690 |
| Lys | Lys | Val | Val | Val | Trp | Gly | Glu | Cys | Asp | Ser | Thr | Asp | Asp | Cys |
| | | | | 695 | | | | | 700 | | | | | 705 |
| Ile | Glu | His | Asn | Ile | Gly | Pro | Cys | Ser | Ser | Val | Leu | Asp | Val | Gly |
| | | | | 710 | | | | | 715 | | | | | 720 |
| Gly | Ala | Val | Thr | Ala | Val | Ser | Val | Cys | Pro | Val | Leu | His | Pro | Ser |
| | | | | 725 | | | | | 730 | | | | | 735 |
| Gln | Arg | Tyr | Val | Val | Ala | Val | Gly | Leu | Glu | Cys | Gly | Lys | Ile | Cys |
| | | | | 740 | | | | | 745 | | | | | 750 |
| Leu | Tyr | Thr | Trp | Lys | Lys | Thr | Asp | Gln | Val | Pro | Glu | Ile | Asn | Asp |
| | | | | 755 | | | | | 760 | | | | | 765 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Thr | His | Cys | Val | Glu | Thr | Ser | Gln | Ser | Gln | Ser | His | Thr | Leu |
| | | | | 770 | | | | | 775 | | | | | 780 |
| Ala | Ile | Arg | Lys | Leu | Cys | Trp | Lys | Asn | Cys | Ser | Gly | Lys | Thr | Glu |
| | | | | 785 | | | | | 790 | | | | | 795 |
| Gln | Lys | Glu | Ala | Glu | Gly | Ala | Glu | Trp | Leu | His | Phe | Ala | Ser | Cys |
| | | | | 800 | | | | | 805 | | | | | 810 |
| Gly | Glu | Asp | His | Thr | Val | Lys | Ile | His | Arg | Val | Asn | Lys | Cys | Ala |
| | | | | 815 | | | | | 820 | | | | | 825 |

Leu

<210> 27

<211> 618

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3029920CD1

<400> 27

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Lys | Lys | Asp | Val | Arg | Ile | Leu | Leu | Val | Gly | Glu | Pro | Arg | Val |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
| Gly | Lys | Thr | Ser | Leu | Ile | Met | Ser | Leu | Val | Ser | Glu | Glu | Phe | Pro |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Glu | Glu | Val | Pro | Pro | Arg | Ala | Glu | Glu | Ile | Thr | Ile | Pro | Ala | Asp |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Val | Thr | Pro | Glu | Arg | Val | Pro | Thr | His | Ile | Val | Asp | Tyr | Ser | Glu |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Ala | Glu | Gln | Ser | Asp | Glu | Gln | Leu | His | Gln | Glu | Ile | Ser | Gln | Ala |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Asn | Val | Ile | Cys | Ile | Val | Tyr | Ala | Val | Asn | Asn | Lys | His | Ser | Ile |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Asp | Lys | Val | Thr | Ser | Arg | Trp | Ile | Pro | Leu | Ile | Asn | Glu | Arg | Thr |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Asp | Lys | Asp | Ser | Arg | Leu | Pro | Leu | Ile | Leu | Val | Gly | Asn | Lys | Ser |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Asp | Leu | Val | Glu | Tyr | Ser | Ser | Met | Glu | Thr | Ile | Leu | Pro | Ile | Met |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Asn | Gln | Tyr | Thr | Glu | Ile | Glu | Thr | Cys | Val | Glu | Cys | Ser | Ala | Lys |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Asn | Leu | Lys | Asn | Ile | Ser | Glu | Leu | Phe | Tyr | Tyr | Ala | Gln | Lys | Ala |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Val | Leu | His | Pro | Thr | Gly | Pro | Leu | Tyr | Cys | Pro | Glu | Glu | Lys | Glu |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Met | Lys | Pro | Ala | Cys | Ile | Lys | Ala | Leu | Thr | Arg | Ile | Phe | Lys | Ile |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Ser | Asp | Gln | Asp | Asn | Asp | Gly | Thr | Leu | Asn | Asp | Ala | Glu | Leu | Asn |
| | | | | 200 | | | | | 205 | | | | | 210 |
| Phe | Phe | Gln | Arg | Ile | Cys | Phe | Asn | Thr | Pro | Leu | Ala | Pro | Gln | Ala |
| | | | | 215 | | | | | 220 | | | | | 225 |
| Leu | Glu | Asp | Val | Lys | Asn | Val | Val | Arg | Lys | His | Ile | Ser | Asp | Gly |
| | | | | 230 | | | | | 235 | | | | | 240 |
| Val | Ala | Asp | Ser | Gly | Leu | Thr | Leu | Lys | Gly | Phe | Leu | Phe | Leu | His |
| | | | | 245 | | | | | 250 | | | | | 255 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Leu | Phe | Ile | Gln | Arg | Gly | Arg | His | Glu | Thr | Thr | Trp | Thr | Val |
| | | | | 260 | | | | | 265 | | | | | 270 |
| Leu | Arg | Arg | Phe | Gly | Tyr | Asp | Asp | Asp | Leu | Asp | Leu | Thr | Pro | Glu |
| | | | | 275 | | | | | 280 | | | | | 285 |
| Tyr | Leu | Phe | Pro | Leu | Leu | Lys | Ile | Pro | Pro | Asp | Cys | Thr | Thr | Glu |
| | | | | 290 | | | | | 295 | | | | | 300 |
| Leu | Asn | His | His | Ala | Tyr | Leu | Phe | Leu | Gln | Ser | Thr | Phe | Asp | Lys |
| | | | | 305 | | | | | 310 | | | | | 315 |
| His | Asp | Leu | Asp | Arg | Asp | Cys | Ala | Leu | Ser | Pro | Asp | Glu | Leu | Lys |
| | | | | 320 | | | | | 325 | | | | | 330 |
| Asp | Leu | Phe | Lys | Val | Phe | Pro | Tyr | Ile | Pro | Trp | Gly | Pro | Asp | Val |
| | | | | 335 | | | | | 340 | | | | | 345 |
| Asn | Asn | Thr | Val | Cys | Thr | Asn | Glu | Arg | Gly | Trp | Ile | Thr | Tyr | Gln |
| | | | | 350 | | | | | 355 | | | | | 360 |
| Gly | Phe | Leu | Ser | Gln | Trp | Thr | Leu | Thr | Thr | Tyr | Leu | Asp | Val | Gln |
| | | | | 365 | | | | | 370 | | | | | 375 |
| Arg | Cys | Leu | Glu | Tyr | Leu | Gly | Tyr | Leu | Gly | Tyr | Ser | Ile | Leu | Thr |
| | | | | 380 | | | | | 385 | | | | | 390 |
| Glu | Gln | Glu | Ser | Gln | Ala | Ser | Ala | Val | Thr | Val | Thr | Arg | Asp | Lys |
| | | | | 395 | | | | | 400 | | | | | 405 |
| Lys | Ile | Asp | Leu | Gln | Lys | Lys | Gln | Thr | Gln | Arg | Asn | Val | Phe | Arg |
| | | | | 410 | | | | | 415 | | | | | 420 |
| Cys | Asn | Val | Ile | Gly | Val | Lys | Asn | Cys | Gly | Lys | Ser | Gly | Val | Leu |
| | | | | 425 | | | | | 430 | | | | | 435 |
| Gln | Ala | Leu | Leu | Gly | Arg | Asn | Leu | Met | Arg | Gln | Lys | Lys | Ile | Arg |
| | | | | 440 | | | | | 445 | | | | | 450 |
| Glu | Asp | His | Lys | Ser | Tyr | Tyr | Ala | Ile | Asn | Thr | Val | Tyr | Val | Tyr |
| | | | | 455 | | | | | 460 | | | | | 465 |
| Gly | Gln | Glu | Lys | Tyr | Leu | Leu | Leu | His | Asp | Ile | Ser | Glu | Ser | Glu |
| | | | | 470 | | | | | 475 | | | | | 480 |
| Phe | Leu | Thr | Glu | Ala | Glu | Ile | Ile | Cys | Asp | Val | Val | Cys | Leu | Val |
| | | | | 485 | | | | | 490 | | | | | 495 |
| Tyr | Asp | Val | Ser | Asn | Pro | Lys | Ser | Phe | Glu | Tyr | Cys | Ala | Arg | Ile |
| | | | | 500 | | | | | 505 | | | | | 510 |
| Phe | Lys | Gln | His | Phe | Met | Asp | Ser | Arg | Ile | Pro | Cys | Leu | Ile | Val |
| | | | | 515 | | | | | 520 | | | | | 525 |
| Ala | Ala | Lys | Ser | Asp | Leu | His | Glu | Val | Lys | Gln | Glu | Tyr | Ser | Ile |
| | | | | 530 | | | | | 535 | | | | | 540 |
| Ser | Pro | Thr | Asp | Phe | Cys | Arg | Lys | His | Lys | Met | Pro | Pro | Pro | Gln |
| | | | | 545 | | | | | 550 | | | | | 555 |
| Ala | Phe | Thr | Cys | Asn | Thr | Ala | Asp | Ala | Pro | Ser | Lys | Asp | Ile | Phe |
| | | | | 560 | | | | | 565 | | | | | 570 |
| Val | Lys | Leu | Thr | Thr | Met | Ala | Met | Tyr | Pro | His | Val | Thr | Gln | Ala |
| | | | | 575 | | | | | 580 | | | | | 585 |
| Asp | Leu | Lys | Ser | Ser | Thr | Phe | Trp | Leu | Arg | Ala | Ser | Phe | Gly | Ala |
| | | | | 590 | | | | | 595 | | | | | 600 |
| Thr | Val | Phe | Ala | Val | Leu | Gly | Phe | Ala | Met | Tyr | Lys | Ala | Leu | Leu |
| | | | | 605 | | | | | 610 | | | | | 615 |

Lys Gln Arg

<210> 28
 <211> 596
 <212> PRT
 <213> Homo sapiens

<223> Incyte ID No: 3332415CD1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Pro | Glu | Leu | Asp | Ala | Gln | Lys | Gln | Pro | Arg | Pro | Arg | Arg | 15 |
| 1 | | | | 5 | | | | | 10 | | | | | | |
| Arg | Ser | Arg | Arg | Ala | Ser | Gly | Leu | Ser | Thr | Glu | Gly | Ala | Thr | Gly | 30 |
| | | | | 20 | | | | | 25 | | | | | | |
| Pro | Ser | Ala | Asp | Thr | Ser | Gly | Ser | Glu | Leu | Asp | Gly | Arg | Cys | Ser | 45 |
| | | | | 35 | | | | | 40 | | | | | | |
| Leu | Arg | Arg | Gly | Ser | Ser | Phe | Thr | Phe | Leu | Thr | Pro | Gly | Pro | Asn | 60 |
| | | | | 50 | | | | | 55 | | | | | | |
| Trp | Asp | Phe | Thr | Leu | Lys | Arg | Lys | Arg | Arg | Glu | Lys | Asp | Asp | Asp | 75 |
| | | | | 65 | | | | | 70 | | | | | | |
| Val | Val | Ser | Leu | Ser | Ser | Leu | Asp | Leu | Lys | Glu | Pro | Ser | Asn | Lys | 90 |
| | | | | 80 | | | | | 85 | | | | | | |
| Arg | Val | Arg | Pro | Leu | Ala | Arg | Val | Thr | Ser | Leu | Ala | Asn | Leu | Ile | 105 |
| | | | | 95 | | | | | 100 | | | | | | |
| Ser | Pro | Val | Arg | Asn | Gly | Ala | Val | Arg | Arg | Phe | Gly | Gln | Thr | Ile | 120 |
| | | | | 110 | | | | | 115 | | | | | | |
| Gln | Ser | Phe | Thr | Leu | Arg | Gly | Asp | His | Arg | Ser | Pro | Ala | Ser | Ala | 135 |
| | | | | 125 | | | | | 130 | | | | | | |
| Gln | Lys | Phe | Ser | Ser | Arg | Ser | Thr | Val | Pro | Thr | Pro | Ala | Lys | Arg | 150 |
| | | | | 140 | | | | | 145 | | | | | | |
| Arg | Ser | Ser | Ala | Leu | Trp | Ser | Glu | Met | Leu | Asp | Ile | Thr | Met | Lys | 165 |
| | | | | 155 | | | | | 160 | | | | | | |
| Glu | Ser | Leu | Thr | Thr | Arg | Glu | Ile | Arg | Arg | Gln | Glu | Ala | Ile | Tyr | 180 |
| | | | | 170 | | | | | 175 | | | | | | |
| Glu | Met | Ser | Arg | Gly | Glu | Gln | Asp | Leu | Ile | Glu | Asp | Leu | Lys | Leu | 195 |
| | | | | 185 | | | | | 190 | | | | | | |
| Ala | Arg | Lys | Ala | Tyr | His | Asp | Pro | Met | Leu | Lys | Leu | Ser | Ile | Met | 210 |
| | | | | 200 | | | | | 205 | | | | | | |
| Ser | Glu | Glu | Glu | Leu | Thr | His | Ile | Phe | Gly | Asp | Leu | Asp | Ser | Tyr | 225 |
| | | | | 215 | | | | | 220 | | | | | | |
| Ile | Pro | Leu | His | Glu | Asp | Leu | Leu | Thr | Arg | Ile | Gly | Glu | Ala | Thr | 240 |
| | | | | 230 | | | | | 235 | | | | | | |
| Lys | Pro | Asp | Gly | Thr | Val | Glu | Gln | Ile | Gly | His | Ile | Leu | Val | Ser | 255 |
| | | | | 245 | | | | | 250 | | | | | | |
| Trp | Leu | Pro | Arg | Leu | Asn | Ala | Tyr | Arg | Gly | Tyr | Cys | Ser | Asn | Gln | 270 |
| | | | | 260 | | | | | 265 | | | | | | |
| Leu | Ala | Ala | Lys | Ala | Leu | Leu | Asp | Gln | Lys | Lys | Gln | Asp | Pro | Arg | 285 |
| | | | | 275 | | | | | 280 | | | | | | |
| Val | Gln | Asp | Phe | Leu | Gln | Arg | Cys | Leu | Glu | Ser | Pro | Phe | Ser | Arg | 300 |
| | | | | 290 | | | | | 295 | | | | | | |
| Lys | Leu | Asp | Leu | Trp | Ser | Phe | Leu | Asp | Ile | Pro | Arg | Ser | Arg | Leu | 315 |
| | | | | 305 | | | | | 310 | | | | | | |
| Val | Lys | Tyr | Pro | Leu | Leu | Leu | Lys | Glu | Ile | Leu | Lys | His | Thr | Pro | 330 |
| | | | | 320 | | | | | 325 | | | | | | |
| Lys | G | | | | | | | | | | | | | | |

```

Gln Arg Asp Pro Arg Ile Glu Ala Ser Lys Val Leu Leu Cys His
380 385 390
Gly Glu Leu Arg Ser Lys Ser Gly His Lys Leu Tyr Ile Phe Leu
395 400 405
Phe Gln Asp Ile Leu Val Leu Thr Arg Pro Val Thr Arg Asn Glu
410 415 420
Arg His Ser Tyr Gln Val Tyr Arg Gln Pro Ile Pro Val Gln Glu
425 430 435
Leu Val Leu Glu Asp Leu Gln Asp Gly Asp Val Arg Met Gly Gly
440 445 450
Ser Phe Arg Gly Ala Phe Ser Asn Ser Glu Lys Ala Lys Asn Ile
455 460 465
Phe Arg Ile Arg Phe His Asp Pro Ser Pro Ala Gln Ser His Thr
470 475 480
Leu Gln Ala Asn Asp Val Phe His Lys Gln Gln Trp Phe Asn Cys
485 490 495
Ile Arg Ala Ala Ile Ala Pro Phe Gln Ser Ala Gly Ser Pro Pro
500 505 510
Glu Leu Gln Gly Leu Pro Glu Leu His Glu Glu Cys Glu Gly Asn
515 520 525
His Pro Ser Ala Arg Lys Leu Thr Ala Gln Arg Arg Ala Ser Thr
530 535 540
Val Ser Ser Val Thr Gln Val Glu Val Asp Glu Asn Ala Tyr Arg
545 550 555
Cys Gly Ser Gly Met Gln Met Ala Glu Asp Ser Lys Ser Leu Lys
560 565 570
Thr His Gln Thr Gln Pro Gly Ile Arg Arg Ala Arg Asp Lys Ala
575 580 585
Leu Ser Gly Gly Lys Arg Lys Glu Thr Leu Val
590 595

```

<210> 29

<211> 589

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4031536CD1

<400> 29

```

Met Ser Lys Pro Gly Lys Pro Thr Leu Asn His Gly Leu Val Pro
1 5 10 15
Val Asp Leu Lys Ser Ala Lys Glu Pro Leu Pro His Gln Thr Val
20 25 30
Met Arg Ile Phe Ser Ile Ser Ile Ile Ala Gln Gly Leu Pro Phe
35 40 45
Cys Arg Arg Arg Met Lys Arg Lys Leu Asp His Gly Ser Glu Val
50 55 60
Arg Ser Phe Ser Leu Gly Lys Lys Pro Cys Lys Val Ser Glu Tyr
65 70 75
Thr Ser Thr Thr Gly Leu Val Pro Cys Ser Ala Thr Pro Thr Thr
80 85 90
Phe Gly Asp Leu Arg Ala Ala Asn Gly Gln Gly Gln Gln Arg Arg

```

| | | | | | |
|---------------------|-----------------|---------------------|-----|--|-----|
| | 95 | | 100 | | 105 |
| Arg Ile Thr Ser Val | Gln Pro Pro Thr | Gly Leu Gln Glu Trp | Leu | | |
| | 110 | | 115 | | 120 |
| Lys Met Phe Gln Ser | Trp Ser Gly Pro | Glu Lys Leu Leu Ala | Leu | | |
| | 125 | | 130 | | 135 |
| Asp Glu Leu Ile Asp | Ser Cys Glu Pro | Thr Gln Val Lys His | Met | | |
| | 140 | | 145 | | 150 |
| Met Gln Val Ile Glu | Pro Gln Phe Gln | Arg Asp Phe Ile Ser | Leu | | |
| | 155 | | 160 | | 165 |
| Leu Pro Lys Glu Leu | Ala Leu Tyr Val | Leu Ser Phe Leu Glu | Pro | | |
| | 170 | | 175 | | 180 |
| Lys Asp Leu Leu Gln | Ala Ala Gln Thr | Cys Arg Tyr Trp Arg | Ile | | |
| | 185 | | 190 | | 195 |
| Leu Ala Glu Asp Asn | Leu Leu Trp Arg | Glu Lys Cys Lys Glu | Glu | | |
| | 200 | | 205 | | 210 |
| Gly Ile Asp Glu Pro | Leu His Ile Lys | Arg Arg Lys Val Ile | Lys | | |
| | 215 | | 220 | | 225 |
| Pro Gly Phe Ile His | Ser Pro Trp Lys | Ser Ala Tyr Ile Arg | Gln | | |
| | 230 | | 235 | | 240 |
| His Arg Ile Asp Thr | Asn Trp Arg Arg | Gly Glu Leu Lys Ser | Pro | | |
| | 245 | | 250 | | 255 |
| Lys Val Leu Lys Gly | His Asp Asp His | Val Ile Thr Cys Leu | Gln | | |
| | 260 | | 265 | | 270 |
| Phe Cys Gly Asn Arg | Ile Val Ser Gly | Ser Asp Asp Asn Thr | Leu | | |
| | 275 | | 280 | | 285 |
| Lys Val Trp Ser Ala | Val Thr Gly Lys | Cys Leu Arg Thr Leu | Val | | |
| | 290 | | 295 | | 300 |
| Gly His Thr Gly Gly | Val Trp Ser Ser | Gln Met Arg Asp Asn | Ile | | |
| | 305 | | 310 | | 315 |
| Ile Ile Ser Gly Ser | Thr Asp Arg Thr | Leu Lys Val Trp Asn | Ala | | |
| | 320 | | 325 | | 330 |
| Glu Thr Gly Glu Cys | Ile His Thr Leu | Tyr Gly His Thr Ser | Thr | | |
| | 335 | | 340 | | 345 |
| Val Arg Cys Met His | Leu His Glu Lys | Arg Val Val Ser Gly | Ser | | |
| | 350 | | 355 | | 360 |
| Arg Asp Ala Thr Leu | Arg Val Trp Asp | Ile Glu Thr Gly Gln | Cys | | |
| | 365 | | 370 | | 375 |
| Leu His Val Leu Met | Gly His Val Ala | Ala Val Arg Cys Val | Gln | | |
| | 380 | | 385 | | 390 |
| Tyr Asp Gly Arg Arg | Val Val Ser Gly | Ala Tyr Asp Phe Met | Val | | |
| | 395 | | 400 | | 405 |
| Lys Val Trp Asp Pro | Glu Thr Glu Thr | Cys Leu His Thr Leu | Gln | | |
| | 410 | | 415 | | 420 |
| Gly His Thr Asn Arg | Val Tyr Ser Leu | Gln Phe Asp Gly Ile | His | | |
| | 425 | | 430 | | 435 |
| Val Val Ser Gly Ser | Leu Asp Thr Ser | Ile Arg Val Trp Asp | Val | | |
| | 440 | | 445 | | 450 |
| Glu Thr Gly Asn Cys | Ile His Thr Leu | Thr Gly His Gln Ser | Leu | | |
| | 455 | | 460 | | 465 |
| Thr Ser Gly Met Glu | Leu Lys Asp Asn | Ile Leu Val Ser Gly | Asn | | |
| | 470 | | 475 | | 480 |
| Ala Asp Ser Thr Val | Lys Ile Trp Asp | Ile Lys Thr Gly Gln | Cys | | |
| | 485 | | 490 | | 495 |
| Leu Gln Thr Leu Gln | Gly Pro Asn Lys | His Gln Ser Ala Val | Thr | | |
| | 500 | | 505 | | 510 |

Cys Leu Gln Phe Asn Lys Asn Phe Val Ile Thr Ser Ser Asp Asp
 515 520 525
 Gly Thr Val Lys Leu Trp Asp Leu Lys Thr Gly Glu Phe Ile Arg
 530 535 540
 Asn Leu Val Thr Leu Glu Ser Gly Gly Ser Gly Gly Val Val Trp
 545 550 555
 Arg Ile Arg Ala Ser Asn Thr Lys Leu Val Cys Ala Val Gly Ser
 560 565 570
 Arg Asn Gly Thr Glu Glu Thr Lys Leu Leu Val Leu Asp Phe Asp
 575 580 585
 Val Asp Met Lys

<210> 30

<211> 3375

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 708398CB1

<400> 30

```

ggggagaagg gagcccgag gatcaggggt cagagttagg gggcttccct cctgctgcac 60
cctcatctca gggccgcca cttccagctg cagcggcgac tttcagtttc atttccacgg 120
acctctctgc ctgggcccgc agccgcccgc gcgatgcccc gtaagttcag ctgccggcag 180
ctccggggagg cgggccagt tttcgagagt ttcttggtcg ttccggggact ggacatggag 240
acagatcgcg agcggctgcg gaccatttat aaccgcgact tcaagatcag ctttgggacc 300
cccgcccctg gcttctcctc catgctgtat ggaatgaaga ttgcaaactt ggccctacgtc 360
accaagactc gggtcagggt cttcagactc gaccgctggg ccgacgtgcg gttcccagaa 420
aagaggagaa tgaagctggg gtcagatata agcaaacacc acaagtcact gctagccaag 480
atcttttatg acagggctga gtatcttcat gggaaacatg gtgtggatgt ggaagtccag 540
gggccccatg aagcccagaga tgggcagctc cttatccgcc tggatttgaa ccgcaaagag 600
gtgctgaccc tgaggcttcg gaatggcgga acccagctcg ttacctcac tcacctcttc 660
ccactctgcc ggacacccca gtttgctttc tacaatgaag accaggagt gacctgtcca 720
ctgggccccg gtgaatgcta tgaactccat gtccattgta agaccagctt tgtgggctac 780
ttcccagcca cagtgtctcg ggagctgctg ggacctgggg agtcgggttc agaaggagcc 840
ggcacattct acattgccc cttcttggtt gccgtcgccc acagccccct ggctgcacag 900
ctgaagccca tgactccctt caagcggacc cggatcaccc gaaaccctgt ggtgaccaat 960
cggatagagg aaggagagag acctgaccgc gctaaggggt atgacctgga gttaagtatg 1020
gcgctgggga catactacct acctccccgc ctcaggcagc tgctcccat gcttcttcag 1080
ggaacaagta tcttactgct ccctaaggag atcgcagaga tcaaggccca gctggagaca 1140
gccctgaagt ggaggaacta tgaggtgaag ctgcggctgc tgctgcacct ggaggaactg 1200
cagatggagc atgatatccg gcactatgac ctggagtcgg tgcccatgac ctgggacctt 1260
gtggaccaga acccagggt gctcacgctg gaggttcctg gagtgactga gagccgcccc 1320
tcagtgttac ggggcgacca cctgtttgcc cttttgtcct cggagacaca ccaggaggac 1380
cccatcacat ataagggtt tgtgcacaag gtggaattgg accgtgtcaa gctgagcttt 1440
tccatgagcc tctgagccg ctttgtggat gggctgacct tcaagggtgaa ctttaccttc 1500
aaccgccagc cgctgcgagt ccagaccgt gccctggagc tgacagggcg ctggctgctg 1560
tggcccatgc tctttctgtt ggcacctcg gacgtcccg tgctgccctc agatgtgaaa 1620
ctcaagctgt acgaccggag tctggagtca aaccagagc agctgcaggc catgaggcac 1680
attgttacgg gcaccaccg tccagcccc tacatcatct ttgggcctcc aggcacccgg 1740
aagactgtca cgttagtga ggcaattaag caggtggtga agcacttgcc caaagccac 1800
atcttggcct gcgtccatc caactcagg gctgacctac tctgtcaaag gctccgggtc 1860
caccttcta gctccatcta ccgctcctg gccccagca gggacatccg catggtacct 1920

```

```

gaggacatca agccctgctg caactgggac gcaaagaagg gggagtatgt atttcccgcc 1980
aagaagaagc tgcaggaata cggggtctta attaccaccc tcatcactgc cggcaggttg 2040
gtctcggccc agtttcccat tgatcacttc acacacatct tcatcgatga ggctggccac 2100
tgcattggagc ctgagagtct ggtagctata gcaagggtga tggaaagtaa ggaaacaggt 2160
gatccaggag ggcagctggg gctggcagga gaccctcggc agctggggcc tgtgctgcgt 2220
tccccactga cccagaagca tggactggga tactcactgc tggagcggct gctcatctac 2280
aactccctgt acaagaaggg ccctgatggc tatgaccccc agttcataac caagctgctc 2340
cgcaactaca ggtctcatcc caccatcctg gacattccta accagctcta ttatgaaggg 2400
gagctgcagg cctgtgctga tgtcgtggat cgagaacgct tctgccgctg ggcgggccta 2460
cctcgacagg gctttcccat catctttcac ggcgtaatgg gcaaagatga gctgaaggc 2520
aacagcccat ccttcttcaa ccctgaagag gctgccacag tgacttccta cctgaagctg 2580
ctcctggccc cctcctccaa gaagggcaaa gctcgcctga gccctcgaag tgtgggcgtc 2640
atctccccgt accggaaaca ggtggagaaa atccgttact gcatcaccaa acttgacagg 2700
gagcttcgag gactggatga catcaaggac ttgaagggtg gttcagtaga agaattccaa 2760
ggccaagaac gaagcgtcat cctcatctcc accgtgcgaa gcagccagag cttgtgagc 2820
ctggatctgg actttaatct gggtttcctt aagaaccccc agagggtcaa tgtagctgtg 2880
acccgggcca aggcctgct catcatcgtg gggaaccccc ttctcctggg ccatgaccct 2940
gactggaaaag tattcctgga gttctgtaaa gaaaacggag ggtataccgg gtgtcccttc 3000
cctgccaaac tggacctgca acagggacag aatttactgc aaggctctgag caagctcagc 3060
ccctctacct caggggccca cagccatgac tacctcccc aggagcggga ggggaaggg 3120
ggcctgtctc tgcaagtgga gccagagtgg aggaatgagc tctgaagaca cagcaccag 3180
ccttctcgca ccagccaagc cttaactgcc tgctgaccc tgaaccagaa ccagctgaa 3240
ctgccccctc aagggacagg aaggctgggg gagggagtgtt acaaccaag ccattccacc 3300
ccctccccctg ctggggagaa tgacacatca agctgctaac aattggggga aggggaagga 3360
agaaaactct gaaac 3375

```

<210> 31

<211> 2434

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1259937CB1

<400> 31

```

caaggatccg atgggtatat ggagtgtgag gtaatggatc attcatgtgg aaggatgcag 60
gggggtttttg agaccagggg ttggaagaga gttcagcact gctggtagtt ttgggaatca 120
cccatgtgca ggcgacacat gaggcagtaa ggaactctgc aggggtccct gagatttgga 180
aatgtaggga agagcaatgg attgaggtcc gaacctggag gatctgctat acgcagagct 240
gggaggaggg acagagtcag taccagagtc ggaaaaaagc aggggtggga ggggaacctg 300
agtcaggaga cttgcctggc aggcgtgccc ctgccagcag aggcctgaca gtggtttcca 360
tgaactgcat ccctgctgtg ggctgggaca gggccactga cacagtatcg gagcacagaa 420
ggggaaaagga gcaggaggga ttccaactct gccagtttagc agctgtgtgg ctttgggcat 480
gttactttaac ctctctgagc ctcatattatt tcatccataa aatggaaata aaaataatac 540
ttttgtcaaa ggcgcattgt gaatatattag atcctcagaa taatgcctgg cttgtagcaa 600
atggtagctg gaggaaggg aagagaaaac caaagtcagc agctgaagga ttttcatatt 660
agaactgctc tggacctatc tggcagatgc agaagcacac acacacggag gggcatggat 720
ttgccccgcc cttagacatg ttgtgtcttc tctgggatcc ttggtcccag gtgccttacc 780
tgagctcagg tgaatgtggc aagcagagcc ctctgggtgg gtgaatgctg tgtggcgccc 840
gtgctcctgg tgacacaggg acctcacaat ccctccccct acgggtcctc ctcatgtcct 900
cccagcctta ttttctcgtt cctcttctct ccaggccccg aacttgctg tttggctccc 960
caaccaggac gagccccctc ctggcagcag ctgtgccatc caagttgggg ataaagtccc 1020
ctatgacatc tgccggccag accactcagt gttgaccctg cagctgcctg tgacagcctc 1080

```

```

cgtgagagag gtgatggcag cgttggccca ggaggatggc tggaccaagg ggcagggtgct 1140
ggtgaagggtc aattctgcag gtgatgccat tggcctgcag ccagatgccc gtggtgtggc 1200
cacatctctg gggctcaatg agcgtctctt tgttgtcaac ccacaggaag tgcattgagct 1260
gatccacac cctgaccagc tggggccac tgtgggctct gctgaggggc tggacctggt 1320
gagtggcaag gacctggcag gccagctgac ggaccacgac tggagcctct tcaacagtat 1380
ccaccagggtg gagctgatcc actatgtgct gggccccccag catctgcggg atgtcaccac 1440
cgccaacctg gagcgcttca tgcgcgctt caatgagctg cagtactggg tggccaccga 1500
gctgtgtctc tgcctcgtgc ccggcccccg ggcccagctg ctgaggaagt tcattaagct 1560
ggcgggccac ctcaaggagc agaagaatct caattccttc ttgccgtca tgtttggcct 1620
cagcaactcg gccatcagcc gcctagccca cactgggag cggctgcctc acaaagtccg 1680
gaagctgtac tccgcccctg agaggctgct ggatccctca tggaaaccac ggggtataccg 1740
actggccctc gccaaagctct cccctcctgt catcccttc atgccccttc ttctcaaaga 1800
catgaccttc attcatgagg gaaaccacac actagtggag aatctcatca actttgagaa 1860
gatgagaatg atggccagag ccgcgcggat gctgcaccac tgcgaagcc acaaccctgt 1920
gcctctctca ccactcagaa gccgagtttc ccacctccac gaggacagcc aggtggcgag 1980
gatttcacac tgctcggagc agtccctgag ccccgaggat ccagccagca cctgggctta 2040
tgtccagcag ctgaaggctca ttgacaacca gcgggaactc tcccgccctc cccgagagct 2100
ggagccatga ggaggggctg ggactggagc tggagcaggc acttgagcc gggaaaagcca 2160
gggtgtgccc ggccaagata ctacacaggct ggccacagct gggcaaggct ctccgtggag 2220
tggactcgag tccctggagc aggcagtgtg gaggcagcca tccctgtga tgactggcag 2280
ctaaggagga cctcggagtg gacccgagcc aggaataacg aatgacccaa ggccaaggaa 2340
gggaggacag agaggcccca ggagtgggtg gagagtggag tgcgctggga cgttgtgtgc 2400
aatagagagg tctccacacc agaaaaaaaa aaaa 2434

```

<210> 32

<211> 892

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1452285CB1

<400> 32

```

cacgcctctc tctgcacctc cacttgcgct ccccaagtct ctctcgtgag cagagcccag 60
gctgcgcttc cctgggtcagg cacggcacgt ctggccggcc gccaggatgc agggcccgcga 120
caaggagcac ctgtacaagt tgctgggtgat tggcgacctg ggcgtgggga agaccagtat 180
catcaagcgc tacgtgcacc agaacttctc ctgcgactac cgggccacaa tcggcggtgga 240
cttcgcgctc aagggtgctcc actgggaccc ggagactgtg gtgcgcctgc agctctggga 300
tatcgcagggt caagaaagat ttggaaacat gacgaggggtc tattaccgag aagctatggg 360
tgcatttatt gtcttcgatg tcaccaggcc agccacattt gaagcagtgg caaagtggaa 420
aaatgatttg gactccaagt taagtctccc taatggcaaa ccggtttcag tggttttgtt 480
ggccaacaaa tgtgaccagg ggaaggatgt gctcatgaac aatggcctca agatggacca 540
gttctgcaag gagcacggtt tcgtaggatg gtttgaaaca tcagcaaagg aaaatataaa 600
cattgatgaa gcctccagat gcctgggtgaa acacatactt gcaaatgagt gtgacctaat 660
ggagtctatt gagccggagc tcgtgaagcc ccattctaca tcaaccaagg ttgccagctg 720
ctctggctgt gccaaatcct agtaggcacc tttgctgggt tctggtagga atgacctcat 780
tgttccacaa attgtgcctc tatttttacc attttgggtg aacgtcagga tagagatacc 840
acatgtggca agccaaagat ctatgcctcc atatgtgcct ttctgttagc tt 892

```

<210> 33

<211> 2288

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1812894CB1

<400> 33

```
cggctcgagc ccagatggag gcaacagtac taggttcgag gacttgctaa gccggtaggt 60
ggcctgggggt aagagatggg aagagaggct gatccctgtc cccacagca ctggaggact 120
cccgggtccca ggaaggggca aatggtgagg ccgagtcagg tgagctcagc cggcttcggg 180
ctgagctggc aggcgccttg gcagaaatgg aaaccatgaa ggctgtggca gaggtgagcg 240
agagcacgaa ggccgaggct gtggctgcgg tgcagcggca gtgccaagag gaggtggcct 300
cgctgcaggc catcctgaaa gactccatca gcagctatga agcccagatc accgccctga 360
agcaggagcg acagcagcag cagcaggact gtgaggagaa ggagcgggag ctgggccgcc 420
tgaagcagct gctgtcccgg gcctaccccc tggactccct ggagaagcag atggaaaagg 480
cccacgagga ctcggagaag ctgcccggaga tctactgcc catggaaaag gagatcgagg 540
agctgaaggc gaagctgctg agggccgagg agctgattca ggagatccag agacgtcccc 600
ggcatgcccc ttccctgcac ggctccacgg agttgctgcc cctgtcccgg gatccatcgc 660
ccccgctgga gcctctggag gagctgagcg gagatggggg tccagccgct gaggccttcg 720
ctcacaactg cgatgacagc gcctccatct cctccttctc ccttgccggt ggggtcggca 780
gcagctcctc cctgccccaa agccgccagg gcctgagccc tgaacaggaa gagacggcct 840
cgctgggtgtc tacgggcacc ctgggttccc agggcatcta cctgccccct cctggctacc 900
agctcgtccc agacactcag tgggagcagc tgcagacaga gggccgacag ctgcagaagg 960
acctggagag cgtcagtcgc gagcgggagc agctccaaga gggcctgaga cggagcaatg 1020
aggactgtgc caagcagatg cagggtgctcc tggcccaggc ccagaactca gagcagctgc 1080
tgccggaccct gcaagggacc gtgagccagg cccaggagcg ggtgcagctg cagatggcgg 1140
agctgggtcac caccacaag tgccctgcacc atgaggtaaa gcggttgaat gaggaaaacc 1200
aagggtcccg ggccgagcag ctgccatcct cagcccccca gggctcgcag caggagcagg 1260
gcgaggagga atcactgccc agctctgtgc cagagctgca gcagctgctg tgctgcacgc 1320
ggcaagaggc gagggcccggt ctgcaggccc aggagcacgg ggccgagcgc ctgcggatcg 1380
agatcgtgac gctgcgggag gctctggagg aggagacagt ggccaggggc agcctggagg 1440
ggcagctgag ggtgcagcgg gaggagacag aggtgctgga ggcctccctg tgcagcctga 1500
ggacagagat ggagcgggtg cagcaggaac agagcaaggc ccagctccca gacctcctct 1560
cagaacagag ggccaagggt ctgcggctgc aggcagagct ggagaccagt gagcagggtgc 1620
agagggattt cgtgcgactg tcccaggccc tgcagggtgc cctagagcgg atccgccagg 1680
ctgagaccct ggagcaagtg cgcagcatca tggatgaggc gccactcacg gacgtcaggg 1740
acatcaagga cacctgaggg gtcaggatat cccaccccc accctgggaa agacgccttt 1800
ccccactcct gaaccatgag gcctcgtctt ggggtcttgg atggcttttc caccgtccct 1860
gagactgggg ttgaggggac tgacgggggc caccaccgcc ccgcccctca gcgcctcctc 1920
ccagggtggc tgggcctcct gttctcaggg atcacacctg ggtgaggggc ccaagccctt 1980
cccggaaacca aaggtgcagg ctccaggcctg cggctttctg gctgctgtgc tgccctcctg 2040
getccagccc tcccctgccc ccagcccgtc ccctgcccag ggcacagcgg agccatgggg 2100
gctgggagtc cccatcagag gcagtgaggt gggccccggc cctgggacag gcagctgcct 2160
tctggtctgc atgacactaa gacgttgtc cacagcggcg acccaggcct ccaagcttgc 2220
acagaggcaa ggccagactt ttccgtcggt tattttcaat aaataagcag ctacgcgcaa 2280
aaaaaaaa
```

<210> 34

<211> 1813

<212> DNA

<213> Homo sapiens

<220>
<221> unsure
<222> 1708, 1711, 1713, 1715
<223> Incyte ID No: a or g or c or t, unknown, or other

<220>
<221> misc_feature
<223> Incyte ID No: 3074884CB1

<400> 34
gcacgaagga ggcccggcctt caggtggccc tggcggagat gccggaagat gcggacgaga 60
acgccgagga ggagctgctg cgggggagagc ctctgctgcc ggccggggacc cagcgcgtgt 120
gtctgggttca ccctgacgtc aagtggggcc cggggaagtc gcagatgact cgagccgagt 180
ggcaggtggc ggaggccaca gcgctgggtg acacgctgga cggctgggtcc gtggtgcaga 240
caatggctgt gtccaccaa acgccggaca ggaagctcat ctttggcaaa gggaactttg 300
agcacctgac agaaaagatc cgagggtctc cagacgtcac gtgctcttc ctgaacgtgg 360
agaggatggc tgccccgacc aagaaagaac tggagccgc ctggggcgtg gaggtgtttg 420
accgcttcac ggtcgtcctg cacatcttcc gctgtaacgc ccgcacgaag gaggccggc 480
ttcaggtggc cctggcggag atgccgctgc acaggtcgaa cttgaaaagg gacgtcgccc 540
acctgtaccg aggagtcggc tcgcgttaca tcatggggtc aggagaatcc ttcattgcagc 600
tgcagcagcg tctcctgaga gagaaggagg ccaagatcag gaaggccttg gacaggcttc 660
gcaagaagag gcacctgtc cgccggcagc ggacgaggcg ggagttcccc gtgatctccg 720
tggtggggta caccaactgc ggaaagacca cgctgatcaa ggcactgacg ggcatgccg 780
ccatccagcc acgggaccag ctgtttgcca cgctggacgt cacggccac gcgggcacgc 840
tgccctcacg catgaccgtc ctgtacgtgg acaccatcgg ctctctctcc cagctgcgcg 900
acggcctcat cgagtccttc tccgccaccc tggagacgt ggccactcg gatctcatct 960
tgcacgtgag ggacgtcagc caccgccagg cggagctcca gaaatgcagc gttctgtcca 1020
cgctgcgtgg cctgcagctg cccgccccgc tcttgactc catgggtggag gttcacaaca 1080
aggtggacct cgtgccggg tacagcccca cggaaaccgaa cgtcgtgccc gtgtctgccc 1140
tgcggggcca cgggctccag gagctgaaag ctgagctcga tgcggcggtt ttgaaaggca 1200
cggggagaca gatcctcact ctccgtgtga ggctcgagg ggccgagctc agctggctgt 1260
ataaggaggc cacagttcag gaggtggacg tgatccctga ggacggggcg gccgacgtga 1320
gggtcatcat cagcaactca gcctacggca aattccggaa gctctttcca ggatgaacgg 1380
acgccacag aggccttgcg ggtgggggca tcgctgcctg gggagctgag gcgttaccgc 1440
tgtgttgggg gcagcttggg gtcaggtgca gcagggtcct ccttgtctgg ttctgcacc 1500
gtctcgctcc cagccatttg ctgggatgac cgtgcaggcc ggtgacacgg ccgcacctgc 1560
cccaaagcgg gccgccgag cgtccactcc aagcctgagc atccacacaa tccagtgagg 1620
ccctcggtgc ctgctgtgaa ctgctttccc tcggaatgtt tccgtaacag gacattaaac 1680
ctttgttttt acttccgtga aaaaaaanac ngngnaaaaa aaaaaggggc ggcccgtcc 1740
tagaggattc caagccttac cgtaacgcgt tgcattggcg agcggtcata agcttcttct 1800
aatagggggt cac 1813

<210> 35
<211> 1733
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3452277CB1

<400> 35
ctacggcctg gaccgagtga ccaatccgaa tgaagtcaag gtaaaccaga aacaaacagt 60
cgttgctgtc aaaaaagaga tcatgtatta ccaacaggcc ttgatgaggt ccacagtga 120


```

gtctttctgtg tccctgggag ggattgtgaa atacagttag cagttctcat ccaacgatgc 180
catcatgtca ggctgcctcc ccagcaaccc ctggatcacc gatgacaccc agttctggga 240
cttaaagtcc aaattggtgg aaatcccaac caagatgcga gtggaacgat gggccttcaa 300
cttcagcgaa ttgatccgag accccaaagg tcgacagagc ttccagtact tcctcaagaa 360
agaattcagt ggagagaatc tgggattctg ggaagcctgc gaggatctga agtatggaga 420
tcagtccaaa gtcaaggaga aagcagagga gatttacaa ctgttcctgg ccccgggggc 480
gaggcgctgg atcaacatag atggcaaaac catggacatc acagtgaagg ggctgaagca 540
ccccaccgc tatgtgctgg acgccgcaca aaccacatt tacatgctca tgaagaagga 600
ttcttatgct cgctatttaa aatctccgat ctataaggac atgctggcca aagctattga 660
acctcaggaa accaccaaga aaagctccac cctccctttt atgcggcgtc acctgcgtc 720
cagcccaagc cctgtcatcc tgagacagct ggaagaggaa gccaaaggccc gagaagcagc 780
caacactgtg gacatcacc agccgggcca gcacatggct ccagccccc atctgacct 840
gtacaccggg acctgcatgc ccccgctccc ttctagcccc ttctcctcct cctgcgcgtc 900
ccccaggaag cctttcgct caccagccg cttcatccgg cgaccagca ccaccatctg 960
cccctcacc atcagagtgg ccttgagag ctcatcgggc ttggagcaga aaggggagtg 1020
cagcgggtcc atggcccccc gtgggccctc tgtcaccgag agcagcgagg cctccctcga 1080
cacctcctgg cctcgcagcc ggcccagggc cctcctaag gcccgcatgg ctctgtcctt 1140
cagcaggttt ctgagacgag gctgtctggc ctacctgtc ttgcccaggc tctcacccaa 1200
gtgccctgct gtgtcccacg ggaggggtgca gcccctgggg gacgtggggc agcagctgcc 1260
acgattgaaa tccaagagag tagcaaactt ttccagatc aaaatggatg tgcccacggg 1320
gagcgggacc tgcttgatgg actcggagga tgctggaaca ggagagtgcg gtgaccgggc 1380
cacagaaaag gaggtcatct gcccctggga gagcctgtaa ggaaagaggc aggtgagct 1440
gggggctctg gaccaggaag atgctctgac agatgccatg gtatgggcca caggacacac 1500
ttgctcgaga accaaagtgc atttgggtga catttgaaga ttggggagac aagatggggt 1560
agattgtggc aaagaatgct ctggctgggt accaggggccc aactccttct cctctcctg 1620
accctcctc cctgggcag aagaaacgca tgtggaccag aagactttcc ctgctgcctt 1680
aaaaccaata aaaggttaac ttttaagttt ttggaaaaaa aaaaaaaaag ggg 1733

```

<210> 36

<211> 1776

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4203832CE1

<400> 36

```

cccagccgag cccagcctag cccgagccca gcccgagcga accgcgagcc ccaagcccga 60
gccgcgcccc gcccgagcag agccctccag cgcctcacc cgcgtgccac cccagcgacc 120
ctcagccgct ctctgccctt ctctcgcccc cgcgcccgc ctcgcgcccc ctctgcccaa 180
tgaaactggc cgcgatgac aagaagatgt gcccgagcga ctcgagctg agtatcccgg 240
ccaagaactg ctatcgcatg gtcatacctc gctcgtccaa ggtgggcaag acggccatcg 300
tgtcgcgctt cctcaccggc cgtctcgagg acgctacac gcctaccatc gaggacttcc 360
accgcaagtt ctactccatc cgcggcgagg tctaccagct cgacatcctc gacacgtccg 420
gcaaccaccc gttccccgcc atgcggtgac tctccatcct cacaggagac gttttcatcc 480
tggtgttcag tctggacaac cgcgactcct tcgaggaggt gcagcggctc aggcagcaga 540
tcctcgacac caagtcttgc ctcaagaaca aaaccaagga gaacgtggac gtgcccctgg 600
tcacttgccg caacaagggt gaccgcgact tctaccgcca ggtggaccag cgcgagatcg 660
agcagctggt gggcgacgac cccagcgct gcgcctact cgagatctcg gccaagaaga 720
acagcagcct ggaccagatg ttccgcgcgc tcttcgccat ggccaagctg cccagcgaga 780
tgagcccaga cctgcaccgc aaggtctcgg tgcagtact cgacgtgctg cacaagaagg 840
cgctgcggaa caagaagctg ctgcgggccc gcagcggcgg cggcgggcgg gacccgggcg 900
acgcctttgg catcgtggca cccttcgcgc gccggcccag cgtacacagc gacctcatgt 960

```

```

acatccgcga gaaggccagc gccggcagcc aggccaaagga caaggagcgc tgcgtcatca 1020
gctaggagcc ccgccgcgct ggcgacacaa cctaaggagg acctttttgt taagtcaaat 1080
ccaacggccc ggtgcgcccc agggcgggag cgcgcgcgga ctggcgtctc ccctcccggc 1140
gatccgcccc cagcactggg gaggcgccac tgaaccgaga agggacggtc atctgctccg 1200
gaaggaaaga gaacgggcca agactgggac tattccccac ccccggtccc ccattgaggc 1260
ccgccacccc cataactttg ggagcgaggg cccagccgag ggtggattta tcttctcaaa 1320
gacctaaagag tgagcgcggg gtgggggagg gatgtgaagt tatccagcct ctgctaggct 1380
tcaagaaacc gtcatgcccg cttgagggtc aggaccacag gggcattatc ttgtctgtga 1440
ttccgggttg ctgtgacagc cggtagagcc tctgccctcc cgaaactaag cgggggggag 1500
tgggtcaaat catagccaag tgacttgttt acatgtgagt gaaactgcac aaaggaaacac 1560
aaaacaaaac ttgcacttta acggtagtcc cgggtgtcaac atggacacga acaaaacctt 1620
acccaggtgt ttatactgtg tgtgtgtgag gtcttttaag ttattgcttt atttggtttt 1680
ttaatatata ataaaataat ttaaaatgga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa gaaaaaaaaa aaaaaa 1776

```

<210> 37

<211> 1316

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 104368CB1

<400> 37

```

cggacgcgtg gggcggcttt tctcttttagc gctcagggcg ctgaccact gctcttcctc 60
ttaagaaagt gctccattcc ttccggcgcc cggagctgct ggcccaaagg gatccggagc 120
gagctagggc agacaccatg accacccttg atgataagtt gctggggggag aaactgcagt 180
actactatag cagcagtgag gatgaggaca gtgaccacga ggacaaggac cgaggcagat 240
gtgccccagc cagcagttct gtgcctgcag aggtgagct ggcaggcgaa ggcattctcag 300
ttaacacagg cccaaaaggt gtgatcaatg actggcgccg cttcaagcag ttggagacag 360
agcagagggg ggagcagtg cgggagatgg aaaggctgat caagaagctg tcaatgactt 420
gcaggtccca tctggatgaa gaggaggagc aacagaaaaca gaaagacctc caggagaaga 480
tcagtgggaa gatgactctg aaggagtttg ccataatgaa tgaggaccaa gatgatgaag 540
agtttctgca gcagtaccgg aagcagcgaa tggaagagat gcggcagcag cttcacaagg 600
ggccccaatt caagcaggtt tttgagatct ccagtggaga agggttttta gacatgattg 660
ataaagaaca gaaaagcatt gtcattcatg ttcattttta tgaggatggc attccagggg 720
ccgaagccat gaatggttgc atgatctgcc ttgccgcaga gtaccagct gtcaagttct 780
gcaaggtgaa gagctcagtt attggcgcca gcagtcagtt caccaggaat gcccttcctg 840
ccctgctgat ctataagggg ggtgaattga tcggcaattt tgttcgtgtt actgaccagc 900
tggggggatga tttcttttgc gtggaccttg aagcttttct ccaggaattt ggattactcc 960
cagaaaagga agtcttggtg ctgacatctg tgcgtaactc tgccacgtgt cacagtgagg 1020
atagcgacct ggaaatagat tgaactgata gtctagtgtc atagatttct cattgtttgg 1080
gttggaaatac acgtcattgt ttatttttgc tcctttgtct tctggctttt cagctgttct 1140
ttgtagctccc ttttattatg cataaaaataa agaaattctt agattaaatc agaatgctga 1200
ataaccttgt agctagcaat aaggtgactt acagttgtat aaacaggaag ccaggctttt 1260
gaactgttta ctttaagattc tgtggtgtga catctctgtt attgtttcca gtcaat 1316

```

<210> 38

<211> 1554

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1441680CB1

<400> 38

```
gtggcttggtg gagtggcgac cgttagttag gcggttgctg agacagacgc tgaggcgggg 60
aggaggagcc cgagccgtaa ggggaagccgt gatgagggcc gtgttgacgt ggagagataa 120
agccgagcac tgtataaatg acatcgcatc taagcctgat ggaactcaac tgattttggc 180
tgccggaagc agattactgg tttatgacac ctctgatggc accttacttc agccccctcaa 240
gggacacaaa gacactgtgt actgtgtggc atatgcgaag gatggcaagc gctttgcttc 300
tggatcagct gacaaaagcg ttattatctg gacatcaaaa ctggaaggca ttctgaagta 360
cacgcacaat gatgctatac aatgtgtctc ctacaatcct attactcatc aactggcatc 420
ttgttctctc agtgactttg ggttggtggc gacaaatgat ggtcagtacc tggcgctggg 540
atcaagcagc aagatcatct gctgcagctg gacaaatgat ggtcagtacc tggcgctggg 540
gatgttcaat gggatcatca gcatacggaa caaaaatggc gaggagaaag taaagatcga 600
gcggccgggg ggctccctct cgccaatatg gtccatctgc tgggaaccctt caagagagga 660
acgtaatgac atcctggctg tggctgactg gggacagaaa gtttccctct accagctgag 720
tggaaaacag attggaaggg atcgggcact gaactttgac ccctgctgca tcagctactt 780
tactaaaggc gagtacattt tgctgggggg ttcagacaag caagtatctc ttttcaccaa 840
ggatggagtg cggcttgagg ctgttgggga gcagaactcc tgggtgtgga cgtgtcaagc 900
gaaaccggat tccaactatg tgggtggtcg ctgccaggac ggcaccattt ccttctacca 960
gcttattttc agcacagtcc atggagttta caaggaccgc tatgcttaca gggatagcat 1020
gactgacgtc attgtgcagc acctgatcac tgagcagaaa gttcggatta aatgcaaaga 1080
gcttggtcaag aagattgcca tctacagaaa tctgattggc atccaactgc cagagaaaat 1140
cctcatctat gattgtgatt cagaggactt atcagacatg cattaccggg taaaggagaa 1200
gattatcaag aagtttgagt gcaacctcct ggtggtgtgt gccaatcaca tcatcctgtg 1260
ccaggagaaa cggctgcagt gcctgtcctt cagcggagtg aaggagcggg agtggcagat 1320
ggagtctctc attcgttaca tcaagggtgat cgggtggcct cctggaagag aaggcctctt 1380
agtggggctg aagaagatgt acttgtagt gtattcattc atattgattg taaaggatta 1440
tttttctact agtactgatg tcttggaata tcttacctgg aaacatgttt gcaaaaaaca 1500
ttattgggtc tttcatcttt tttcttggtt ttacatattt gttcaataaa aata 1554
```

<210> 39

<211> 2320

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1494955CB1

<400> 39

```
ggcgccccgc gtactcacta gctgaggtgg cagtgggtcc accaacatgg agctctcgca 60
gatgtcggag ctcattggggc tctcgggtgt gcttgggctg ctggccctga tggcgacggc 120
ggcggttagc cgggggtggc tgccgcgggg ggaggagagg agcggccggc ccgcttgcca 180
aaaagcaaat ggatttccac ctgacaaatc ttcgggatcc aagaagcaga aacaatatca 240
gcggattcgg aaggagaagc ctcaacaaca caacttcacc caccgcctcc tggctgcagc 300
tctgaagagc cacagcggga acatatcttg catggacttt agcagcaatg gcaaatacct 360
ggctacctgt gcagatgatc gcaccatccg catctggagc accaaggact tctgcagcg 420
agagcaccgc agcatgagag ccaacgtgga gctggaccac gccaccctgg tgcgcttcag 480
ccctgactgc agagccttca tctctgggtt ggccaacggg gacaccctcc gtgtcttcaa 540
gatgaccaag cgggaggatg ggggctacac cttcacagcc accccagagg acttccctaa 600
aaagcacaag gcgcctgtca tgcacattgg cattgctaac acagggaagt ttatcatgac 660
tgccctccagt gacaccactg tctcatctg gagcctgaag ggtcaagtgc tgtctaccat 720
```

```

caacaccaac cagatgaaca acacacacgc tgctgatatc cctgtggca gatttgtagc 780
ctcgtgtggc ttcacccag atgtgaaggt ttgggaagtc tgctttggaa agaaggggga 840
gttccaggag gtggtgagc ccttcgaact aaagggccac tccgcggtg tgcactcgtt 900
tgctttctcc aacgactcac ggaggatggc ttctgtctcc aaggatggta catggaaact 960
gtgggacaca gatgtggaat acaagaagaa gcaggacccc tacttgctga agacaggccg 1020
ctttgaagag gcggcggtg ccgcccgtg ccgcctggcc ctctcccca acgcccaggt 1080
cttgcccttg gccagtggca gtagtattca tctctacaat acccgggcggg gcgagaagga 1140
ggagtgtctt gaicgggtcc atggcgagtg tatcgccaac ttgtcctttg acatcactgg 1200
ccgctttctg gcctcctgtg gggaccgggc ggtgcggtg tttcacaaca ctctggcca 1260
ccgagccatg gtggaggaga tgcagggcca cctgaagcgg gcctccaacg agagcaccg 1320
ccagaggctg cagcagcagc tgaccagggc ccaagagacc ctgaagagcc tgggtgccct 1380
gaagaagtga ctctgggagg gcccggcgca gaggattgag gaggaggat ctggcctcct 1440
catggcgctg ctgccatctt tcctcccagg tggaaacctt tcagaaggag tctcctgggt 1500
ttcttactgg tggcctgct tcttccatt gaaactactc ttgtctactt aggtctctct 1560
cttcttctg gctgtgactc ctccctgact agtggccaag gtgcttttct tctcccagg 1620
cccagtgggt ggaatctgtc cccacctggc actgaggaga atggtagaga ggagaggaga 1680
gagagagaga atgtgatttt tggccttgtg gcagcacatc ctcacacca aagaagtttg 1740
taaagtgtcc agaacaacct agagaacacc tgagtactaa gcagcagttt tgcaaggatg 1800
ggagactggg atagcttccc atcacagaac tgtgttccat caaaaagaca ctaagggatt 1860
tccttctggg cctcagttct atttgtaaga tggagaataa tcctctctgt gaactccttg 1920
caaagatgat atgaggctaa gagaatatca agtccccagg tctggaagaa aagtagaaaa 1980
gagtagtact attgtccaat gtcataaaag tggtaaaagt gggaaaccagt gtgctttgaa 2040
accaaattag aaacacattc cttgggaagg caaagttttc tgggacttga tcatacatct 2100
tatatgggtg ggacttctct cttcgggaga tgatatcttg ttttaaggaga cctcttttca 2160
gttcatcaag ttcatacagat atttgagtgc ccactctgtg cccaaataaa tatgagctgg 2220
ggattaaata cgaataagac atggtttctg ccatcaaaga tggctggtgg gagagagaga 2280
tacaccctta ttaagtgtt tgtgttagtt tattcatagc 2320

```

<210> 40

<211> 879

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1508161CB1

<400> 40

```

gaagaatttg ttcaggcgtt cgtgcagaag gaccctttgg ataatgacaa gagttgctac 60
agtgaacgga agaaaacacg aaacttagaa gcttacgtgg aatggtttaa tcgcctcagc 120
tacttggttg ctacagaaat ctgtatgcct gttaagaaaa aacaccgagc aagaatgatt 180
gagtatttca ttgacgtagc tcgggagtggt ttttaacattg gcaacttcaa ctcttgatg 240
gcgataatct ctggtatgaa tatgagccca gtctctcgac taaaaaaac ttgggccaac 300
gtgaagactg caaaatttga cattcttgag catcagatgg acccttcaag caatttctat 360
aattatcgaa cagctcttcg tggggcagca caaaggctct taactgctca tagtagtaga 420
gaaaagattg tgataccatt cttcagtcct ttaatcaaag atatttattt cctcaatgag 480
ggttgtgcca accgccttcc caatggccat gtcaattttg agaaattttg ggaactggcc 540
aaacaagtga gtgaatttat gacatggaaa caagtggagt gtccatttga gagggaccgg 600
aagatcttgc agtatctgct cacagtacca gtcttcagtg aagatgctct ctacttggct 660
tcttatgaga gtgaaggacc tgaaaatcat atagagaaag acagatggaa gtctttaagg 720
tcgagcctct taggcagagt ttaacacatg ggagctgcct gcctgctgct gctgctgctt 780
cctgcagatc atggaggggc tggcctttgt tttctggcat ctcgtaaccac gaacactcat 840
gaagaccctg cagtcattgg agcaccggg tcagcaaaag 879

```

<210> 41
<211> 2248
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1811877CB1

<400> 41
ggaggaccag gaggacatca ctgcctttga cctcagccct gacaacgagg tgctggtgac 60
agccagtcgg gcattgctgc tggctcagtg ggcctggcaa gagggcagcg ttacccgcct 120
gtggaaggcg atacacacgg ccccgctggc caccatggcc ttcgacccca cctccactct 180
gctagccaca ggtggctgtg atggggccgt gcgctctgg gacatcgtgc ggcactacgg 240
gacacaccac ttccgaggct cgcccgggtgt cgtgcaccta gtggccttcc acccggaacc 300
tacacgcctg ctgctcttct cctcggccac ggatgccgac atccgcgtgt ggtcactgca 360
ggaccgggtca tgcctggctg tgctgactgc ccactacagc gccgtcacct cactggcctt 420
cagcgccgac ggccacacca tgctcagctc cggccgtgac aagatatgta tcatctggga 480
ccttcagagc tgccaggcca cgaggaccgt gcctgtgttt gagagcgtgg aggctgctgt 540
gctgtttgcc gaggagccag tgtcccagct ggggtgtgaag tccccagggc tgtactttct 600
gacagctggc gaccaaggca ctctgcgcgt gtgggaggca gcttctgggc agtggtgtgta 660
cacgcaggcc cagccgcggg gccctgggca ggagctgacc cactgcaccc tggcacacac 720
cgccggcgtg gtcttcaccg ccaccgccga ccacaacctg ttgctctacg aggtctgctc 780
cctgcggctg cagaaacagt tcgctggcta cagtggagg gttttggatg tccggtttct 840
tgggcccag gactcccacg ttgtcgtggc ctccaatagc ccctgcctaa aagtgtttga 900
gctgcagacg tcagcctgcc agatcctcca cggccacacg gatatcgtcc tggccctgga 960
tgtgtttccg aaggggtggc tctttgccag ctgtgccaag gatcagagcg tccgtatctg 1020
gagaatgaac aaggctggcc aggtgatgtg cgtggctcag gggtccggc acacacacag 1080
tgtgggcacc gtctgctgct ctaggctgaa ggagtccttc ctggtgacag gcagccagga 1140
ctgcaactgt aagctgtggc ctcttcccaa agccttgctg tccaagaaca cagccccaga 1200
caacggccct atcctcctgc aggccagac cactcagcgc tgccatgata aggacatcaa 1260
cagcgtggct attgccccca acgacaagct gctggccaca ggctcacagg accgcacggc 1320
caagctctgg gccctgccac agtgccagct gctgggtgtc ttctcaggcc accggcgtgg 1380
cctctggtgc gtccagttct ctcccatgga ccaggtgctg gccacggcct cagctgatgg 1440
caccatcaag ctctgggcac tccaggactt cagctgtctc aagacatttg aggggcacga 1500
tgcttctgtg ctgaagggtg cctttgtgag ccgtggcacg cagctgctgt ccagcggttc 1560
ggatggcctc gtgaagctct ggaccatcaa gaacaacgag tgtgtgcgga cgctggatgc 1620
ccacgaggac aaggtctggg ggctgcaact cagccggctg gacgaccacg cctcactgg 1680
ggccagtgac tcccagtgca tctctggaa ggatgtgacc gaggcggagc aggcagagga 1740
gcaggccagg caagaggagc aggtggtcag gcagcaagag ctggacaacc tgctgcatga 1800
gaagcggtac ctgcgggcgc tgggcctggc catctccctg gatcggtccc acaccgtgct 1860
gactgtcatc caggccatcc ggagggaccc tgaggcctgc gagaagctgg aagccaccat 1920
gctccgactg cggcgcgacc agaaagaggc cctgctgcgc ttctgctca cgtggaacac 1980
caactgcgg cactgccacg aggccaggc cgtgctgggt gtgctcttga ggcgagaggc 2040
ccccgaggag ctgctggcct acgaaggcgt gcgggcagcg cttgaggccc tgctgcccta 2100
cactgagcgg cactttcagc ggctcagcag gacctccag gccgcccgtt tcttgactt 2160
cctgtggcac aacatgaagc tccctgtgcc ggccgcggcc cccacccctt gggaaaccca 2220
taaaggcgca ctgccctaaa aaaaaaaa 2248

<210> 42
<211> 2146
<212> DNA
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1848674CB1

<400> 42

```
gttattggca agttcccctg cagttgtttg ggctgtccct gtggctgggt ctgggggtgtg 60
cggccagcca tggagcgctc tgggcccagc gaagtgcacg gctcagacgc gtcgggaccg 120
gacccgcagc ttgcggtcac catgggcttc acgggggttcg gtaaaaaagc tcgcacattt 180
gacttggaag caatgtttga acaaaactcg aggacagctg tggaaaagaag tcgcaaaaaca 240
ctggaagcaa gagaaaaaga ggaagaaatg aacagagaga aagaattaag aagacaaaat 300
gaagatattg agccaacatc ctcaagatca aatgtggtca gagattgctc caaatcatct 360
tccagggata cgagcagcag tgaaagtga cagagttctg actcttctga tgatgagtta 420
attggccctc ctttaccccc taaaatggta ggaaaaccag ttaattttrt ggaggaagat 480
atcctcgggt ctttacctcc acctcttaat gaagaagaag aagaagcaga ggaagaagaa 540
gaggaagagg aggaagagga aaatcctgtt cacaagattc ctgactcgca tgagataacg 600
ctgaagcatg gcactaaaac agtgtctgct ttgggtctgg atccctcagg tgcccgtttg 660
gtgacaggag gatattgacta tgatgttaag ttttggtgatt ttgctggaat ggatgcttct 720
tttaaggcat ttcgatccct tcagccctgt gagtgccatc agatcaagtc attacagtat 780
agtaacacag gagacatgat tcttgttgta tctggaagct ctcaggccaa ggtgattgac 840
agagatgggt ttgaagtaat ggaatgtata aaaggagacc agtatattgt ggacatggcc 900
aacaccaagg gtcatacagc aatgcttcat actggctcat ggcattccaa aataaaggga 960
gaatttatga cttgctcaaa tgatgcgact gtgaggacgt gggaagtga aaatccaaag 1020
aagcaaaaaa gtgtgtttaa accacggacg atgcaaggca aaaaagtcatt tccactacg 1080
tgcacatata gtagagatgg aaacctcata gcagctgcct gccagaatgg aagcatacag 1140
atctgggacc gaaatttgac tgttcatcct aagttccact ataaacaggc tcatgactcg 1200
ggcacagaca cttcttgctg gactttttcc tatgatggta atgtccttgc ctctcgtgga 1260
ggtgacgatt cattaataat atgggacatc cgacaattta ataaaccact ttttccagcc 1320
tcgggtcttc ccaccatgtt cccaatgact gactgctgtt tcagtccaga tgataagctc 1380
atagtcactg gtacatctat tcaaagagga tgtggcagcg gcaaacttgt tttctttgag 1440
cgtaggactt tccaaagggt gtatgaaata gacatcacag atgcgagtgt tgttcgctgc 1500
ctgtggcatc caaagctgaa ccagatcatg gttggaactg gaaatggatt ggctaaagtc 1560
tattacgacc ccaacaagag tcagagggga gcaaaattat gtgtgggttaa aaccagcgg 1620
aaggcaaaac aagctgagac tctaactcag gactacatca tcacctca tgccttgcc 1680
atgttccgtg agccccgcca acggagtaca aggaaacagc tggagaagga cagactggat 1740
ccctgaagt cgcataaaac tgaacctcct gtagcaggcc caggctcgtg tgggcgagtt 1800
ggaacccacg ggggcactct ctcttcctat attgtgaaga acattgcttt ggacaagacc 1860
gatgacagta atcctcggga agccattttg cgtcatgcc aagcagcaga agacagccca 1920
tattgggttt ctccagcata ttccaagact cagcccaaaa ccatgtttgc ccaagttgaa 1980
tctgatgatg aggaagcaaa gaatgagcca gaatggaaaa aacgtaaaat ttgaagaatc 2040
tcatttgaga gctgtttgca tgagtgggag gggtatggga caggtttggg tttttttttt 2100
atgctcatga aattaaaaat tcatttttat gaaaaaaaaa aaaaaa 2146
```

<210> 43

<211> 714

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2012970CB1

<400> 43

```
ggatggcgag cagcggaggc gaggcggtga cgagagcagc ggctccgcca ttggacgagg 60
```

```

aggcctgagg gacggggccag cggtgcacaa gaagagaccg aggcgggtgg ccccgagaga 120
gccagggcca tggaggccaa catgccgaag cggaaggagc ctggcaggtc tctccgtatc 180
aaagtcacat ccatggggcaa cgccgaagtg gggaaaagct gtattataaa gcgatactgt 240
gagaaaagat tegtgtctaa atacctggca acaattggaa ttgactatgg agtcacaaag 300
gtacacgtca gagacagaga aatcaaagtt aacatctttg atatggctgg acatcccttc 360
ttctatgagg ttcgaaatga gttttacaag gacacacagg gtgtgatact ggtctatgat 420
gttgggcaga aagactcctt tgacgccctt gatgcgtggc tggcagaaat gaagcaagag 480
cttggacctc atggaaacat ggaaaatatt atattttagt tttgtgccaa caagattgat 540
tgtaccaaac atcgctgtgt agatgaaagt gaaggacgtc tttgggctga aagcaaaggg 600
ttcctgtact ttgaaacttc agcacaactt ggagaaggca ttaatgagat gttccagata 660
catcttggat agaactaatg gataaattag tctgttttaa aaagaaaaaa aaaa 714

```

<210> 44

<211> 1779

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2254315CB1

<400> 44

```

caggaggaag atggcggcgt ccgcagctgc cgctgagctc caggcttctg ggggtccgcg 60
gcacccagtg tgtctgttgg tgttgggaat ggcgggatcc gggaaaacca cttttgtaca 120
gaggctcaca ggacacctgc atgcccaagg cactccaccg tatgtgatca acctggatcc 180
agcagtcacat gaagtccctt ttcttgccaa tattgatatt cgtgatactg taaagtataa 240
agaagtaatg aaacaatatg gacttggacc caatggcggc atagtgcctt cactcaatct 300
ctttgctacc agatttgatc aggtgatgaa atttattgag aaggcccaga acatgtccaa 360
atatgtgttg attgacacac ctggacagat tgaggatatt acctggtcag cttctgggac 420
aattatcact gaagcccttg catcctcatt tccaacagtt gtcattctatg taatggacac 480
atcgagaagt accaaccacg tgaccttcatt gtccaacatg ctctatgcct gcagcatctt 540
atacaaaaacc aagctgcctt tcatttgtgt catgaataaa actgacatca ttgaccacag 600
ctttgcagtg gaatggatgc aggattttga ggctttccaa gatgccttga atcaagagac 660
tacatacgtc agtaacctga ctogttcaat gagcctggtg ttagatgagt tttacagctc 720
actcagggtg gtgggtgtct ctgctgttct gggtaactgga ttagatgaac tctttgtgca 780
agtaccagt gctgccgaag aatatgaaag ggagtatcgt cctgaatatg aacgtctgaa 840
aaaatcactg gccaacgcag agagccaaca gcagagagaa caactggaac gccttcgaaa 900
agatatgggt tctgtagcct tggatgcagg gactgccaaa gacagcttat ctctgtgtct 960
gcaccccttct gatttgatcc tgactcgagg aaccttggat gaagaggatg aggaagcaga 1020
cagcgatact gatgacattg accacagagt tacagaggaa agccatgaag agccagcatt 1080
ccagaatttt atgcaagaat cgatggcaca atactggaag agaaacaata aataggagac 1140
ttagcacac ttacttggtt tctagaagtc cagaattttg gacctccacg tgaaagaact 1200
gttcttacct ctgaactggg ggctcccata agggataatt ttcttcagag tagcaaagtt 1260
tctcttatta gagaaatctt gtgactcaga tgaagtcagg gatagaagac ccttggacct 1320
ggcagggttaa tgctgattat tccttggcct ttcccttgta tttatgcaag gaaggatata 1380
ctgagctgat actcttccaa gcctacaact tcaagtttta tcatttgaac tcaagtactt 1440
ttgctgctga ggaatggaat caaaagaacg tagtctcctg gtgaccacct cagatctcta 1500
ttattaggct agatgtatag cctctactcc ccagcttctt tgctcttgac cctgcactgt 1560
aagttgccct tctatttaga gccaaaggaaa agggaaacat gagcttatcc agaacggtgg 1620
cagagtctcc ttggcaatca accaacgttg ctatgaaata tgcctcacac tgtatagctc 1680
attataggac gtcaggtttg ttgaaaaaag tgggcaagac atgattaatg aatcagaatc 1740
ctgtttcatt ggtgacttgg ataaagactt ttttaatttt 1779

```

<210> 45
 <211> 2234
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 2415545CB1

```

<400> 45
ccccttctga aaaatggttt caccgctcc ttctctagaa cgggtcgggc cgctaccact 60
gtccggcccc gaggggaact gttttctccg gaagtgacaa cacgctgact agggaaaagga 120
ggaggcgggg cagtggggcc ttccggcgcg actatggaag gagccggcta cagggtggtg 180
tttgagaagg gcggagtgtg cctgcacacc agcgttaaga agtatcagga ccgagactct 240
ctcatcgctg gtgtcatccg tgtcgtggaa aaggacaatg acgtcctcct gcactgggct 300
cctgtagagg aggctggaga ttccacccaa atcctcttct ccaagaagga ctccagtggg 360
ggtgactcat gtgcttctga ggaggaacca accttgacc ccggctatga acctgactgg 420
gctgtcatca gcactgtgcg gccacagccc tgccactcag agcccacgag aggtgcagag 480
cccagctgcc cccagggtct ctgggccttc tcagtgaagt tgggggagct aaagtccatc 540
cgccgctcca agccaggcct cagctgggct tacctgggtc tggtgaccca ggctggaggt 600
tccctgcccc cactgcactt ccaccgcggg ggcacccgcg cctgctccg cgtcctcagc 660
cgctacctgc tgttgccag ctccccgcag gactcccgcc tctacctgt cttccccac 720
gactcctctg ctctctccaa ctcttccac cacttcgagc tctttgacca ggacagctcc 780
aatgtggtgt cactctcct ccaggatccc tactccacca ccttcagcag cttctccga 840
gtgaccaact tcttcgggg tgccctgcag ccacagcctg agggagcgc ctccgacctt 900
ccccgcccac ccgacgatga gcccgagcct ggattcgagg tcatttctct tgtggagctg 960
gggcctcggc caaccgtgga gcggggcccc ccagttacag agggaggagt ggcacgccac 1020
gtgggccccg aaggctgcct gcagcaggtc cctgagctga agaaccggat cttctcgggg 1080
ggtctgagcc ccagcctgcg gcgcgaggcc tggaaagtcc tcctagggta cctcagctgg 1140
gaaggcacag ctgaggagca caaggcccac atacgcaaga aaacggatga gtatttccgc 1200
atgaagctgc agtggaaatc tgtgagccct gagcaggagc ggagaaaact acttctgcat 1260
ggataccgca gcctcatcga aagggatgtg agccgcaact acaggaccaa caagttctac 1320
gagggtcccc agaaccgggg gctgggcctg ctgaacgata tcctcctcac ctactgcatg 1380
tatcacttct acctcggtca cgtccagggc atgagtgatc ttctctcccc gatcctctac 1440
gtcattcaga acgaggtgga tgctttcttg tgtttctgtg gcttcatgga gctcgtgcaa 1500
gggaactttg aagagagcca ggagaccatg aagcggcaac tcgggcgact gctgctgctc 1560
ctgagggtgc tggaccccc gctctgcgac ttcttgatt cccaggactc cggctctctc 1620
tgcttctgtt tccggtggct gctcatctgg ttcaagaggg aattccccct ccgggatgtc 1680
cttcggctgt gggaggtgct gtggacaggg ctccctggcc ccaatctgca cctgctggtg 1740
gcctgcgcca tcctggacat ggagagggac acctcatgc tgtccggctt cggctccaat 1800
gagatcctca agcacatcaa cgagctgact atgaagctga gcgtggagga cgtgctgacc 1860
cgcgccgagg cctgcaccg ccagctaacc gcctgcaccc gagctgcccc acaacgtgca 1920
ggagatcctg gggctggccc cgccacgcag agccccacag cccctcgccc accgcctccc 1980
cgctgcctct gtacgcccac ccgggccccg cccacccgca cgccctccac ggacacagcc 2040
ccgcagcccc acagcagcct ggagatcctg cccgaggagg aggacgaggg cgccgactcc 2100
taacccccgc aggcagcctc gttctgcaca ggcactttag cccgagccag gcacacctgc 2160
gagggggcag gtgtgctccg ccgcctgct gataagctgg cttcattaaa ctgacacttc 2220
tcaaaaaaaaa aaaa 2234

```

<210> 46
 <211> 3150
 <212> DNA
 <213> Homo sapiens

<220>

<221> unsure

<222> 96, 97, 99, 3070-3072, 3074, 3078, 3080-3082, 3085-3087, 3091,

<222> 3099, 3100, 3103, 3107, 3110-3112, 3114, 3115, 3121, 3123, 3125,

<222> 3128, 3136, 3138, 3140, 3141, 3143, 3145, 3147, 3149

<223> Incyte ID No: a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte ID No: 2707969CB1

<400> 46

```

acacaggagc aatgcaaaat ttgataaagc atttttctgt cagatcagct gagccctact 60
gcccttcctc tcaagattcc tggagaccca gatgtngna tctttcattg acaacaaaat 120
aatgtgtcat gatgatgatg ataaagaccc tgtactccgg gtatttgatt cccgagttga 180
caagatcagg ctgttgaatg ttcggacacc tactctccgt acatccatgt accagaagtg 240
taccactgtg gatgaagcag agaaagcaat tgagctgcgt ctggcaaaaa ttgaccatac 300
tgcaattcac ccacatttac ttgacatgaa gattggacaa gggaaatatg agccgggctt 360
cttccttaag ctgcagtctg atgtactttc cactgggcca gccagcaaca agtggacgaa 420
aaggaatgcc cctgccagt ggaggcggaa agatcggcag aagcagcaca cagaacacct 480
gcgtttagat aatgaccaga gggagaagta catccaggaa gccaggacta tgggcagcac 540
tatccgccag cccaaactgt ccaacctctc tccatcagtg attgccaga ccaattggaa 600
gtttgtagag ggctgtctga aggaatgccg caataagacc aagaggatgc tgggtgaaaa 660
gatgggccga gaagctgttg agctagggca tggggagggtg aacatcacag ggggtggaaga 720
gaacacctg attgccagcc tttgtgatct cctggaaagg atctggagtc atggactaca 780
agtgaacag gggaaatcag ccttatggtc ccacctgtta cattatcagg acaaccggca 840
gagaaaactc acatcaggaa gcctcagtac ctccaggaata cttcttgatt cagaacgtag 900
gaagtctgat gccagctcac tcatgcctcc cctgaggatc tccctgattc aggatatgag 960
gcacatccag aacatcgggg aaatcaagac tgatgtggga aaggccagag catgggtgag 1020
actgtccatg gaaaaaaagt tactttccag acacctgaag cagctcctct cagaccatga 1080
gctcaccaaa aagttatata agcgctatgc ctctctgcgc tgtgatgacg agaaggagca 1140
gttcctctat cacctcctgt ctttcaatgc cgtcgattac ttttgcttca ccaatgtctt 1200
cacaactatc ctgatcccg accacattct gatcgtaaca agcaagaagc tggggggctc 1260
catgttctac gccaacccat ggatctgtat atcaggagaa ttgggtgaga cacagatcat 1320
gcagattccc aggaatgtgc tagagatgac ctccgagtg cagaacttgg ggaagcttac 1380
tactgtccag attggccatg ataactctgg gctgtatgcc aaatggctgg tggagtatgt 1440
gatggtcagg aatgagatca caggacatac ctacaagttc ccgtgtggcc ggtggttagg 1500
gaagggcatg gatgatggaa gcctggagcg gatcctagtt ggggagctgc tcacatccca 1560
gcctgagggt gatgagaggg catgccggac ccgcgcgtg cagcagtcct ccagtgtcat 1620
ccggaggctt gttaccatct caccacaaca caagcccaag ctgaacactg ggcagatcca 1680
ggagtccatc ggggaggcag tcaatggcat tgtgaagcac ttccataagc ctgagaaaga 1740
gcgaggcagt ctgacgctgt tgctctgtgg agagtgtggc cttgtctcgg ccttggaaca 1800
ggctttccag catggattta aatcgccccg gctcttcaaa aatgtcttca tttgggattt 1860
cctggaaaaa gcacaaacct attatgagac attagagaag aatgaagtag tccctgagga 1920
aaactggcat acaagagccc ggaacttctg ccgatttgtc actgcaatca acaatactcc 1980
ccggaacatc ggcaaggatg gcaagtttca gatgtggtg tgcttgggag ccagagatca 2040
cctcctacac cactggattg cctgtctggc tgactgcccc atcactgcac acatgtatga 2100
ggatgtggca ctgatcaaag accatacact tgtcaattcc ttgattcgtg tgctgcagac 2160
attgcaggag ttcaacatca cgctggagac gtcccttgtc aagggcatcg acatctgacc 2220
tcccagcacc agccagcagc aggactgaga aagactcacc ctgcagctct gacctttttt 2280
cccaaaggga cttaagcgat tgtgcaggag taggagacaa aatgtacact cactgtaaaa 2340
agagaactag aggatttttg gaataaataa tctattttag agtttatttg ctgatttgct 2400
ttttacacac tttcatgtga aagagtgata gggagagggg gcgaggctgg tgccgcttat 2460
tttgaagctg gtgccccccc tcgccgtggc cacatgctgg aagcctgagg cctccctgga 2520
ctgagcctgt ggcactgcgt gcgggacagt tatgtttcct tgccccgtcg cattaatgag 2580

```

```

gcccttccac atcattttta aactaatggt tttctatatt aacattatta tggatatttg 2640
gctttcatag gccacacaca ggtgtgctgc gcgggaagcc ccatgctcca atcaaaggga 2700
tttttagtag tgcctctaag caagcaccga tgagtcagtc ccacgtattt tcttttttgt 2750
cagtattggt tgggaaggag acatgccggg atgtgtcatc gtgccaaata ccacatttcc 2820
tggtggcaca gtttcacaga agtaaacata agcatgtttt aacaggtttt tcttttcttt 2880
tttctttttt aaaatgtttt atttatttaa cccgccattg tgtgttttta agtattttct 2940
ttttttaagg aaaggaaaag cttgtcacia tctaactggc tatgttatta ttattaaatt 3000
tatgttttgc aacttagaaa ccagctacag tatggcccac ttaataaaac acctgaaaca 3060
aaaaaaaaagn nngngggngn nngtnnngag naggagggnn ggngggnggn nngnngggag 3120
ntnanttttg ggggtgngng nngnngnt 3150

```

<210> 47

<211> 1806

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2817769CB1

<400> 47

```

gtctgcgcgc aggtgcccgt cggcgcccgg gcgcgcggtt ccgcggctgt cgccgccgtc 60
gtgcgtgccg ctgcggcggag gggacggggc tgcgttctct cctccttctt ccccgctcc 120
agctgccggc aggacctttc tctcgtctgc gctgggaccc cgtgtcatcg cccaggccga 180
gcacgatgcc ccttaaaaaag ggaggtgatg gaattaaacc accccaatc attggaagat 240
ttggaaacctc actgaaaatt ggtattgttg gattgcaaaa tgttgggaaa tctactttct 300
tcaatgtgtt aaccaatagt caggcttcag cagaaaactt cccgttctgc actattgatc 360
ctaattgagag cagagtacct gtgccagatg aaaggtttga ctttctttgt caataccaca 420
aaccagcaag caaaattcct gcctttctaa atgtggttga tattgctggc cttgtgaaag 480
gagctcacia tgggcagggc ctggggaatg cttttttatc tcatattagt gcctgtgatg 540
gcattcttca tctaaccagt gcttttgaag atgatgatat caccgacgtt gaaggaagtg 600
tagatcctat tcgagatata gaaataatac atgaagagct tcagcttaaa gatgaggaaa 660
tgattggggc cattatagat aaactagaaa aggtggctgt gagaggagga gataaaaaac 720
taaaacctga atatgatata atgtgcaaaag taaaatcctg ggttatagat caaaagaaac 780
ctgttcgctt ctatcatgat tggaaatgaca aagagattga agtggtgaat aaacacttat 840
ttttgacttc aaaaccaatg gtctacttgg ttaatctttc tgaaaaagac tacattagaa 900
agaaaaacaa atggttgata aaaattaaag agtgggttga caagtatgac ccagggtgctt 960
tggtcattcc ttttagtggg gccttggaaac tcaagttgca agaattgagt gctgaggaga 1020
gacagaagta tctggaagcg aacatgacac aaagtgtttt gccaaagatc attaggctg 1080
ggtttgcagc actccaacta gaatactttt tcaactgcagg cccagatgaa gtgcgtgcat 1140
ggaccatcag gaaagggact aaggctcctc aggtgcagg aaagattcac acagattttg 1200
aaaagggtatt cattatggct gaagtaatga aatacgaaga ttttaaagag gaaggttctg 1260
aaaatgcagt caaggctgct ggaaagtaca gacaacaagg cagaaattat attgttgaag 1320
atggagatat tatcttcttc aaatttaaca cacctcaaca accgaagaag aaataaaatt 1380
tagttattgc tcagataaac atacaacttc caaaaggcat ctgattttta aaaaattaaa 1440
atttctgaaa accaatgcga caaataaagt tggggagatg ggaatctttg acaaacaaat 1500
tatttttatt tgttttaaaa ttaaaatact gtgtaccccc cccactcca tgaaatgcag 1560
gttcactaaa tgtgaacagc tttgcttttc acgtgattaa gaccctactc caaattgtag 1620
aagcttttca ggaaccatat tactctcatg atacttcatt aatctccatc atgtatgcca 1680
agcctgacac atttgacagt gaggacaatg tggttgctc ctttttgaat ctacagataa 1740
tgcattgttt acagtactcc agatgtctac actcaataaa acatttgaca aaacaaaaaa 1800
aaaaaa 1806

```

<210> 48
<211> 2880
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2917557CB1

<400> 48
gaggaggagg aggaggaaga agaggaagaa gaagatgaag aaagtgaaga agaggaggaa 60
gaggagggag aaagtgaagg cagtgaagg gatgaggaag atgaaaagg gtcagatgag 120
aaggattcag ggaagacatt agataaaaaag ccaagtaaag aaatgagctc agattctgaa 180
tatgactctg atgatgatcg gactaaagaa gaaagggctt atgacaaaagc aaaacggagg 240
attgagaaac ggcgacttga acatagtaaa aatgtaaaca ccgaaaagct aagagccct 300
attatctgcg tacttgggca tgtggacaca ggggaagacaa aaattctaga taagctccgt 360
cacacacatg tacaagatgg tgaagcagg ggatcacac aacaaattgg ggccaccaat 420
gttcctcttg aagctattaa tgaacagact aagatgatta aaaattttga tagagagaat 480
gtacggattc caggaatgct aattattgat actcctgggc atgaatcttt cagtaatctg 540
agaaatagag gaagctctct ttgtgacatt gccattttag ttgttgatat tatgcatggt 600
ttggagcccc agacaattga gtctatcaac cttctcaaag ctaaaaaatg tcccttcatt 660
gttgactca ataagattga taggttatat gattggaaaa agagtcctga ctctgatgtg 720
gctgctactt taaagaagca gaaaaagaat acaaaagatg aatttgagga gcgagcaaag 780
gctattattg tagaatttgc acagcagggt ttgaatgctg ctttgtttta tgagaataaa 840
gatccccgca cttttgtgtc tttggtacct acctctgcac atactggtga tggcatggga 900
agtctgatct acctcttgt agagttaact cagaccatgt tgagcaagag acttgcacac 960
tgtgaagagc tgagagcaca ggtgatggag gttaaagctc tcccggggat gggcaccact 1020
atagatgtca tcttgatcaa tgggcgtttg aagggaaggag atacaatcat tgttctgga 1080
gtagaagggc ccattgtaac tcagattcga ggcctcctgt tacctctcc tatgaaggaa 1140
ttacgagtga agaaccagta tgaaaagcat aaagaagtag aagcagctca gggggtaaag 1200
attcttggaa aagacctgga gaaaacattg gctggtttac cctccttgt ggcttataaa 1260
gaagatgaaa tccctgttct taaagatgaa ttgatccatg agttaaagca gacactaaat 1320
gctatcaaat tagaagaaaa aggagtctat gtccaggcat ctacactggg ttctttggaa 1380
gctctactgg aatttctgaa aacatcagaa gtgccctatg caggaattaa cattggccca 1440
gtgcataaaa aagatgttat gaaggcttca gtgatgttgg aacatgaccc tcagtatgca 1500
gtaatttttg ccttcgatgt gagaattgaa cgagatgcac aagaaatggc tgatagttta 1560
ggagttagaa tttttagtgc agaaattatt tatcatttt acatagcagt atttccctgc 1620
agacaagact acaagaaaca gaaacaagaa gaatttaagc acatagcagt atttccctgc 1680
aagataaaaa tccctcctca gtacattttt aattctcgag atccgatagt gatgggggtg 1740
acgggtggaag caggtcaggt gaaaacaggg acacccatgt gtgtcccaag caaaaatttt 1800
gttgacatcg gaatagtaac aagtattgaa ataaaccata aacaagtgga tgttgcaaaa 1860
aaaggacaag aagtttgtgt aaaaatagaa cctatccctg gtgagtcacc caaaatgttt 1920
ggaagacatt ttgaagctac agatattctt gttagtaaga tcagccggca gtccattgat 1980
gcactcaaag actggttcag agatgaaatg cagaagagtg actggcagct tattgtggag 2040
ctgaagaaag tatttgaaat catctaattt ttccacatgg agcaggaact ggagtaaagt 2100
caatactgtg ttgtaatatc ccaacaaaaa tcagacaaaa aatggaacag acgtattttg 2160
acactgatgg acttaagtat ggaaggaaga aaaatagggt tataaaatgt ttccatgag 2220
aaaccaagaa acttacactg gtttgacagt ggtcagttac atgtccccc agttccaatg 2280
tgctgttca ctcacctct ccttccccca ccttctctta cttggctgct gttttaaagt 2340
ttgccttcc ccaaatttgg atttttatta catagctaaa gctctttcga ttttatactg 2400
attaaatcag tactgcagta tttgattaac caagcttctg cagattttgt gattcttggg 2460
acttttttga cgtagaagaa acttctttat ttatgcatat tcttcccaca gtgatttttc 2520
cagcattctt ctgccatag cctttagggc ttttataaaa tagaaaatta ggcattctga 2580
tatttcttta gctgctttgt gtgaaaccat ggtgtaaaag cacagctggc tgctttttac 2640
tgcttgtgta gtcacgagtc cattgtaatc atcacaattc taaaccaaac taccaataaa 2700

gaaaacagac atccaccagt aagcaagctc tgtaggctt ccatgttagt gtagcttctc 2760
 tcccacaagt tgcctccta ggacaagaat tatcttataa actaaactat catcacacta 2820
 ccttgtagtc cagcacctgg taacagtaga gattttata cattaatctt gatctgtttt 2880

<210> 49
 <211> 1109
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3421335CB1

<400> 49
 cccacgcgtc cgctcgctct tgggtcatgc ctggccagca gaaagcagct ccatagggga 60
 ggagagccac gcaggatctc acagctgcag tctaataagta acacagagga ttcagcagtg 120
 gccaccatgg gttctgtgaa ttccagaggt cacaaggcgg aagcccaggt ggtgatgatg 180
 ggccctggact cggcggggcaa gaccacgctc ctttacaagc tgaagggcca ccagctggtg 240
 gagaccctgc ccactgttgg tttcaacgtg gagcctctga aagctcctgg gcacgtgtca 300
 ctgactctct gggacgttgg ggggcaggcc ccgctcagag ccagctggaa ggactatctg 360
 gaaggcacag atatcctcgt gtacgtgctg gacagcacag atgaagccc cttaccgag 420
 tcggcggctg agctcacaga agtccctgaac gacccaaca tggctggcgt ccccttcttg 480
 gtgctggcca acaagcagga ggcacctgat gcacttccgc tgcttaagat cagaaacagg 540
 ctgagtcctag agagattcca ggaccactgc tgggagctcc ggggctgcag tgccctcact 600
 ggggagggggc tgcccgaggc cctgcagagc ctgtggagcc tcctgaaatc tcgcagctgc 660
 atgtgtctgc aggcgagagc ccatggggct gagcgaggag acagcaagag atcttgatcc 720
 agacagagca gcatactctt gctcatacaa actagaagaa ccagctgatc cttgagaaat 780
 ttacgcttag tctatcaaac aagaaatgct ggcttggccc ggtggctcat gcctgtaatc 840
 ccagcactgt gggagaccac ggtgggggaa tcccttgagc ccaggagttg gagagcaaca 900
 tcacaacacc ccatttctac taataatcaa aaaattggcc gggcatggtg gcctgtgctc 960
 gtagtccag ctacttggga ggctgaggca ggagaatcgc ttgagcccaa gaggtagagg 1020
 ttgcagttag ccaagatcgc gccactgcac tccagtctgg gcaacagagt gagaccctgt 1080
 tctagtggty ataataataa tgatgtagt 1109

<210> 50
 <211> 2407
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 605761CB1

<400> 50
 ctttcgctgg cgccattacc tgagttctcc tccagcgttt ccgcaccctc tccgattagc 60
 ggtcccagga gtttccaagg taaccgcgca gtagggcgga tctcattagg cggaaagcga 120
 aacccggaag tgacgctctt accgggtgtc agcagcgaga gggttcgaag atggcggcgc 180
 gcaagggctg gcgtcgcacg tgtgaaaccg gggaacccat ggaagccgag tccggcgaca 240
 caagtccga gggcccgccc caggctctacc tgcccggccc ggggcccgcg ctacgcgaag 300
 gggaggagct ggtcatggac gaggaggcct atgtgctcta ccaccgagcg cagactggcg 360
 cccctgtct cagctttgac atagtccggg atcacctggg agacaaccgg acagagcttc 420
 ctcttacact ttacttgtgt gctgggaccc aggctgagag cggccagagc aacagactga 480
 tgatgcttcg gatgcacaat ctgcatggga caaagcccc accctcagag ggcagtgatg 540

aagaagaaga ggaggaagat gaagaggatg aagaagagcg gaaacctcag ctggagctgg 600
ccatgggtgcc ccactatggg ggcatacaacc gagttcgggt gtcattggctg ggtgaagagc 660
ctgtggctgg ggtgtggtca gagaagggcc aggtggaggt gtttgcgctg cggcggttc 720
tgcaggtggg ggaggagccc caggccctgg cagccttcct ccgggatgag caggcccaaa 780
tgaagcccat cttctccttc gctggacaca tgggcgaggg ctttgcctt gactggtccc 840
cccgggtgac cggctgcctg ctgaccggtg actgtcaaaa gaacatccac ctctggacac 900
ctacggacgg cggctcctgg cacgtggacc agcggccatt cgtgggccac acacgctctg 960
tggaggacct gcagtgggtca ccgactgaga acacgggtgt tgcctcctgc tcagctgacg 1020
cctccatccg catctgggac atccgggcag cccccagcaa ggcttgcag ctccaccacg 1080
ccaccgcccc tgatggggac gtcaatgtca tcagctggag ccgcccggag ccttccctg 1140
tcagtggcgg ggatgatggg gccctcaaga tctgggacct tcggcagttc aagtctgggt 1200
ccccagtggc caccttcaag cagcacgtgg ccccgctgac ctccgctgag tggcaccccc 1260
aggacagcgg ggtctttgca gcctcgggtg cagaccacca gatcacacag tgggacctgg 1320
cagtggagcg ggaccctgag gcgggcgacg tggaggccga ccccgactg gccgacctcc 1380
cgacgacgt gctgttcgtg caccagggcg agaccgagct gaaggagctg cactggcacc 1440
cgcagtggcc agggctcctg gtcagcacgg cgctgtcagg cttcaccatc ttccgcacca 1500
tcagcgtctg aggcgtccca ctggctctga tcttgccttc tgcttggaaa ctgaagtcca 1560
attgggctcc cctggaaggg gttcattcag gtctgttgac tgagactggc cggcctgtgg 1620
gctgccgtga tggattctgt ttgacgtatt gttctctaga aggctgggt ctgatccagt 1680
gacccctctc accaaagaac tcggtttaac cagggtctctg taagaccact cccaccaga 1740
gacttgtgtg gcctgggtgt gcctgtgtgt cggattcctt cctgtcagct gtgaccatt 1800
tgacctgtgt cccagaacc cagttttttg tttgtttgt tgagacggag tcttgggtctg 1860
tcgcccaggc tggagtgcag tagcacgac ttggctcact gcaacctccg cctcctgggt 1920
taaagtgatt ctctcagctc agtctccag gtacgtggga ttacaggcat gtgccaccac 1980
accccgtaaa tttttgtatt tttagttag acgggggttc accatgttgg ccaggctggg 2040
ctcaaatct tgatctcaag tgatctgtcc gcccggcct cccagagtgc tgggttggga 2100
ttacaggcgt gagccaccgc gtccggctca ggaccagtt ttggctgctg gttcccagca 2160
ggggactcgg gggatataca gtggctgcac caaattggag gtgtgggttc ctccaacaca 2220
atttgccttc gcccggtgtc ttctgcccag ctgggtttgg ccaggatttc tccgtgtggg 2280
ggctacatgc gaccctctcc cctcctccct gacttttagag gctggtgctg tgcggggagg 2340
aaggtcaggg ctcttgagca gcaataaagg accaggaaga ggctgaggt gtaaaaaaaa 2400
aaaaaaa 2407

<210> 51

<211> 1158

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 483862CB1

<400> 51

ggaagaccgt cccggatggc ctccgggact gccagtgtgt ggaggtgagc tccgggattg 60
ccggcatttc cgcttctgct ggttgcctca tgctgcaggc tgcggccgct agccctcgt 120
cgcattgggt gcgctgaggt gccggggcag caagtgcacat gtcgtcgggc ctccgcgcg 180
ctgacttccc ccgctggaag cgcacatct cggagcaact gaggcgccgg gaccggctgc 240
agagacaggc gttcgaggag atcatcctgc agtataacaa attgctggaa aagtgcagatc 300
ttcattcagt gttggcccag aaactacagg ctgaaaagca tgacgtacca aacaggcacg 360
agataagtcc cggacatgat ggcacatgga atgacaatca gctacaagaa atggcccaac 420
tgaggattaa gcaccaagag gaactgactg aattacacaa gaaacgtggg gagttagctc 480
aactgggtgat tgacctgaat aaccaaattgc agcggaagga caggagatg cagatgaatg 540
aagcaaaaat tgcagaatgt ttgcagacta tctctgacct ggagacggag tgcctagacc 600
tgcgcactaa gctttgtgac cttgaaagag ccaaccagac cctgaaggat gaatatgatg 660

```

ccctgcagat cacttttact gccttggagg gaaaactgag gaaaactacg gaagagaacc 720
aggagctggt caccagatgg atggctgaga aagcccagga agccaatcgg cttaatgcag 780
agaatgaaaa agactccagg aggcggcaag cccggctgca gaaagagctt gcagaagcag 840
caaaggaacc tctaccagtc gaacaggatg atgacattga ggtcattgtg gatgaaactt 900
ctgatcacac agaagagacc tctcctgtgc gagccatcag cagagcagcc acgtaagtag 960
gcaggtttgg gccagggaaa agacagcttg aggagcaata tgaaggcaca tctgtggaca 1020
tgacaaagaa tgcagtcaga tgcacccaac cccttactcc ttttctggga caccagcgt 1080
cgaacacacc acagaggtgt ctagtctttc tcagttcacc tctgcttaat gggaggggaag 1140
cagaacacgg gtggcttc                                     1158

```

<210> 52

<211> 1026

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1256777CB1

<400> 52

```

ctgcgggctt ctctccgtcg ccatggaaac gaaagcggcc aagtagagct ccgtcctgac 60
gcgcgcgctc cegtgggctc cggccggcta agccgcggcg gacaactatg ctgaaagcca 120
agatcctctt cgtggggcct tgcgagagtg gaaaaactgt tttggccaac tttctgacag 180
aatcttctga catcactgaa tacagcccaa cccaaggagt gaggatccta gaatttgaga 240
accgcgatgt taccagcaac aacaaaggca cgggctgtga attcgagcta tgggactgtg 300
gtggcgatgc taagtttgag tctgtctggc cggccctgat gaaggatgct catggagtgg 360
tgatcgtctt caatgctgac atcccaagcc accggaagga aatggagatg tggatttcct 420
gctttgtcca acagcgcgtc ttacaggaca cacagtgtat gctaattgca caccacaaac 480
caggctcttg agatgataaa ggaagcctgt ctttgtcgcc acccttgaac aagctgaagc 540
tggtgcactc aaacctggaa gatgaccctg aggagatccg gatggaattc ataaagtatt 600
taaaaagcat aatcaactcc atgtctgaga gcagagacag ggaggagatg tcaattatga 660
cctagccagc cttcacctgg gactgccaca tccccagtga aatcagcatg tttctcggtg 720
cagatctgaa atcacatcca gctcctgatg ttttctctc cctctgactg cagaggaagt 780
gttcttacct gcaggaaggc acctgtcaca cagggcgctt actcagacca tctgtgctct 840
gacctgagtt cagttgagaa aatcctatta tcaaatttgg atttctggc cccagaactt 900
cccaaagacc tgtaaaatgg agggatttac cacctcacat atgtccagtt aaacagtttg 960
tggacttgta accgtcgcag cccaatgata caacagtagt ttaatcacgt gaaaaaaaaa 1020
aaaaaa                                     1026

```

<210> 53

<211> 2456

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2198779CB1

<400> 53

```

gacgagcgac gagatgacgg aggagcgggt ggccaacgca tgccggcagt cgggtgtaaac 60
aaggcctcgc gccgctgcgg gtccctgcgac cgctcctggc tgggatttcg attggctcgg 120
cagagaggtt acctggaaat ccaacaccgc ccaacacccc tcccgcctcc cagtcggggg 180
acttcgatag gattggagaa ggagttgaca ggaggagccc ccgcacagga cctaagaatg 240

```

```

ctgtgaccag aagatgggat cgcggaacag cagcagtgcg ggatccgggt cgggagaccc 300
ctccgagggc ttgccccgaa gaggggctgg cctgcgtcgg agtgaggaag aggaagaaga 360
ggatgaagat gtggatctgg cccaggctact ggcctatctc ctccgcagag gccaaagtga 420
gttggtgcag ggaggagggtg cagcaaatctt acaattcatt caggccctct tggactcaga 480
ggaagagaat gacagagcct gggatggctg tcttggggat cgatacaacc cacctgtgga 540
tgctacccct gacacccggg agctggaatt caatgagatc aagacacaag tggaaactggc 600
cacagggcag ctggggctta ggcgggcccgc ccagaagcac agctttcctc gaatgttgca 660
ccagagagaa cggggcctct gccatcgggg aagcttctcc cttggagaac agtctcgagt 720
gatatctcac ttcttgccca atgatctggg cttcactgat agctactctc agaaggcttt 780
ctgtggcatc tacagcaaag atgggtcaaat attcatgtct gcttgccaag accagacaat 840
ccgactctat gactgccgat atggccgttt ccgtaaatc aagagcatca aggcccgca 900
tgtaggctgg agcgtcttgg atgtggcctt caccctgat gggaaccact tctctactc 960
tagctggtct gattacattc atatctgcaa tatctatggg gagggagata cacacactgc 1020
cctggatctc aggcagatg agcgtcgtct tgctgtcttc tccattgctg tctcctcaga 1080
tggacgagaa gtactaggag gggccaatga tggctgcctg tatgtctttg accgagaaca 1140
gaaccggcgc acccttcaga ttgagtcaca tgaggatgat gtgaatgcag tggcctttgc 1200
tgatataagc tcccaaatcc tgttctctgg gggagatgat gccatctgca aagtgtggga 1260
tcgacgcacc atgcgggagg atgaccccaa gcctgtgggt gcactggctg gacaccagga 1320
tggcatcacc ttcatgaca gcaagggtga tgcccgggtat ctgatctcca actctaaaga 1380
ccagaccatc aaactctggg atatccgacg cttttccagc cgggaaggca tggaaacttc 1440
acgccaggct gccacacagc aaaactggga ctatcgggtg cagcaagtgc caaaaaagg 1500
gtttactctg cateccctacc cagcctggcg gaagctgaag ctcccagggg acagctcctt 1560
gatgacctac cggggccacg gagtgtgca caccctcatc cgctgccggg tctcccccat 1620
tcatagcact ggccagcagt tcatctacag tggctgctcc actggcaaag tggttgtgta 1680
cgaccttcta agtggccaca ttgtgaagaa gctgaccaac cacaaggcct gtgtgctga 1740
cgtcagttgg caccctttg aagagaagat tgtcagcagt tcgtgggacg ggaacctgcg 1800
tctgtggcag taccgccagg ctgagtactt ccaggatgac atgccagaat ctgaggaatg 1860
tgccagcgcc cctgccccag tgccccaatc ctctacaccc ttttctctac ccagtagat 1920
ccaacctcca gccccatata ggggtgaacct cttgataagc tctctgcctc ctccctccctt 1980
tctcccttgt ggggaatgtt tggaggaatc actggcattt gatgggggaat aacataagcc 2040
tgggctctga gcctcagctg agccctggaa gattctcccc atggggcaga gtgggtctct 2100
tacgtgctca caccagtcga gcttgggtcc ctatctctgg ccagagtttg gcaggactgc 2160
cattatctgg ggtgtggcct ctgccagcaa gagaagtgtc ctgggtgttt ttaatcatgt 2220
ttgaatgtta ggggttggat cctagagtag atgcctgagg ccacatctga acagacctgt 2280
cagccaggcc tgccaggtct tcacgttgag gattcaactg gccaatcaca ggacaggtgt 2340
cctggccttt ctctctgagg tctctagggg aggggcctgg gtaagggtgt ttcctcagca 2400
ccctcctggg gtggggatta tgtctgctgt catgtctggg tctttaagggt aggaca 2456

```

<210> 54

<211> 1771

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2226116CB1

<400> 54

```

cggctcgagt taatatcttc gttgagcgga accttgctat tccataagag gatgtgtcca 60
gtgtgttgga agatttcatt ttttaaattc tttgtacaga aatcctgctc ccaagtcaca 120
gataggctga cgggtcagag ggcaagacgt gacccagggc cgagaggggtg agtgaccagg 180
aaaatcggat tcatcagttc acttgtttgt ttcagaaacg tgcacaaaga cctgctgcat 240
gaggccctcg tcttcagttt ctgtttcatg cccagcatta aaccaagtat ctcatcttgc 300
caatttgact tctgtagggg ccatggcacc tgcaagggtg ttctcagcaa gattgaggac 360

```

```

cgtgttttcag ggcgtggggc attgggcttt gtccacatgg gctggcctga agcccagccg 420
gctactgccca cagcgggctt ctcccaggct gctctcggtc ggccgtgcgg acctcgccaa 480
gcatcaggaa ctcccgggga agaagctgct ctctgagaaa aagctgaaaa ggtactttgt 540
ggactatcgg agagtgcctt tctgtggagg aaacggaggc gctggggcaa gctgcttcca 600
cagtgaagccc cgcaaggagt ttggaggccc tgatggaggg gacggaggca acggtggaca 660
cgtcattctg agagttgacc agcaagtcaa gtccctgtcg tcggtcctgt cgcggtacca 720
gggttttcagt ggagaagatg gagggagtaa aaactgcttc gggcgcagtg gcgcgctect 780
ctacatccgg gtccccgtgg gcacgctggt gaaggaggga ggcagagttg tggccgacct 840
gtctttgcgtg ggagatgagt acattgccgc gctgggcggg gcaggaggga aaggcaaccg 900
cttcttctctg gccacaaca accgtgcccc tgtgacctgt acccctggac agccaggaca 960
gcagcgagtt ctccacctgg agctcaagac ggtggcccac gccggaatgg tgggattccc 1020
caacgcggg aagtcctcac tgctccgggc catttcaaac gccagaccgg ccgtggcttc 1080
ctaccggttc accaccctga agccccacgt cgggatcgtc cactacgaag gccacctaca 1140
aatagcagtg gccgacatcc ccggcatcat acgaggcgcc caccagaaca ggggtctggg 1200
gtccgccttc ctccaggcaca tcgagcgctg ccgctttctc ttgttcgtgg tggatcttcc 1260
tcagcctgag ccgtggactc aagttgacga tttaaaatat gaactggaga tgtatgaaaa 1320
gggcctgtct gcgaggcccc acgcaatcgt cgaaaacaag attgacctcc ctgaagccca 1380
agccaatctg tcccagctcc gggatcactt gggacaggag gtcacgtgctc tgcggcgctt 1440
gaccggcgag aacctggagc agctgctgtt gcacctgaag gtgctgtatg acgcctacgc 1500
ggaggccgag ctggggccagg gccgccagcc gctcagggtg tagccacgcc agagcggggg 1560
cgccctctggg cctctgtctg agcaaacctg ggtgtgaatt cgggtggttt gaatgcataa 1620
agtgccttgt ggacacgggg gagttgtggt gcttctgggt ctctgggccc cgcctgctgg 1680
cctgagatgc cctcatgttg ggaagcattc cgtgcccccc accccgectg ccctcgtat 1740
ttcctgcacc tgtcagcctg cgctgactga t 1771

```

<210> 55

<211> 2724

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2504472CB1

<400> 55

```

gctgaccagt tggcgacatg gtggcacccg tgctggagac ttctcacgtg ttttgcctgc 60
caaaccgggt gcggggagtc ctgaactgga gctctgggcc cagaggactt ctggcctttg 120
gcacgtcctg ctccgtgggt ctctatgacc ccctgaaaag ggttggtgtt accaacttga 180
atgggtcacac cgcccgagtc aattgcatac agtggatttg taaacaggat ggctccccct 240
ctactgaatt agtttctgga ggatctgata atcaagtgat tcaactggga atagaggata 300
atcagctttt aaaagcagtg catcttcaag gccatgaagg acctgtttat gcggtgcagt 360
ctgtttacca gaggaggaca tcagatcctg cattatgtac actgacgtt tctgcagctg 420
cagattctgc tgttcgactc tggctctaaa agggctccaga agtaatgtgc cttcagactt 480
taaacttttg aaatggattt gctttggctc tctgcttate ttttttgcca aatactgatg 540
taccaatatt agcatgtggc aatgatgatt gcagaattca catatttgct caacaaaatg 600
atcagtttca gaaagtgcct tctctctgtg gacatgagga ttggattaga ggagtggaa 660
gggcagccct tggtagagat cttttcctag caagctgttc acaagattgc ctgataagaa 720
tatggaagct gtatataaag tcaacatctt tagaaactca ggatgacgat aacataagac 780
tgaaagaaaa tacttttacc atagaaaatg aaagtgttaa aatagcattt gctgttactc 840
tggagacagt gctagccggt catgaaaact gggtaaactg agttcactgg caacctgtgt 900
tttaciaaaga tgggtgtccta cagcagccag tgagattatt atctgcttcc atggataaaa 960
ccatgattct ctgggctcca gatgaagagt caggagtttg gctagaacag gttcgagtag 1020
gtgaagtagg tgggaataact ttgggatttt atgattgcca gttcaatgaa gatggctcca 1080
tgatcattgc tcatgctttc cacggagcgt tgcacctttg gaaacagaat acagttaacc 1140

```



```

caagagagtg gactccagag attgtcattt caggacactt tgatggtgtc caagacctag 1200
tctgggatcc agaaggagaa tttattatca ctgttggtac tgatcagaca actagacttt 1260
ttgctccatg gaagagaaaa gaccaatcac aggtgacttg gcatgaaatt gcaaggcctc 1320
agatacatgg gtatgacctg aaatgttttg caatgattaa tcgggtttcag tttgtatctg 1380
gagcagatga aaaagttctt cgggtttttt ctgcacctcg gaattttgtg gaaaattttt 1440
gtgccattac aggacaatca ctgaatcatg tgctctgtaa tcaagatagt gatcttccag 1500
aaggagccac tgtccctgca ttgggattat caaataaagc tgtctttcag ggagatatag 1560
cttctcagcc ttctgatgaa gaggagctgt taactagtac tgggtttgag tatcagcagg 1620
tggcctttca gccctccata cttactgagc ctccactga ggatcatctt ctgcagaata 1680
ctttgtggcc tgaagttcaa aaactatatg ggcacggtta tgaaatattt tgtgttactt 1740
gtaacagttc aaagactctg cttgcctcag cttgtaaggc agctaagaaa gagcatgcag 1800
ctatcattct ttggaacact acatcttgga aacagggtgca gaatttagtt ttccacagtt 1860
tgacagtcac gcagatggcc ttctcaccta atgagaagtt cttactagct gtttccagag 1920
atcgaacctg gtcattgttg aaaaagcagg atacaatctc acctgagttc gagccagttt 1980
ttagtctttt tgctttcacc aacaaaatta cttctgtgca cagtagaatt atttggctct 2040
gtgattggag tcttgacagc aagtatttct tcaactgggag tcgagacaaa aagggtggtg 2100
tctggggtga gtgcgactcc actgatgact gtattgagca caacattggc cctgtctcct 2160
cagtccctga cgtgggtggg gctgtgacag ctgtcagcgt ctgccagtg ctccacctt 2220
ctcaacgata cgtggttgca gtaggatttg agtgtggaaa gatttgctta tatacctgga 2280
aaaagactga tcaagttcca gaaataaatg actggaccca ctgtgtagaa acaagtcaa 2340
gccaaagtca tacactggct atcagaaaat tatgtctgga gaattgcagt ggaaaaactg 2400
aacagaagga agcagaaggt gctgagtggg tacactttgc aagctgtggt gaagatcaca 2460
ctgtgaagat acacagagtc aataaatgtg cactgtaatg gacttaataa ctacatgctt 2520
gcagtcactg gtatcttaaa atattatcat gtaaacaggt catctttacc ttcataactg 2580
aattgagttt ctgggttttt tttttttttg agatggagtc ttgctttgtc acaacctcca 2640
cctcccaggt tcaagcgatt ctctttcttc agcctcctga gtagctggga ctagaggcac 2700
accaccatgc ccggctaatt ttg 2724

```

<210> 56

<211> 2963

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3029920CB1

<400> 56

```

ggccgaagag gctggcaggt ggccgctggt ggtgggtgct cctggtgaga ggagtccact 60
ccgtgcgtgc gggcggaggc cggccccga gagccgccga catgaagaaa gacgtgcgga 120
tctgtctggt gggagaacct agagttggga agacatcact gattatgtct ctggtcagtg 180
aagaatttcc agaagaggtt cctccccggg cagaagaaat caccattcca gctgatgtca 240
ccccagagag agttccaaca cacattgtag attactcaga agcagaacag agtgatgaac 300
aacttcatca agaaatatct caggctaattg tcatctgtat agtgatgcc gttaacaaca 360
agcattctat tgataaggta acaagtcgat ggattcctct cataaatgaa agaacagaca 420
aagacagcag gctgccttta atattgggtg ggaacaaatc tgatctggtg gaatatagta 480
gtatggagac catccttcct attatgaacc agtatacaga aatagaaacc tgtgtggagt 540
gttcagcgaa aaacctgaag aacatatcag agctctttta ttacgcacag aaagctgttc 600
ttcatcctac agggcccttg tactgccag aggagaagga gatgaaacca gcttgataa 660
aagcccttac tcgtatattt aaaatatctg atcaagataa tgatggtact ctcaatgatg 720
ctgaactcaa cttctttcag aggatttggt tcaacactcc attagctcct caagctctgg 780
aggatgtcaa gaatgtagtc agaaaacata taagtgatgg tgtggctgac agtgggttga 840
ccctgaaagg ttttctcttt ttacacacac tttttatcca gagagggaga cacgaaacta 900
cttggaactgt gcttcgacga tttggttatg atgatgacct ggatttgaca cctgaatatt 960

```

```

tggtccccct gctgaaaata cctcctgatt gcactactga attaaatcat catgcatatt 1020
tattttctcca aagcaccttt gacaagcatg atttgatag agactgtgct ttgtcacctg 1080
atgagcttaa agattttattt aaagttttcc cttacatacc ttggggggcca gatgtgaata 1140
acacagtttg taccaatgaa agaggctgga taacctacca gggattcctt tcccagtgga 1200
cgctcacgac ttatttagat gtacagcggg gcctggaata tttgggctat ctaggctatt 1260
caatattgac tgagcaagag tctcaagctt cagctgttac agtgacaaga gataaaaaga 1320
tagacctgca gaaaaaacia actcaaagaa atgtgttcag atgtaatgta attggagtga 1380
aaaactgtgg gaaaagtggg gttcttcagg ctcttcttgg aagaaactta atgaggcaga 1440
agaaaattcg tgaagatcat aaatcctact atgcgattaa cactgtttat gtatatggac 1500
aagagaaata cttgttggtg catgatattc cagaatcgga atttctaact gaagctgaaa 1560
tcatttgatga tgttgatgac ctggtatag atgtcagcaa tcccaaatcc tttgaatact 1620
gtgccaggat ttttaagcaa cactttatgg acagcagaat accttgctta atcgtagctg 1680
caaagtcaga cctgcatgaa gttaaacaag aatacagtat ttcacctact gattttctgca 1740
ggaaacacaa aatgcctcca ccacaagcct tcacttgcaa tactgtctgat gccccagta 1800
aggatatctt tgttaaattg acaacaatgg ccattgtatcc gcacgtgaca caagctgacc 1860
tcaagagctc cacgttttgg cttcgagcaa gttttgggtgc tactgttttt gcagttttgg 1920
gctttgctat gtacaaagca ttattgaaac agcgatgata taaaagaaa tactgtccct 1980
acaaaaaaca aatactttta tgtacattct gaatgcttta agttctgcta gaattattga 2040
gatatttata catgcagagt tactttatta atatttgtaa ttcatgcata agagtatttt 2100
aatgatagtt ataactgcag tattggctag catatggaaa gaaaacagct aacagccaaa 2160
ctaaaatggc taaattccag agggcaaaaag ggaatatattt gtaaataatat gtacatatc 2220
aggcaagata tgggtctcca agctgagttc tagaaatgat gttcttagac atttctaagt 2280
ggtattgtta gtgctcactt ggctcactct tctaggttta agttagccca gagattgtat 2340
ttactcatgg atcactttat ttatttcaca tttactcaga atgacctttt gggttctata 2400
aggacataag gtacaatttg ccattgtctc tccattttta aaaacataca agtcagtgtc 2460
agcttaccaa catgacattt tttcagtcag ttgtggtagg ccagccttga agccatcgca 2520
cagtctagaa acttgtgtag ctgagtggtc agctcacctt taagggtgaa gttaggtaaa 2580
agcaattagc agaggcgta tctatgtgat tatgttgctt ccttgtcagt atgttgaatt 2640
ttatagccct ttcaatgaaa taaaaaaaaa atttgtatat taccaatgtt tttagtttaa 2700
ataaagagtc acccttacta ctgttgtaatt tcatcccaag tgtaaatcat tctataatgg 2760
ctgtgtctgt tatagtatat tacagtaact gcattgtgtc ccaagtgttc tatatcaggc 2820
taggataacc tagaggcagt aattttttta atgataaaat aaatctaatt aatataaact 2880
ctcatgataa acctattttt tccatcatca gccttttcaa gtattttaat aaataactgc 2940
tgtgtactgt gaaaaaaaaa aaa

```

<210> 57

<211> 3332

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3332415CB1

<400> 57

```

gcctggcaga ggctggcggg catcgtgccc gtcctgccc gtctcccggg caccgggcca 60
ccgccccacc cctcctccc tgccatggag cccgagctgg acgctcagaa gcagcctcga 120
ccgcgagggc gaagccgccc ggctctgagg ctgagcacgg agggagcgac ggggccttcg 180
gccgacacct ccgggtcgga gctggacggg agatgttccc ttcggagagg cagctccttc 240
acattcttaa cacctggccc caactgggac ttcactttga aaagaaaacg cagagagaaa 300
gatgatgatg ttgtaagcct tagcagcctt gatctgaagg agccaagcaa taaaagagtt 360
cgacctctgg ctctgtgtac gtccttggca aatttaattc ctctgttaag aaatggagct 420
gtcagacgtt ttggtcaaac aatacagtc tttacccttc gtggtgacca cagatcccca 480
gcctctgccc agaagttttc tagcaggtca acagtcccaa caccgcca gagaaggagc 540

```

```

agtgcactgt ggtcagagat gctggacatc accatgaagg agtctctcac caccagggag 600
atcagacggc aggaggcaat atatgaaatg tcccagggtg aacaggatTT aattgaggat 660
ctcaaacttg caagaaaggc ctaccatgac cccatgttaa agttgtccat catgtcagaa 720
gaggaaactca cacatatatt tggatgatctg gactcttaca tacctctgca tgaagatttg 780
ttgacaagaa taggagaagc aaccaagcct gatggaacag tggagcagat tggtcacatt 840
ctcgtgagct gggtaccgcg cttgaatgcc tacagagggt actgtagtaa ccagctggca 900
gccaaagctc ttcttgatca aaagaaacag gatccaagag tccaagactt cctccagcga 960
tgtctcgagt ctcccttcag tcaaaaacta gatcttttga gtttcttaga tatccctcga 1020
agtcgcctag tcaaataccc ttactgttta aaagaaattc ttaaacacac tccaaaagag 1080
caccctgatg ttcagcttct ggaggatgct atattgataa tacaggggag cctctctgat 1140
atcaacttga agaaagggtga atccgagtgc cagtattaca tgcacaagct ggagtagctg 1200
gatgaaaagc agaggggacc cagaatcgaa gcgagcaaaag tgctgctgtg ccatggggag 1260
ctgaggagca agagtggaca taaactttac attttctgtt ttcaagacat cttgggttctg 1320
actcggcccg tcacacggaa cgaacggcac tcttaccagg tttaccggca gccaatccca 1380
gtccaagagc tagtcttaga agacctgcag gatggagatg tgagaatggg aggtcctttt 1440
cgaggagctt tcagtaactc agagaaagct aaaaatatct ttagaattcg cttccatgac 1500
cctctccag cccagtctca cactctgcaa gccaatgacg tgttccacaa gcagcagtgg 1560
ttcaactgta ttcgagcggc cattgcccc ttccagtcgg caggcagtcc acctgagctg 1620
cagggcctgc cggagctgca cgaagagtgt gaggggaacc acccctctgc gaggaaactc 1680
acagcccaga ggagggcac caccgtttcc agtggttactc aggtagaagt tgatgaaaac 1740
gcttacagat gtggctctgg catgcagatg gcagaggaca gcaagagctt aaagacacac 1800
cagacacagc ccggcatccg aagagcgagg gacaaagccc tttctggtgg caaacggaaa 1860
gagactttgg tgtagagaag gctctgtgtg ttaactgatg ggagagactg tttgtttata 1920
aatgtgtaca gttttgtttt ctgtaagggt gagcatcata gggttacttt ataccagttg 1980
taacattttc attgtttttg gttgttcttt tttctttttt taatggcagc taaagatata 2040
cagattactg ttaaattgca gtcttttttt ttttaaagat attttcttga gttatttaga 2100
acattgtaag cctgggtattt tttaatacaa caaaatatatt atgaaatggg ttttctctta 2160
attctggatt catcatggct ttctaatacc aattgttaata tttacaatat tcacccaaac 2220
ttagaatttt gcaaattgct gaattctgcc agtgtttctt tgctaagcct tgcattgcaa 2280
atgtgaaatt ttaacattgg caccacaaac ctacatggaa tgtatgtctg gagtatttca 2340
aactttacat tgaaacataa tttccttgga aaacaaacca taagcctgag gaggttttta 2400
tcaactggaa tgctttatat tagttttggt tttactgtac attcctcatt ttacattcat 2460
ttaacctgcc gattatttaa tttttttatt gtaaagtagt ttttagcatt tgcttttatt 2520
tttttacttt gatgcctttt caaattggca tgtctttaa gtatttttct tctgattaa 2580
aaatgtgtgt gtatgtgtgt gtgtgtgtgt atatatatat atttttttta atcacattaa 2640
ttttaccaag tgaaaccaag ccatactgtt tttgagccaa ttaagaaaaat tgccattttt 2700
aaagtgtagc atttcagggt aaagacccat gaaatggctt gatgtattct agactactga 2760
aagaaaaacca cttcaaaagat tttgttgaaa gtttttagtgt tgtctgaaat gcaagaggga 2820
aggtgattgg tagtgagtta aaagaaaaag agaggaaaag agagttagtt tgtcttcaag 2880
taaaatgtct ggttgtgcca gacatttcac aagtgtgaaa ggagatagga gaagctcaac 2940
ttgagggcgt gtagtaagtt gtagaaggct cgaggggacg tggacttatt tgccttgggt 3000
tgcaatacct gcaataaatg agtttgaaaa gaaacaatga aatgtgttaa aaatttgacc 3060
atattagata aattttgggt gatttagtca taagatggaa aaagactggg gaattcttta 3120
ttacaaaatg tttctgttaa aatgggatca tcatctttga aaggggggag gaggagtaaa 3180
agccccgatta taatgggtgat caattcaagt cagtgttgac tattctgtga aatatatttg 3240
gccagtggaa atgataatca gaaaagactg taaatagatc catccaaatg atttctctgt 3300
acaaatgaat gatactatta aaaaaaaaaa aa 3332

```

<210> 58

<211> 2617

<212> DNA

<213> Homo sapiens

<220>

<223> Incyte ID No: 4031536CB1

<400> 58

```

tttagtaatg tgctgtatt acatgtagag agtattcgct aaccaagagg agttttaaaa 60
tgtcaaaacc gggaaaacct actctaaacc atggcttggt tctgttgat cttaaaagtg 120
caaaagagcc tctaccacat caaactgtga tgaggatatt tagcattagc atcattgccc 180
aaggcctccc tttttgtcga agacggatga aaagaaagt ggaccatggg tctgagggtcc 240
gctctttttc tttgggaaag aaaccatgca aagtctcaga atatacaagt accactgggc 300
ttgtaccatg ttcagcaaca ccaacaactt ttggggacct cagagcagcc aatggccaag 360
ggcaacaacg acgccgaatt acatctgtcc agccacctac aggcctccag gaatggctaa 420
aaatgtttca gagctggagt ggaccagaga aattgcttgc tttagatgaa ctcatgata 480
gttgtgaacc aacacaagta aaacatatga tgcaagtgat agaaccacag tttcaacgag 540
acttcatttc attgctccct aaagagtggg cactctatgt gctttcattc ctggaaccca 600
aagacctgct acaagcagct cagacatgct gctactggag aattttggct gaagacaacc 660
ttctctggag agagaaatgc aaagaagagg ggattgatga accattgcac atcaagagaa 720
gaaaagtaat aaaaccagggt ttcatacaca gtccatggaa aagtgcatac atcagacagc 780
acagaattga tactaactgg aggcgaggag aactcaaacc tcttaagggt ctgaaaggac 840
atgatgatca tgtgatcaca tgcttacagt tttgtggtta ccgaatagtt agtgggtctg 900
atgacaacac tttaaaagtt tggtcagcag tcacaggcaa atgtctgaga acattagtgg 960
gacatacagg tggagtatgg tcatcaca aa tgagagacaa catcatcatt agtggatcta 1020
cagatcggac actcaaagtg tggaatgcag agactggaga atgtatacac accttatatg 1080
ggcatacttc cactgtgcgt tgtatgcac ttcatgaaaa aagagttgtt agcggttctc 1140
gagatgccac tcttaggggt tgggatattg agacaggcca gtgtttacat gttttgatgg 1200
gtcatgttgc agcagtcgcg tgtgttcaat atgatggcag gaggggtgtt agtggagcat 1260
atgattttat ggtaaaaggtg tgggatccag agactgaaac ctgtctacac acgttgccag 1320
ggcatactaa tagagtctat tcattacagt ttgatggtat ccatgtggtg agtggatctc 1380
ttgatacatc aatccgtgtt tgggatgtgg agacagggaa ttgcattcac acgttaacag 1440
ggcaccagtc gttaacaagt ggaatggaac tcaaagacaa tattcttgtc tctgggaatg 1500
cagattctac agttaaaatc tgggatatca aaacaggaca gtgtttacaa acattgcaag 1560
gtcccaacaa gcatcagagt gctgtgacct gtttacagtt caacaagaac tttgtaatta 1620
ccagctcaga tgatggaact gtaaaactat gggacttgaa aacgggtgaa tttattcgaa 1680
acctagtac attggagagt ggggggagtg ggggagttgt gtggcggtac agagcctcaa 1740
acacaaagct ggtgtgtgca gttgggagtc ggaatgggac tgaagaaacc aagctgctgg 1800
tgctggactt tgatgtggac atgaagtga gagcagaaaa gatgaatttg tccaattgtg 1860
tagacgatat actccctgcc ctccccctg caaaaagaaa aaaagaaaag aaaaagaaaa 1920
aaatcccttg ttctcagtgg tgcaggatgt tggcttgggg caacagattg aaaagacct 1980
cagactaaga aggaaaagaa gaagagatga caaacataa ctgacaagag aggcgtctgc 2040
tgtctcatca cataaaaggc ttcacttttg actgagggca gctttgcaaa atgagacttt 2100
ctaaatcaaa ccagggtgcaa ttattttctt attttcttct ccagtgggtc ttgggcagtg 2160
ttaatgctga aacatcatta cagattctgc tagcctgttc ttttaccact gacagctaga 2220
cacctagaaa ggaactgcaa taatatcaaa acaagtactg gttgactttc taattagaga 2280
gcatctgcaa caaaaagtca tttttctgga gtggaaaagc ttaaaaaaat tactgtgaat 2340
tgtttttgta cagttatcat gaaaagcttt tttttttttt tttgccaaac attgccaatg 2400
tcaatcaatc acagtattag cctctgttaa tctatttact gttgcttcca tatacattct 2460
tcaatgcata tgttgcctca aggtggcaag ttgtcctggg ttctgtgagt cctgagatgg 2520
atttaattct tgatgctggg gctagaagta ggtcttcaaa tatgggattg ttgtcccaac 2580
cctgtactgt actcccagtg gccaaactta tttatgct 2617

```



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 16/18, A61K 38/17, G01N 33/68 | | A3 | (11) International Publication Number: WO 00/31263 |
| | | | (43) International Publication Date: 2 June 2000 (02.06.00) |
| (21) International Application Number: PCT/US99/28013 (22) International Filing Date: 23 November 1999 (23.11.99) (30) Priority Data: 60/109,592 23 November 1998 (23.11.98) US 60/118,610 4 February 1999 (04.02.99) US 60/127,990 6 April 1999 (06.04.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/109,592 (CIP) Filed on 23 November 1998 (23.11.98) US 60/118,610 (CIP) Filed on 4 February 1999 (04.02.99) US 60/127,990 (CIP) Filed on 6 April 1999 (06.04.99) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, | | CA 94040 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 14 September 2000 (14.09.00) | |
| (54) Title: GTPASE ASSOCIATED PROTEINS | | | |
| (57) Abstract | | | |
| <p>The invention provides human GTPase associated proteins (GTPAP) and polynucleotides which identify and encode GTPAP. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GTPAP.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/28013

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K16/18 A61K38/17 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | MOOSLEHNER K ET AL: "STRUCTURE AND EXPRESSION OF A GENE ENCODING A PUTATIVE GTP-BINDING PROTEIN IDENTIFIED BY PROVIRUS INTEGRATION IN A TRANSGENIC MOUSE STRAIN" MOLECULAR AND CELLULAR BIOLOGY 1991, vol. 11, no. 2, 1991, pages 886-893, XP000891270 ISSN: 0270-7306 abstract; figure 1 | 1-12 |
| A | WO 98 37196 A (LUDWIG INST CANCER RES) 27 August 1998 (1998-08-27) abstract; claims 1-52; examples 1-8 | 1-20 |
| A | WO 94 16069 A (SCHERING CORP ;NAKAFUKU MASATO (JP); KAZIRO YOSHITO (JP)) 21 July 1994 (1994-07-21) abstract; claims 1-39 | 1-6, 9-15 |
| | - / - - | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

24 March 2000

Date of mailing of the international search report

05. 07. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/28013

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | WO 91 15582 A (CETUS CORP) 17 October 1991 (1991-10-17) abstract; claims 1-46; example 10 --- | 1-16, 19, 20 |
| A | WO 90 00607 A (CETUS CORP) 25 January 1990 (1990-01-25) abstract; claims 1-55; figures 3,4 ----- | 1-14 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/28013

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 19,20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 17 18 20
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
claims 1-20 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17 18 20

Claims 17,18,20 refer to an antagonist and agonist and the use of antagonist of polypeptide of claim 1 without giving a true technical characterization. Moreover, no such compound is defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (art.5 and 6 PCT). No search can be carried out for such speculative claims the wording of which, is in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-20 (partially)

A protein with amino acid with seq.id. 1 and corresponding nucleotide sequence with seq.id. 30 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

2. Claims: 1-20 (partially)

A protein with amino acid with seq.id.2 and corresponding nucleotide sequence with seq.id. 31 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

3. Claims: 1-20 (partially)

A protein with amino acid with seq.id.3 and corresponding nucleotide sequence with seq.id. 32 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

4. Claims: 1-20 (partially)

A protein with amino acid with seq.id.4 and corresponding nucleotide sequence with seq.id. 33 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

5. Claims: 1-20 (partially)

A protein with amino acid with seq.id.5 and corresponding nucleotide sequence with seq.id. 34 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

6. Claims: 1-20 (partially)

A protein with amino acid with seq.id.6 and corresponding nucleotide sequence with seq.id. 35 , method for detecting a polynucleotide, expression vector ,host cell , method for

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

7. Claims: 1-20 (partially)

A protein with amino acid with seq.id.7 and corresponding
nucleotide sequence with seq.id. 36 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

8. Claims: 1-20 (partially)

A protein with amino acid with seq.id.8 and corresponding
nucleotide sequence with seq.id. 37 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

9. Claims: 1-20 (partially)

A protein with amino acid with seq.id.9 and corresponding
nucleotide sequence with seq.id. 38 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

10. Claims: 1-20 (partially)

A protein with amino acid with seq.id.10 and corresponding
nucleotide sequence with seq.id. 39 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

11. Claims: 1-20 (partially)

A protein with amino acid with seq.id.11 and corresponding
nucleotide sequence with seq.id. 40, method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

12. Claims: 1-20 (partially)

A protein with amino acid with seq.id.12 and corresponding nucleotide sequence with seq.id. 41 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

13. Claims: 1-20 (partially)

A protein with amino acid with seq.id.13 and corresponding nucleotide sequence with seq.id. 42 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

14. Claims: 1-20 (partially)

A protein with amino acid with seq.id.14 and corresponding nucleotide sequence with seq.id. 43 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

15. Claims: 1-20 (partially)

A protein with amino acid with seq.id.15 and corresponding nucleotide sequence with seq.id. 44 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

16. Claims: 1-20 (partially)

A protein with amino acid with seq.id.16 and corresponding nucleotide sequence with seq.id. 45 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

17. Claims: 1-20 (partially)

A protein with amino acid with seq.id.17 and corresponding nucleotide sequence with seq.id. 46 , method for detecting a polynucleotide, expression vector ,host cell , method for

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

18. Claims: 1-20 (partially)

A protein with amino acid with seq.id.18 and corresponding
nucleotide sequence with seq.id. 47 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

19. Claims: 1-20 (partially)

A protein with amino acid with seq.id.19 and corresponding
nucleotide sequence with seq.id. 48 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

20. Claims: 1-20 (partially)

A protein with amino acid with seq.id.20 and corresponding
nucleotide sequence with seq.id. 49 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

21. Claims: 1-20 (partially)

A protein with amino acid with seq.id.21 and corresponding
nucleotide sequence with seq.id. 50 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

22. Claims: 1-20 (partially)

A protein with amino acid with seq.id.22 and corresponding
nucleotide sequence with seq.id. 51 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

23. Claims: 1-20 (partially)

A protein with amino acid with seq.id.23 and corresponding nucleotide sequence with seq.id. 52 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

24. Claims: 1-20 (partially)

A protein with amino acid with seq.id.24 and corresponding nucleotide sequence with seq.id. 53 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

25. Claims: 1-20 (partially)

A protein with amino acid with seq.id.25 and corresponding nucleotide sequence with seq.id. 54 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

26. Claims: 1-20 (partially)

A protein with amino acid with seq.id.26 and corresponding nucleotide sequence with seq.id. 55 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

27. Claims: 1-20 (partially)

A protein with amino acid with seq.id.27 and corresponding nucleotide sequence with seq.id. 56 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

28. Claims: 1-20 (partially)

A protein with amino acid with seq.id.28 and corresponding nucleotide sequence with seq.id. 57 , method for detecting a polynucleotide, expression vector ,host cell , method for

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

29. Claims: 1-20 (partially)

A protein with amino acid with seq.id.29 and corresponding
nucleotide sequence with seq.id. 58 , method for detecting a
polynucleotide, expression vector ,host cell , method for
producing a polypeptide , pharmaceutical composition ,
antibody , agonist and antagonist , method for preventing a
disorder

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: International Application No

PCT/US 99/28013

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|--|--|
| WO 9837196 A | 27-08-1998 | AU 6661298 A EP 0981613 A | 09-09-1998 01-03-2000 |
| WO 9416069 A | 21-07-1994 | AU 6083894 A CA 2153486 A EP 0679185 A JP 8507204 T | 15-08-1994 21-07-1994 02-11-1995 06-08-1996 |
| WO 9115582 A | 17-10-1991 | AU 7554691 A EP 0537155 A | 30-10-1991 21-04-1993 |
| WO 9000607 A | 25-01-1990 | US 5104975 A AT 156518 T AU 627764 B AU 4034989 A DE 68928242 D DE 68928242 T EP 0466688 A EP 0649908 A US RE35171 E US 5234839 A US 5760203 A US 5763573 A US 5830684 A | 14-04-1992 15-08-1997 03-09-1992 05-02-1990 11-09-1997 18-12-1997 22-01-1992 26-04-1995 05-03-1996 10-08-1993 02-06-1998 09-06-1998 03-11-1998 |